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ABSTRACT
The structural, functional and antigenic properties of the envelope glycoproteins
of Rift Valley fever virus (RVFV) were analyzed using a panel of monoclonal
antibodies (MAbs). In order to gain a better understanding of the role of the
RVFV surface proteins in infection and pathogenesis, the mechanisms ofanti:~ody-
mediated neutralization of the virus were examined, as well as the fl}action of the
glycoproteins in viral attachment and penetration.
Of the twenty three MAbs which were generated, fourteen were directed against
the G1 and nine against the G2 protein of RVFV. The topological relationship
of the antigenic determinants to each other on the viral glycoproteins was achieved
using competitive binding assays with enzyme-labelled MAbs. For the RVFV 01
protein, four antigenic domains which may be interlinked were identified. The
domains G1 I, II and IV were involved in virus neutralization and
haemagglutination, while G1 III was associated with low level C'-dependent
neutralization.
With regard to the G2 protein, four antigenic domains which appear to be
spatially distinct were identified. Domain G2 I exhibited significant neutralizing
and haemagglutination activity, while G2 II was involved in haernagglutination
and weak C(-dependent neutralization. The remaining 02 regions neutralized to
a low level only in the presence of C'. The majority of the epitopes on bath viral
glycoproteins were highly conformational, indicating that the native protein
structure is necessary for the recognition and expression of the functional
activities of these particular antibodies.
Protective determinants were shown to occur on both Gland 02, demonstrating
that both RVFV envelope proteins are important in viral pathogenesis. The
neutralization studies, in turn, revealed that the inhibition of virus attachment is
not the principal means of antibody-mediated neutralization of RVFV. Instead,
such ..ieutralization appears to be the result of several different processes,
including synergistic neutralization by combinations of different antibodies,
prevention of virus binding, virus internalization and the blocking of the viral life
cycle at an intracellular stage. Further insight into RVFV infectivity was obtained
by showing that both glycoproteins are involved in virus entry into the host cell.
Finally, the present. findings strongly support an endosomal route of entry and
penetration for RVFV, associated with concomitant allosteric changes in the 01
protein.
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1. GENERAL INTRODUCTION
1.1 General aspects of RVFV
1.1.1 Epidemiology and transmission
Rift Valley fever is an important arthropod-borne disease of both livestock and
humans in much of sub-Saharan Africa (Shope et al, 1982). Infection causes
acute febrile illness, abortions and death in cattle and sheep, and a dengue like
illness in man (Easterday, 1965; McIntosh et al, 1973; Peters and Meegan, 1984).
The etiologic agent) Rift Valley fever virus (RVFV), was first isolated in 1930
from the blood of a newborn lamb during an epizootic of fatal hepatic necrosis
and abortion in sheep in Kenya (Daubney et al, 1931). It has subsequently
become evident that. this zoonosis had existed in this area since at least 1912
(Davies, 1975) and that it is widespread in Africa (Hoogstraal ct al, 1979;
Madkour, 1978; Meegan, 1981) with extensive epizootics described in countries
such as South Africa (Van Velden et al, 1977). Zimbabwe (Swanepoel e( al,
1979)1 Sudan (Davies, 1990) and Mauritania (Jouan et al, 1989).
In South Africa, RVF infection was first identified in 1951 (Gear et al, 1951).
In this outbreak it is estimated that 20 000 people were infected and at least
100 000 sheep and cattle died. The disease reappeared in South Africa in
epizootic form in 1953 (Gear et al, 1955) and again in 1955~1956 (Weiss, 1957).
In 1974/1975 a severe epizootic of RVF swept through the sheep and cattle-
farming districts of the Orange Free State and the Cape Province, also affecting
livestock in Namibia (Barnard and Botha, 1977). Many humans were infected
and for the first time in South Africa human deaths due to RVF were recognized
(Van Velden et al, 1977).
Unti11977, the disease was restricted to man and domestic animals in sub-Saharan
Africa (Shope et ai, 1982). However, an explosive epidemic of RVF occurred
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in Egypt in 1977 and 1978, demonstrating the potential for this disease to escape
its normal endemic area, as well as to spread to livestock populations worldwide
(Hoogstraal et al, 1979; Meegan et al, 1979). The Egyptian RVF epizootic
resulted in widespread involvement of human populations, with 598 fatal human
cases reported (Meegan, 1979). More recently, a large epizootic occurred in the
Senegal river basin in 1987 and again there was extensive severe human disease
and mortality (Jouan et al, 1989).
In contrast to the epizootic situation, RVF infection in other parts of sub-Saharan
Africa is enzootic/endemic as indicated by the isolation of the virus from
mosquitoes, sporadic cases in animals and man, and serological surveys. These
include Mali, Nigeria, Gabon, Uganda, the Congo, Chad (Easterday, 1965),
Zambia (Davies and Highton, 1980; Davies et al, 1992), Angola (Kokernot et al,
1965), Botswana (Tessier et al, 1987) and Mozambique (Valadaao, 1969). As
well as being present in Africa, RVFV has also been isolated in Madagascar
(Mathiot et al, 1984) and a RVFV outoreak has recently been reported there
(Morvan et aI, 1991a; b).
Epizootic transmission of RVFV is primarily by mosquito (Shope, 1985) and
epidemics are very often linked with unusually high rainfall or warm seasons
which favour mosquito density (Davies et al, 1985; Mclntosh et al, 1980a).
Other modes of transmission are nevertheless not uncommon and may be
subsequently important when virus loads are high (Hoogstraal et al, 1979).
During epidemics in sub-Saharan Africa, RVFV has been isolated frequently from
several culicine mosquitoes (Gear et al, 1955; McIntosh, 1972; McIntosh et ai,
1980b). In South Africa the main epizootic vector among sheep and cattle on the
inland plateau is Culex theiieri where it probably causes some human infection
(McIntosh et al, 1980b). Although the vector responsible for the 1977-1978
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Egyptian epizootic was not proved, epidemiologic and laboratory evidence have
implicated Culex pipiens (Meegan et al, 1980).
The identity of the possible arthropod vector as well as the vertebrate reservoir
which serve to maintain the virus in the absence of epizootics is still uncertain
(Peters and Le Due, 1991), Attempts to implicate rodents, primates, birds, game
animals and reptiles as the predominant maintenance reservoir host have been
largely unsuccessful (Davies, 1975; Davies and Addy, 1979; Mclntosh and Jupp,
1981~ Swanepoel, 1981; Swanepoel et al, 1978).
An alternative to vertebrate reservoir hosts could be the maintenance of the virus
by transovarial transmission in insect vectors (Alexander, 1957; Meegan et al,
1980). This would explain the dormancy of the virus over several years when
rainfall is low and the sudden outbreaks in livestock during years of excess
rainfall and large mosquito populations. In Kenya, transovarial transmission of
RVFV has been reported for Aedes mcintoshi (Linthicum et al, 1985), but despite
extensive studies undertaken in South Africa, the results have been inconclusive
(Gargan et al, 1988; Jupp, pers comm),
1.1.2 RVFV pathogenesis, diagnosis and control
RVFV is pathogenic for sheep, cattle, goats, mice, rats and hamsters. The
natural disease in domestic ruminants causes abortions and many deaths in
pregnant and newborn animals (Davies, 1975; Scott et al, 1956). RVF infection
may also affect buffalo, camels and antelopes (Easterday, 1965; Gear et al, 1955).
In susceptible animals, the liver is the primary site of viral replication and the
characteristic lesion is focal liver necrosis (Easterday et al, 1962; Erasmus and
Coetzer, 1981).
The virus multiplies readily in both suckling and weaned mice following
intracranial (i.c.), intraperitoneal (i.p.), or subcutaneous injection, causing death
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within four days (Peters and Meegan, 1981). While the virus is a predominantly
hepatotropic pathogen, it has a latent neurotropic attribute (Kitchen, 1950).
Unlike virulent RVFV isolates, neurotropic strains of RVFV obtained by
numerous serial intracerebral passages in mice do not kill mice after i.p.
inoculations, but will do so if inoculated i.c. (Smithburn, 1949; Weinbren es al,
1957).
Man is susceptible to RVF virus infection via the bite of infected mosquitoes and
exposure to aerosols or infected tissues. Human infection is usually a self-
limiting, acute febrile disease, but in some cases severe complications such as
haemorrhagic fever, encephalitis and retinal lesions ensue (Laughlin et al, 1979;
Meegan et al, 1981; Van Velden et al, 1977).
The virus can be readily isolated in suckling and adult mice, hamsters (Anderson
et al, 1989; Weiss, 1957) and Vero or Aedes pseudoscutellaris cells (D.igoutte et
al, 1989). An alternative, approach to virus isolation is the detection of circulating
viral antigen in serum by enzyme-linked immunoassay (ELISA) (Meegan et al,
1989) or immunoperoxidase demonstration of antigen in fixed liver tissue (Arborio
and Hall, 1989).
Demonstration of RVFV specific IgM antibodies in acute phase sera can be
performed using an IgM capture ELISA (Soliman et al, 1988), indirect fluorescent
antibody (IFA) assay (Swanepoel et al, 1976) or a solid-phase immunosorbent
technique (SPfn (Soliman et al, 1988). If paired sera are available, serologic
diagnosis by haemagglutination-inhibition (HI), complement-fixation (CP) or
neutralization is also possible (Swanepoel et al, 1976).
Control of RVF infection is necessary to limit spread of the disease and prevent
the possible dissemination of the virus outside Africa (Shope et al, 1982). One
approach is that of mosquito control by ultra low volume spraying of chemical
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pesticides to reduce populations of adult mosquitoes (Meegan, 1979).
Nevertheless, such measures are of little practical use in widespread epizootics
(Shope, 1985).
A more effective approach to preventing spread of RVF is that of immunization
of domestic animals (Assaad et al, 1.983; Rossi and Turell, 1988; Shope et al,
1982). Several vaccines against RVF for veterinary use are currently available.
A live attenuated vaccine for sheep and cattle was originally developed by
Smithburn by neuroadaptation to mice (Smithburn, 1949). Some years later, a
live veterinary vaccine derived from the Smithburn neurotropic strain was
prepared in South Africa at the Onderstepoort Veterinary Research Laboratory
(Randall et al, 1962). These vaccine strains are efficacious and inexpensive, and
have played a major role in limiting epizootic disease in countries such as South
Africa and Kenya (Shope et al, 1982). However, since these vaccines may cause
abortions and have shown changes in mouse virulence under certain circumstances
(Coetzer and Barnard, 1977; Shimshany and Barzilai, 1983), they are not
recommended for use in unaffected enzootic areas (Shope et al, 1982).
In addition to the live attenuated vaccines, inactivated tissue culture vaccines
(Barnard, 1979) are produced in South Africa and Kenya. These are safe and
induce antibodies in sheep and cattle in a high percentage of recipients, but
require frequent boosting (Barnard, 1979),
Several formalin-inactivated monkey cell culture vaccines are also available for
humans at high-risk (Meadors et al, 1986; Niklasson, 1982; Randall et al, 19ij2;
1964), While these vaccines appear to offer good protection, annual booster
injections are needed to maintain detectable antibody levels (Eddy et al, 1981;
Niklasson, 1982). Unfortunately, these vaccines are expensive to produce and
available in limited supply, so that widespread use in Africa is not feasible. An
experimental RVF vaccine candidate has since been developed by passaging a
5
human isolate in tissue culture under the influence of the mutagen 5-fiuor(mraGil
(Caplan et al, 1985). This mutant virus variant (MV P12) is currently being
evaluated for use as a live attenuated vaccine (Hubbard et al, 1991; Morril et al,
1991; Saiuzzo and Smith, 1990; Turell and Rossi, 1991).
1.2 Properties of RVl?V
1.2.1 Classification, morphology and physicochemical properties
RVFV is a member of the genus Phlebovirus of the family Bunyaviridae (Bishop
et al, 1980). The 45 members of the phlebotomus fever serogroup (Peters and
Le Due, 1991) have similar morphological, physical and biochemical properties
(Bishop et al, 1980; Elliot, 1990; Murphy et al, 1973; Rice et al, 1980).
Morpho», _ cally, the viruses are lipid-enveloped spherical structures typically 90-
120 nm in diameter (Ellis et al, 1988). Associated with the RVFV envelope are
two structural glycoprcteins, G1 and G2 (Coilett et al, 1985), which are present
in equivalent numbers on the virus surface (Robeson et al, 1979). By electron
microscopy, these appear as a fringe of regularly arranged spikes measuring 10··
18 nm in length (Ellis et al, 1988; Martin et al, 1985). In addition to the two
external glycoproteins G1 and G2, there are two internal proteins, the N
(nucleocapsid) and L (transcriptase component) proteins (Bishop and Shope,
1979). The virus has a single-stranded RNA genome consisting of three segments
(Bishop et al, 1980; Collett et al, 1985). Each virus particle contains three
nucleocapsids corresponding to the three RNA segments, and containing the RNA,
the N protein, and the L protein in a supercoiled fashion (Obijeski et at, 1976).
The central nucleocapsid structure in turn incorporates the internal ends of the
estimated 350-375 glycoprotein spikes, as well as ribosomes (Ellis et al, 1988).
The physical and chemical properties of RVFV are similar to the other members
of the phlebovirus genus (Bishop et al, 1980; Rice et al, 1980). A sedimentation
coefficient of 450 S, as well as an additional slower sedimenting 156 S infectious
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particle has been reported for RVFV (Polson and Levitt, 1963). The buoyant
density of RVFV is 1,21 g/ml in caesium chloride gradients (Rice et al, 1980).
The virus, like other phleboviruses, is destroyed easily by heati- 6 at 56°C, is
inactivated by acidic pH and is also sensitive to lipid solve.its and detergents
(cited in Calisher, 1991).
1.2.2 Molecular and antigenic characteristics
The three RNA segments comprising the RVFV genome are designated L
(2,7 x 106d), M (1,38 x 106d) , and S (0,6 x 106d) (Collett et al, 1985; Rice et
al, 1980). The corresponding sediment coefficients of the RNA are ~7-31 S for
the L segment, 22-26 S for the M and 16-20 S for the S (Bishop et a., 1980).
The viral envelope glycoproteins Gland G2 are coded for by the M segment, the
expression of which has been studied in detail (Collett et al, 1985; Kakach et al,
1988; Suzich and Collett, 1988). It consists of 3884 nucleotides and has a single,
major open reading frame in the viral complementary-sense RNA (Collett et al,
1985; Takehara et al, 1989). The regions coding for the start of the mature G2
and Gl polypeptides are located at the codons corresponding to positions 481 and
2092 respectively (Collett et al, 1985). ThJJs the alignment of the protein-coding
information with respect to the genomic M RNA is (3')-G2-Gl-(5') (Collett et al,
1985; Ihara et al, 1985). The expression strategy employed by the RVFV M
segment is complex, not only involving multiple translational initiation events, but
distinct bios vnthetic pathways for the two major viral glycoproteins G1 and G2
(Suzich et al, 1990).
In addition to the structural glycoproteins Gl and G2, two other proteins are
encoded by the M gene : a glycosylated 78K and a non-glycosylated 14K NSm
protein (Kakach et al, 1988). All four proteins can be detected in RVF virus-
infected cells (Kakach et al, 1988; Wasmoen et al, 1988). The 78K protein
probably represents an unprocessed polyprotein of NSm and G2 sequences, while
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the 14K protein contains pre-G2 sequences (Kakach et al, 1988; Suzich and
Collett, 1988). The significance of these nonstructural proteins is not known, but
they are apparently not required for synthesis or processing of mature G2 or G 1
(Kakach et al, 1988; Suzich and Collett, 1988; Takehara et al, 1990; Wasmoen
et al, 1988). All the M segment gene products have a high cysteine content,
suggesting that extensive disulphide bridge formation may occur (Collett et al,
1985; Ihara et ai, 1985).
The S segment RNA encodes the viral nucleocapsid protein (1\:·16-28 K) in the
viral complementary sense RNA, and a non structural protein, NSs (29-31 K) in
the virion-sense RNA (Parker et al, 1984). The latter is a phosphorylated protein
which is synthesized early in infection (Smith et al, 1990). While the function of
the NSs protein in virus replication is not yet known, studies have suggested that
this protein carries protective determinants and that an altered NSs can result in
significant virus attenuation (Dreier et al, 1990).
Little information is available regarding the L segment of RVFV. It is, however,
believed to contain information coding for the viral transcriptase or L protein and
to employ a negative-sense coding strategy (Suzich et al, 1990) as has been
substantiated experimentally for some bunyaviruses (Endres et al, 1989).
As has been shown for other members of the Bunyaviridae family (Bishop and
Shope, 1979), the segmented nature of the RVFV genome allows the rapid
generation of virus reassortments when multiple strains of RVFV infect the same
cell in vitro or in vivo (Saluzzo and Smith, 1990; Turell et al, 1990). These
reassortant viruses presumably have the potential to be transmitted in nature,
thereby possibly providing a mechanism for increased heterogeneity (Turell et al,
1990).
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1.2.3 Morphogenesis
The early events in the infection process of RVFV and other Bunyavuidae
members are not well defined (Schmaljohn and ...'atterson, 1990). Several viruses
in the Bunyaviridae family appear to fuse infected cells at low pH values
(Arikawa et al, 1985; Gonzalez-Scarano, 1985; Gonzalez-Scarano et al, 1984)
suggesting an entry pathway involving endocytosis into acidic intracellular vesicles
(lHarsh, 1984; Marsh and Helenius, 1980; 1989). While direct evidence for this
process with RVFV has not yet been obtained (Schmaljohn and Patterson, 1990),
by electron microscopy RVP viral particles appear to enter cells in phagocytic
vacuoles (Ellis et al, 1988), which is consistent with the endocytic mode of entry
(Marsh and Helenius, 1980). The mildly acidic pH in the endosornal
compartment (Tycko and Maxfield, 1982) then triggers virus-cell membrane
fusion, resulting in the release of the nucleocapsid into the cytoplasm and the
initiation of .he replication process (Lenard and Miller, 1982; Lentz, 1990;
Marsh, 1984; Marsh and Helenius, 1989; Matlin et al, 1981; White et al, 1983).
The first sign of replication of RVFV within an infected host cell. is the
appearance in the nucleus of a fibrillar rod containing viral antigen (Ellis et at,
1988; Swanepoel and Blackburn, 1977). Viral components aggregate next in the
cytoplasm to form cores which bud into vacuoles to assemble mature particles
(Ellis et al, 1988). The site of virus maturation and intracellular transport of
RVFV membrane proteins varies as a function of both the cell type and strain of
virus (Anderson and Smith, 1987). RVFV replication in hepatocytes, for
example, is associated with maturation at cellular surface membranes in addition
to the smooth internal membranes of the Golgi and endoplasmic reticulum
cbserved in other cell types (Anderson and Smith, 1987).
Virus release is believed to be both by rupture of cells and fusion of particle-
containing vacuoles with the plasma membrane and subsequent egestion (Murphy
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et al, 1973). A single cycle of RVFV replication in Vero cell cultures is
complete in about 13 hours (Ellis et al, 1988).
1.3 Envelope glycoproteins Gl and G2
1.3.1 Functional role and antigenic properties
Knc , "edge of the structural, functional and antigenic properties of the viral
envelope proteins is an essential requirement for the understanding of virus
infection at both the molecular level and the host immune response to infection
(Keegan and Collett) 1986; Parsonson and Mcl'hee, 1985).
Studies on the function of the G 1. and G2 structural proteins of several members
of the Bunyaviridae family have shown that they play a critical role in viral
infection and pathogenesis and elicit neutralizing and haemagglutination ...inhibition
antibodies (Ankawa et al, 1989; Dantas et al, 1986; Kingsford and Hill, 1981;
1983; Pifat et al, 1988). One or both surface glycoprotein spikes appear to be
involved in virus attachment and possibly penetration and subsequent virus
replication in a susceptible host cell (Gonzalez-Scarano et al, 1982; Ludwig et at,
1989; 1991).
1.3.2 Analysis of viral epitopes by monoclonal antibodler
The antigenic reactivity of viruses represents their capacity to undergo specific
binding with antibodies and cellular receptors, and resides in restricted parts of
the viral surface (Crumpton, 1974; Milton and Van Regenmortel, 1979; Van
Regenmortel and Neurath, 1985; Westhof et al, 1984) These antigenic
determinants or epitopes possess a three-dimensional structure complementary to
that of the binding site of the antibody molecule. The binding site in turn is
composed of a series of hypervariable loops forming a cleft at the distal end of
the Fab regions of the immunoglobulin molecule (reviewed in Capra and Kehoe,
1975; Hasemann and Capra, 1989), Recent X-ray crystallographic studies have
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revealed that the antibody binding site is able to accommodate protein epitopes
consisting of about 15-22 amino acid residues (reviewed in Laver et al, 1990).
Antigenic sites. have beer. broadly divided into two categories ie "sequential" or
"conformational" depending on whether their specificities rely on the amino acid
sequence only, or on the conformation of the whole protein (Atassi, 1980;
Crumpton, 1974; Sela, 1969). A more recently held concept is that all
determinants recognized by antibodies are conformational, in that antibodies will
bind with measurable affinity only to those molecules presenting in the right
conformation (reviewed in Laver et al, 1990). Conformational determinants may
be continuous or discontinuous (Atassi and Smith, 1978). In the former, all the
residues in contact with the antibody are contained within a single segment of the
amino acid sequence of the antigen. Discontinuous sites, on the other hand, are
composed of distantly located amino acid sequences which are brought together
by folding of the polypeptide chain (Atassi and Smith, 1978). Both non-covalent
interactions as well covalent bonds, such as disulphide bridges, play important
roles in maintaining protein conformation (cited in Berzofsky and Berkower,
1989; Crumpton, 1974).
Since the accessibility of any individual antigenic determinant on the antigenic
molecule is necessary for its interaction with either antibodies or specific cell
receptors (Arnon, 1985), many epitopes can be localized to those parts of the
protein that are on the outer surface of the folded molecule (Atassi, 1978; Nowak
and Wengler, 1987; Westhof et al, 1984). The antigenic epitopes of viral
envelope proteins, for instance, are often associated with hydrophilic protein
domains, particularly regions of the folded polypeptide chain that jut out, such as
loops, carboxy termini, and turns between helices (Atassi, 1978; Eisenberg et al,
1985; Nowak and Wengler, 1987; Pellet et al, 1985; Westhof et al, 1984).
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The localization of epitopes in the sequence of the viral proteins has been
accomplished experimentally by using a number of methods (reviewed in
Berzofsky and Berkower, 1989; Carter and ter Meulen, 1984; Heinz, 1986;
Horsfall et al, 1991). Continuous antigenic sites have been identified and mapped
by binding of antibodies to cleavage fragments and short synthetic pep tides from
the protein sequence (Ball et al, 1992; Eisenberg et al, 1985). To map
discontinuous topographic sites, more complex approaches have been necessary
(Burnens et al, 1987; Geysen et al, 1987a; Horsfall et al, 1991; Jemmerson and
Paterson, 1986). These include the mapping of epitopes by the selection of virus
variants (Carter and ter Meulen, 1984; Pellet et al, 1985), by chemical
modification of free and antibody-bound protein antigen (Burnens et al, 1987) and
by proteolysis of antigen-antibody complexes (Jemmerson and Paterson, 1986).
An alternative has been to use the 'rnimotope' strategy (Geysen et al, 1987a).
In addition to the experimental approaches, continuous antigenic determinants
have also been predicted by computer analysis using programmes that provide
information on the hydrophilicity, surface probability, flexibility and antigenicity
index of the amino-acid sequence in the viral polypeptide chain (Becker, 1990;
1992). The putative antigenic domains have then been compared with the
experimentally reported domains for the envelope glycoproteins of several viruses
(Becker y 1990; 1992). Crystallographic studies of the three- dimensional structure
of proteins have permitted the complete structure of epitopes to be defined
(reviewed by Laver et al, 1990).
Fine analysis of the antigenic structures of viral proteins (Heinz, 1986; Roehrig
et al, 1982) has been made possible by the development of hybridoma technology
by Kohler and Milstein (1975; 19.6). These somatic hybridization techniques
allow the production of cell lines that continuously synthesize monoclonal
antibodies (MAbs) of uniform specifity. The use of such chemically
homogeneous antibodies which react with constant avidity to single antigenic
12
determinants thus permits exquisite analysis of epitope/antibody interactions
(Carter and ter Meulen, 1984).
By means of MAbs, specific viral epitopes involved in biological functions such
as neutralization and haemagglutination can be identified, and the topological
relationship of the epitopes L0 each other on the sur ice of the molecule can be
examined (Heinz, 1986; Stone and Nowinski, 1980; Yewdell and Gerhard, 1981).
Analysis '''If the spatial arrangement of the antigenic sites can he achieved by a
competitive binding assay (CBA) using an ELISA or radioimmunoassay (;-feinz,
1986; Stone and Nowinski, 1980), although selection of virus variants can also
be used (Carter and ter Meulen, 1984; Pellet et at, 1985).
Since MAbs are capable of detecting differences of one amino acid, it is possible
to identify structural alteration in the target molecule (Carter and ter Meulen,
1984) and perform a precise analysis 01: intervirus relationships at both the
structural and biological levels (Massey and Schochetman, 1985; Roehrig et al,
1983). Defined MAbs also have the potential for the assessment and production
control of modern vaccine manufacturing (Heinz, 1986).
MAbs have been used to identify physical and functional antigenic domains within
the envelope glycoproteins of several members of the Bunyavirid .~ family
(Arikawa et al, 1989; Vantas et al, 1986; Gonzalez-Scarano et al, 1982;
Kingsford et al, 1983; Najjar et al, 1985) including the phlebovirus Punta Toro
(pifat et al 19R5).
The structural topography of the surface glycoproteins of several of these viruses
has been examined using MAbs in competitive binding assays. Epitope mapping
studies on La Crosse virus (LACV) have for example revealed the presence of
eight antigenic regions on the G1 glycoprotein (Kingsford et al, 1983). In the
study by Arikawa et al (1989), nine distinct, partially-overlapping antigenic sites,
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two on G1 and seven on G2, were demonstrated for Hantaan virus. Monoclonal
antibodies reactive with the Punta Toro G1protein were shown to bind to epitopes
in two distinct topological sites (Pifat et al, 1988).
Functional antigenic domains involved in virus neutralization and
haemagglutination have furthermore been identified on the envelope glycoproteins
of these viruses. MAbs have revealed that virus neutralization sites were located
on the G1 protein of La Crosse virus (Gonzalez-Scarano et al, 1982; Grady et al,
1983; Kingsford et al, 1983), G1 and G2 proteins of Hantaan virus (Arikawa et
al, 1989; Dantas et at, 1986) and Punta Toro virus (pifat et al, 1988). With the
exception of Hantaan virus (Arikawa et al, 1989), most of the glycoprotein
epitopes with neutralizing activity were also found to be involved in viral
haemagglutination. Some of these antibodies were moreover shown to be capable
(If passive protection from lethal virus infection (Pifat et al, 1988; Schmaljohn et
al, 1990).
1.3.3 RVFV monoclonal antibodies
RVFV MAbs prepared against the Egyptian ZH501 RVF isolate (cited in Battles
and Dalrymple, 1988) and the Entebbe strain (Meegan et at, 1983) have been
useful in defining a limited number of the glycoprotein antigenic determinants
(Keegan and Collett, 1986) and identifying several epitopes involved in virus
neutralization (Collett et al, 1987; Schmaljohn et al, 1989). In the study by
Keegan and Sollett (1986), three neutralizing sites on G2 of the ZH501 strain
were identified and the corresponding gene coding assignments were defined.
Antibodies directed against the G2 protein have furthermore been shown to be
capable of passive protection in mouse studies (cited in Battles and Dalrymple,
1988),
RVFV Mabs produced against the glycoproteins and the nucleocapsid protein
have also been used to examine possible antigenic variation amongst strains
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isolated from Egypt, Central Africa and J ~;adagascar (Meegan et al, 1983;
Morvan, pers comm; Saluzzo et al, 1989 a; b). These have shown that Zinga
virus is a strain of RVFV (Meegan ei at, 1983) and are able to distinguish
between virus strains collected in Egypt and sub-Saharan Africa (Saluzzo et al,
1989a; b). MAbs have also been generated against the nVFV NSs protein in
order to assess the function and antigenic structure of this non structural protein
(Smith et al, 1990). The findings have revealed that the NSs protein appears to
be highly conserved antigenically among RVFV strains isolated from various
regions in Africa.
MAbs have furthermore provided the opportunity to examine the potential of
segment reassortment to serve as a mechanism for generating genetic diversity
among RVF viruses. In a recent study the origin of the Sand M RNA segments
of reassortment viruses was determined using MAbs capable of differentiating the
nucleocapsid protein (S segment marker) or the G 1 (M marker) of the parental
RVFV strains (Turell et al, 1990). The antigenic analysis of reassortment viruses
generated from the attenuated RVFV MV P12 candidate vaccine strain and a wild
strain isolated in Senegal has also been performed using these MAbs (Saluzzo .nd
Smith, 1990). Several G1 and G2-specific MAbs have also been used to study
the candidate MV P12 vaccine strain by examining the properties of baculovirus-
expressed RVFV glycoproteins synthesized in insect cells (Takehara et al, 1990).
1.4 Scope of this study
The RVFV envelope glycoproteins G1 and 02 playa critical role in viral
infection and pathogenesis. The structural, functional and antigenic properties of
the surface glycoproteins, however, have not been fully characterized. There is
little published data, for example, on the actual antigenic determinants responsible
for eliciting RVFV neutralizing, haemagglutination-inhibition and protective
antibodies, particularly for the G1 protein.
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In order to gain a better understanding of the tole of the RVF viral surface
proteins in infection and neutralization, the objectives of the present study will be
to analyse the antigenic structure and function of these proteins using monoclonal
antibodies.
The research proposals are thus to:
1) Generate a panel of MAbs to the RVFV G1 and G2 glycoproteins and use
them to identify functional epitopes on the viral proteins.
2) Analyse the structure of the glycoproteins by mapping the antigenic sites
and examining the conformation of the epitopes.
3) Correlate the epitope specificities with functional activities,
4) Analyse the mechanisms of antibody-mediated neutralization of the virus.
5) Examine the role of the glycoprotein epitopes in virus attachment and
penetration into the host cell.
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2. MONOCLONAL ANTmODY PRODUCTION
AND CHARACTERIZATION
2.1 Introduction
Fine analysis of the antigenic determinants of viral proteins (Roehrig et at, 1982)
'is possible using hybridoma technology (Kohler and Milstein, 1975; 1976) which
allows the production of cell lines that continuously synthesize antibodies of
uniform specificity. By means of these somatic cell hybridization techniques,
immunocompetent lymphocytes are rendered 'immortal' ~y fusion with myeloma
cella. The latter are plasmacytoma cell lines which have for example been
selected to lack the enzyme hypoxanthine guanosine "Ii '1sy1 transferase.
Such mutants cannot grow in medium containing; en1,' supplemented
with hypoxanthine and thymidine (HAT "'1erium) (I.. .u...rield, 1964) because they
are unable to utilize the salvage pathway, Hybrids between the myeloma cells and
spleen cells can be select-:' from the parental components as the only cells that
actively multiply in HAT selective medium. The antiaodies produced by the
resulting cell hybrid (hybridoma) clones are b, definition monocional antibodies
(MAbs) and are, in effect, homogeneous immunological reagents of defined
specificity, avidity, high specific activity and selected isotype (Nowinski et al,
1983), These MAbs react with constant avidity to single antigenic determinants,
thereby permitting exquisite analysis of viral epitope/antibody interactions and
antigenic structure in the target molecule (Carter and ter Meulen, 1984; Heinz,
1986).
In recent years RVFV MAbs have been prepared against the Entebbe and the
Eg: ptian ZH501 strains (Meegan et al, 1983; Smith, cited in Battles and
Dalrymple, 1988), These have been useful in defining a limited number of the
envelope glycoprotein antigenic determinants (Collett et al, 1987; Keegan and
Collett, 1986; Schmaljohn et al, 1989). However, unlike Punta Toro virus, a
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related phlebovirus, a, comprehensive study using MAbs to analyse the antigenic
determinants of the RVFV surface glycoproteins has not been undertaken to date,
Accordingly, it is intended to study the RVFV envelope glycoproteins by
generating a panel of MAbs against the South African 1830 strain of RVFV and
identifying functional epitopes. The latter will be determined on the basis of
reactivity of the M~6...bs in haemagglutination-inhibition, neutralization and
complement fixation tests. The possibility that certain of the RVFV epitopes are
more conserved tha= others will be examined by determining the cross-reactivity
of the MAbs with another member of the phlebovirus genus. The antibodies will
also be tested for their ability to protect otherwise lethally infected mice.
2.2 Materials and Methods
2.2.1 Virus
2.2.1.1 Preparation of stock virus
Stocks of RVFV for use in the various serological assays and for the preparation
of purified virus were grown in Vero cells. Monolayers of the cells in 150 em'
flasks (eel-Cult, Sterilin Ltd., U.K.) were inoculated with 2 ml of the South
African prototype RVF strain AN 1830 (tissue culture passage 2, mouse passage
6) and incubated at 37°C for 1 h to allow adsorption to take place. The inoculum
was then removed, and replaced with Earle's minimrm essential medium
(EMEM) containing 2% foetal calf serum (FCS) and 0,3% gentamicin. The
flasks were reincubated at 37°C and the supernatant harvested when the cells
showed advanced cytopathic effect (CPE). The medium was clarified by
centrifugation at 3000 rpm for 8 min in a Beckman J2-21 centrifuge at 4°C. The
resulting supernatant was amped out and stored at -70°C.
The titre of each batch of stock virus was subsequently determined by titration in
flat-bottomed 96 well micro titre plates (AtS Nunc, Roskilde, Denmark). Serial
ten-fold dilutions of the virus were prepared in Leibovitz-Ic medium
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supplemented with 5% FCS and 0,3% gentamicin. Volumes ofO,l ml virus were
added to the wells of the micro titre plates in quadruplicate. An additional 0,1 ml
Leibovitz medium was added to each well, followed by 3 x 104 Vero cells per
well in 0,025 ml medium. The plates were incubated in a humidified container
at 37°C and on the sixth day examined for CPE. The viral titre was calculated
using the Karber method as described by Hawkes (1979).
2.2.1.2 Purification of RVFV and glycoprotein isolation
RVFV was propagated in Vero cell monolayers as described above and harvested
2-3 days post-infection at maximum CPE. The supernatant fluids were clarified
at 7000 g for 30 min at 4°C in a Beckman J2-21 centrifuge. The clarified
supernatant was precipitated with polyethylene glycol 6000 (PEG) by the addition
of 7,5% (w/v) PEG and 2,5% (w/v) NaC1 and held at 4°C overnight. Following
centrifugation at 10 000 g for 1 h at 4°C the resulting pellets were resuspended
in TNE buffer (O,OIM Tris; 0,1M NaCl; 0,001M EDTA pH 7,2). These were
clarified at 5000 rpm for 15 min at 4°C and the cleared supernatants layered over
a discontinuous CsCI gradient consisting of 2 ml of 35% (w/w) CsCI and 3 ml
of 20% (w/w) CsCI in TNE buffer. The tubes were spun at 15°C for 16 h at
35 000 rpm (155000 g) in a Beckman L8-60M ultracentrifuge using a SW40 Ti
rotor. The visible viral band was harvested and dialysed extensively against TNE
buffer at 4°C. The protein concentration of the purified virus was determined
spectrophotometrically at 280 nm.
The method used to extract the RVFV glycoproteins was based on that of Pifat
et al (1988). Firstly, RVFV was grown and PEG-precipitated as above. Purified
glycoprotein preparations were obtained by disruption of the virus supernatants
with an equal volume of 2% (v/v) Nonidet P40 in TNE for 20 min at room
temperature (rt). The lysate was layered over a discontinuous CsC! gradient and
centrifuged as described above. The supernatant fractions containing Gl and G2
were harvested and dialysed against TNE at 4°C. The extracted glycoprotein
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preparation was then concentrated by ultrafiltration using immersible CX-lO
ultrafiltration units (Millipore Corp., Bedford, U.S.A.) and the protein
concentration determined spectrophotometrically.
2.2.:2 Production of monoclonal antibodies
2.2.2.1 Cells
a) Myeloma cells
The FO-clone of SP2/0 (Fazekas de st. Groth and Scheidegger, 1980) was
obtained from ATCC (U,S.A.). The cells were grown in standard medium
consisting of RPMI-1640 with 15% foetal calf serum, O,OOlM sodium pyruvate,
0,0375% sodium bicarbonate, 0,05% of O,lM 2-mercaptoethanol, 0,01 %
amphotericin B and antibiotics. For the selective medium, 50 x hypoxanthine
aminopterin thymidine ~lIAT) and hypoxanthine thymidine (RT) concentrates
(Flow Laboratories, Irvine, U.K.) were added to give a final concentration of 1%.
Care was taken to maintain the myeloma cultures in an exponential growth phase
so as to optimize the amount of fusion competent cells. As the FO myeloma line
has a doubling rate of 8,7 h (Fazekas de st. Groth and Scheidegger, 1980), this
entailed subculturing the cells almost daily.
b) Immune spleen cells
Balb/e mice were immunized by intraperitoneal (i.p.) inoculation of 0,5 ml of a
10-1suspension of beta-proprio lactone inactivated RVF 1830 mouse brain antigen.
Three days later the inoculation was repeated using inactivated virus, and on days
13 and 18 the mice were boosted i.p, with live virus. After a further ten days,
the mice were given 0~05 ml of purified glycoprotein preparation (17 mg/rnl) plus
0,2 ml i.p. for two successive days. Spleens were removed three days later for
fusion.
20
c) Peritoneal macrophages
Adult mice were killed and the abdominal skin removed aseptically. Five ml of
a 11,6% sterile sucrose solution was injected peritoneally, the abdomen gently
massaged and the fluid withdrawn. The cells were collected in 15 ml
polypropylene tubes (Falcon, Becton Dickinson and Co., Oxnard, U.S.A.), spun
down at 1000 rpm in a Beckman TJ~6 bench top centrifuge and resuspended in
HAT media to yield 6 x l()4/ml macrophages.
2.2.2.2 Cell fusion
The method for production and maintenance of monoclonal antibodies was based
On that of Fazekas de St. Groth and Scheidegger (1980).
A. On the day before fusion:
i) Myeloma cells
Myeloma cultures were subcultured to ensure that the cells were ill a logarithmic
growth phase for fusion the following day.
ii) Pr.eparation of microcultures
0, l:5 ml freshly prepared HAT-medium was added to the wells of six microtitre
tissue culture plates (A/S Nunc, Roskilde, Denmark). Macrophages were
prepared as described above and 0,05 ml drops were distributed in the microtitre
wells. The plates were incubated in a humidified container at 37°C.
B. On the day of fusion
i) Preparation of parental cells for fusion
a) Myeloma cells
Myeloma cells were harvested and pelleted in 50 ml centrifuge tubes at 1000 rpm
for 7 min. The resulting pellets were pooled, topped up to 50 ml with saline
(Dulbecco buffer with 0,28% glucose pH 7,2) and an aliquot mixed with Trypan
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blue and counted to determine that the viability was greater than 90% • The
remaining cells were spun down again and resuspended in saline at a
concentration of 107 cells/ml.
b) Spleen cells
The spleens from two hyperimmune mice were removed under sterile conditions
and carefully washed in saline. Using forceps, the spleen cells were gently teased
into 10 ml saline and transferred to a 15 ml centrifuge tube. The cells were
dispersed by pipetting and the remaining clumps and pieces of connective tissue
allowed to sediment for 10 min. The supernatant was transferred to a 50 ml
centrifuge tube, topped up with saline and spun for 7 min at 1000 rpm. The cell
pellet was taken up in saline, counted in Turck's solution and adjusted to a
concentration of 108 cells/mI.
ii) Fusion
Five ml myeloma cell suspension was combined with 3 ml spleen cell suspension
in a 50 ml centrifuge tube and saline added to a final volume of 50 rnl. The
suspension was centrifuged at 1000 rpm for 7 min, the supernatant carefully
tipped off and the pellet loosened by flicking the bottom of the tube. One ml
polyethylene glycol fusing solution (PEG-4000; Merck Chemicals, Hohenbrunn,
Germany) was added over 1 min under constant agitation of the tube. The tube
was then immersed for 1 min in a 37°C water bath, keeping the contents swirling
all the time. The fusion was stopped by slowly adding 20 ml saline, 1 mlover
the first 30 sec, 3 ml over the next 30 sec and the rest over the second minute.
The mixture was topped up with saline, allowed to stand 5 min and then spun as
before. The saline supernatant was replaced with standard medium and the
solution centrifuged again. The cell pellet was recovered and resuspended in 30
m1HAT-medium by gentle pipetting. 0,05 rnl drops were distributed in the wells
of the microtitre plates prepared the previous day, and the plates returned to the
humidified container at 37°C.
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On the six,' day after fusion, approximately 50% of the supernatant fluid from
each well was removed and replaced with fresh HAT-medium. Feeding of the
cultures was subsequently carried out every second day. The plates were
inspected daily from the sixth day and growing colonies were transferred to new
96 well plates containing freshly prepared macrophages before they were screened
for the presence of RVFV antibodies. This was done to exclude detecting any
antibodies in the supernatants which may have been excreted by the spleen
lymphocytes prior to their death shortly after plating out. The hybridoma colonies
were scored as follows: >50 cells = 1+; 50 to 500 cells = 2+; 500 to 1000
= 3+; > 1000 = 4+. An aliquot of the supernatant fluid of wells containing
3+ and 4+ sized colonies was removed for screening for antibody secretion by
ELISA and indirect immunofluorescent antibody assay.
2.2.2.3 Detection of positive clones
a) ELISA
In order to screen for hybridomas excreting antibodies specifically directed against
the RVFV glycoproteins, an ELISA using extracted glycoprotein (2.2.1.2) as the
capture antigen was developed. The optimal concentration of viral glycoprotein
for use as the solid phase antigen was first established. This was achieved by
preparing a starting dilution of 1:50 of the antigen in carbonate-bicarbonate buffer
pH 9,6 (Appendix A). Serial two-fold dilutions of the viral antigen were then
prepared in polystyrene microtitre ELISA plates (Nunc - Immuno II AIS, Nunc,
Roskilde, Denmark). Following overnight incubation at 4°C, the plates were
washed three times with phosphate buffered saline (PBS) containing 0,01 %
Tween-20 using an automated microplate washer (Bio-Tek Instruments, Flow
Laboratories, Irvine, U,K.) The wells were then blocked with 0,2 ml of 4%
bovine serum albumin (BSA) in PBS for 30 min at room temperature. After
washing as before, 0,1. ml volumes of RVFV hyperimmune ascitic fluid diluted
1.:1000 ~nELISA diluent (PBS with 5% foetal calf serum) were added to the wells
in duplicate. Controls included RVFV hyperimmune ascitic fluid in wells without
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antigen, antigen coated wells without antibody, and antigen coated wells with the
hybridoma supernatant from a MAb prepared against West Nile virus (Besselaar
and Blackburn, 1988). Following incubation for 1 h at 37°C, the plates were
washed again and incubated with a 1:1000 dilution of peroxidase conjugated anti-
mouse immunoglobulins (Zymed Laboratories Inc., San Francisco, C.A., U.S.A.)
in ELISA diluent for a further hour at 37°C. ABTS substrate (Kirkegaard and
Perry Laboratories, Gaithersburg, U.S.A.) was added after washing and optical
densities (O.D.) were measured at 405 nm with a Titertek multiscan apparatus
(Flow Laboratories, Irvine, U.K.).
The supernatants of the hybridoma cultures were screened using plates which had
been coated with the predetermined optimal dilution of glycoprotein extract
(8,5 J.tg/well) and blocked with BSA as above. The hybridoma supernatants were
added to the wells in duplicate (0,1 ml/well) and incubated for 1 h at 31°C. The
plates were 'washed three times, and incubated with peroxidase conjugated anti-
mouse immunoglobulins for 1 h, followed by ABTS substrate as described above.
b) Indirect immunofluorescence antibody assay (IFA)
Colonies positive by ELISA for excretion of antibodies directed against the RVFV
glycoproteins were then tested by Il-A as a confirmatory assay using 8-well
multitest slides (Flow Laboratories) with RVFV infected cells. The slides were
prepared earlier as follows: Vero cells were infected with RVF 1830 tissue
culture passage two or three (TC2 or 3) at an input multiplicity of .0,1 - 1 and
harvested when early signs of cytopathic effect (CPE) vident, The cells
were adjusted to 1,5 x 106/ml and mixed in d 1:3 ratio with urunfected cells. The
cell suspensions were spotted onto the Slides, air dried, theft fixed with acetone
and stored at -'lOoe until use. Immunofluorescence tests were carried out by
incubating slides with neat hybridorna culture fluids for 2 h at 37°C. The slides
were then washed in PBS and treated with affinity purified anti-mouse
immunoglobulin conjugated with fluorescein isothioeyanate (Zymed Laboratories),
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After a further 30 min incubation at 37°C, the slides were washed, mounted with
glycerol and viewed with a Nikon HFX-ll Optiphot ultra-violet microscope.
2.2.2.4 Clontag and expansion
Hybridoma colonies excreting antibodies specific for the RVFV glycoproteins
were cloned by limiting dilution by preparing 10-\ 10-2, and 10-3 dilutions of the
cells in HAT-selective medium. Drops (0,05 ml) of the resulting cell suspensions
were then distributed in a number of wells in a 24 well tissue culture plate
(Costar, Cambridge, MA, U.S.A.) each containing 1 ml medium and 2 x 104
macrophages, The medium was replaced every third day until the secondary
colonies were large enough to be retested by ELISA. Those colonies producing
RVF antibodies were transferred to six well tissue culture plates and later to 15
ml tissue culture flasks (25 cur', Costar). The medium was changed to HT-
selective medium at this stage as the aminopterin was no longer necessary since
the only surviving cells were the myeloma-lymphocyte hybridomas, The cells
were expanded by passaging them firstly into 75 em' and later into 150 crrr'
flasks, and used to prepare both frozen stocks of hybridoma clones and
monoclonal antibody-rich ascitic fluid.
Frozen stocks were prepared as fol1ows: the hybridoma cells were harvested, spun
down and adjusted to a concentration of 107/ml in standard media containing 10%
dimethylsulphoxide. The cell suspensions were aliquoted in 1 ml volumes and
frozen down slowly by cooling first at 4°C for 1 h, then storing at ·7' 'S
overnight before transferring them to liquid nitrogen (N2).
2.2.2.5 Production of ascitic fluid
Balb/c mice were injected i.p. with 0,5 ml Pristane (2,6,10,14-
tetramethylpentadecane; Sigma Chemicals, St. Louis, Mo, U.S.A.) as this is
essential for ascites formation (Brodeur et al, 1984). Two weeks after priming,
the mice were injected i..p. with lOS hybridoma cells which corresponded to the
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optimum number of hybrid cells for ascitic fluid production as determined
previously (Besselaar and Blackburn, 1988). Ten to fourteen days later, the
ascitic fluid was aseptically collected and clarified at 3000 rpm for 15 min. The
fluid was stored at 4 °C overnight, then spun at 7000 g for 30 min in a Beckman
J2-21 centrifuge and the supernatant aliquoted and frozen at -700C,
The initial batch of fluid was produced using cloned hybrid cells which had not
yet been frozen down. For subsequent batches, hybridoma stocks stored in liquid
N2 were thawed quickly, resuspended in standard RPMI medium supplemented
with 5% macrophage extract and grown in 25 ern" flasks. The macrophage
extract was produced by culturing peritoneal macrophages in standard media with
5% FCS in a 150 em" flask and harvesting the supernatant fluid after seven days.
This was then passed through sterile 22 /-tIn Millex OS filter unit (Millipore
Corp., Bedford, U.S.A.) and stored at -70°C as a stock of growth enhancing
medium. The hybridoma cells were passaged once or twice until suff eient viable
cells for inoculation into mice were reached.
2.2.3 Characterization of l\1Ahs
2.2.3.1 Isotyping of monoclonal antibodies
Th-: J.lonoAb-lD ErA kit (Zymed) was used for isotype determination of the
mcnoclonal antibodies. ELISA plates (Nunc Immuno II) were coated with goat
anti-mouse antibody (lOJtg/ml) in coating buffer (PH 9,6) at 4°C overnight. The
wells were washed with PBS-Tween and blocked with 0,2 mllwell of PBS
containing 0,5% bovine serum albumin at 37°C for 1 h. After washing the
plates, 0)05 ml of hybridorna culture supernatants were added to each of 6 wells
and incubated at 37°C for 1 h. The wells were again washed and 0,05 ml of
subclass-specific rabbit anti-mouse immunoglobulins or normal rabbit serum were
added to each of the 6 wells. After incubation at 37°C for 1 h, the plates were
washed thoroughly and 0,05 nil/well of alkaline phosphatase-labelled anti-rabbit
immunoglobulins was added. The plates were incubated at 37°C for 1 11,washed
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as before and 0,1 ml of p-nitrophenyl phosphate substrate solution dispensed in
the wells. The colour reaction was monitored for 2 h and positive results were
read quantitively at 405 nm,
2.2.3.2 Radlolmmune precipitation assay (RIPA)
a) Preparation of radiolabeUed intrilcellular virus induced proteins
Specificity of the monoclonal antibodies war determined by RIPA using detergent
extracts of infected cells. Vero cells in 75 ern' tissue culture flasks were infected
at a multiplicity of infection of 1-10 and incubated in serum-free Eagle's
minimum essential medium with Earle's salts (EMEM). At 3 h post-infection the
medium in each flask was replaced with 8 ml methionine-deficient EMEM (Flow
Laboratories) for 1 h, followed by the addition of L-r~sS] methionine (20ILCi/mi,
sp.act. 1000 Ci. mmol; Amersham Int., U.K.) for ~-20 h post-infection at 37<?C.
Mock infected cultures were labelled in the same way. After discarding the
supernatant, the cells were scraped off using a disposable cell scraper (Costar,
MA, U.S.A.), resuspended in cold PBS and transferred to centrifuge tubes. The
cells were washed three times by spinning at 1000 rpm for 8 min and the final
cell pellet used for immunoprecipitation.
b) Immulloprecipitation
The labelled cell pellets were resuspended in NET/BSA buffer (0,15M NaCl,
0,005M EDTA, 0,05M Tris-Hel pH 7,4; 5% Nonidet P40; 1 mg/rnl BSA) at a
concentration of 1 x lOS cells/ml. Following incubation on ice for 30 min, nuclei
were removed by centrifugation at 3000 rpm for 15 min. The supernatants were
made 0,1% (w/v) with respect to SDS, disrupted with a probe sonicator and
clarified by centrifugation at 15000 rpm (18000 g) for 30 min.
Immunoprecipitation was performed by adding 50 ILlof the required monoclonal
immune ascitic fluid to a 1 ml aliquot of the clarified radiolabelled supernatants.
The virus-antibody mixtures were incubated for 4-6 h rt.
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Protein A-Sepharose CL-4B beads (Pharmacia, Uppsala, Sweden) were
resuspended in NET -BSA buffer and added to each mixture at 10 mg/ml for 2 h
at rt, followed by 4 °C overnight. The immune complex was collected by
centrifugation and washed five times with NET-BSA buffer. The bead pellet was
solubilized by treatment with dissociation buffer (Appendix B) and heated at
!OO°C for 5 min. The beads were pelleted at 1000 rpm for 10 min, the sample
buffer recovered and stored at -70°C until analysis by PAGE.
c) Polyacrylamide gel electrophoresis (PAGE)
The immunoprecipitated viral proteins were analysed on linear 12%
polyacrylamide gels essentially by the method of Smith and Brown (1977). PAGE
was performed in 1,5 mm thick slab gels using a 4% stacking gel and a 12%
resolving gel in the 'Iris-glycine buffer system of T .aemmli (1970) (Appendix B).
In both the stacking and resolving gels, diallyltartardiamide (DATD, Sigma
Chemicals, St. Louis, Mo, U.S.A.) was used as a cross-linker instead of
bisacrylamide to achieve better resolution of the Gl and G2 proteins. Protein
molecular weight determinations were made by running 14C-methylated protein
molecular weight standards (Amersham, U.K.) on the same gel. The marker
proteins were: myosin, 200 kilodaltons (K); phosphorylase b, 100 and 92,5 K;
BSA, 69 K; ovalbumin, 46 K; carbonic anhydrase, 30 K and lysozyme, 14,3 K.
The gels were electrophoresed at 16 mA for 16 h at 4°C treated with Amplify
(Amersham, U.K.) for 30 min and the separated ;noteins visualized by
autoradiography (Appendix B).
2.2.3.3 Serological tests
a) ELISA titres
The titres of the MAbs in the ELISA were determined by preparing serial loglo
dilutions of the ascitic fluids and testing these for reactivity against purified
glycoprotein antigen as described in 2.2.2.3 (a). The reactivity of the MAbs
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against purified whole virus was also examined using purified virus (2.2.1.2) at
a predetermined optimal dilution as the solid phase antigen.
b) Indirect immunof1uoresc~nce antibody QFA) titres
Indirect fluorescent antibody titres were assessed by titrating the MAb ascitic
fluids in serial two-fold steps on multitest slides against RVFV infected Vero cells
as described in section 2.2.2.3 (b).
c) Haemagglutination-inhibition test
The haemagglutination-inhibition (HI) test used was a micro-adaption (Swanepoel
et al, 1986) of the technique of Clarke and Casals (1958). For the
haemagglutination titration, sucrose-acetone extracted RVFV antigen was
reconstituted at a 1:10 dilution in borate buffered saline (BBS), pH 9,0. Serial
two-fold dilutions were made in 0,025 ml volumes of BBS containing 0,4%
bovine albumin (BABS diluent) in micro titre plates (Linbro Division, Flow
Laboratories Inc., Hamden, Conn., U.S.A.). Goose erythrocyte suspensions
containing 10% cells were diluted 1:30 in phosphate adjusting diluents to yield the
predetermined optimal pH for the antigen and 0,05 ml volumes were added to
each well. The plates were read after 30 min to determine the antigen dilution
containing 4 units of haemagglutinin (HA) per 0,025 ml volume.
For the HI test, serial two-fold dilutions of extracted monoclonal immune ascitic
fluids were prepared in 0,025 ml volumes of BABS diluent from 1:10. Equal
volumes of antigen containing four HA units were added to each well. After
overnight incubation at 4 ()C, 0,05 ml volumes of goose erythrocyte suspensions
were added to all wells to yield the final optimal pH for the antigen. In addition
to cell and antigen controls, ascitic fluid controls were included to ensure that the
test specimens were free of nonspecific agglutinins. Haemagglutination-inhibition
titres were recorded as the highest dilutions of monoclonal ascitic fluids which
caused complete inhibition of haemagglutination.
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d) Complement fixation teSt
The complement fixation (CF) method followed was adapted from Bradstreet and
Taylor (1962), using 0,025 ml volumes in microtitre plates (Linbro Division,
Flow Laboratories). Rabbit haemolytic serum (Wellcome Reagents Ltd.,
Beokenham, U.K.) and guinea pig complement were standardized for use in the
test by checkerboard titration. The optimal dilution of RVFV antigen was
determined by chessboard titration against RVPV hyperimmune ascitic fluid
(HAP).
The hybridoma-induced ascitic fluids were diluted 1:4 in verona! buffered saline
(VBS) diluent, pH 7,2 and inactivated at 56cC for 30 min. Doubling dilutions of
the monoclonal immune ascitic fluids were prepared in 0,025 ml VOIU'11~~Sof VBS
in round-bottomed microtitre plates. Equal volumes of complement and antigen
were added and the tests left overnight at 4°C. The following day the pJates we.e
incubated at 37°C for 30 min, then one volume of 2% sensitised sheep
erythrocytes was added to each well. The plates were incubated at 3rC for 30
min, shaking after 15 min. The complement fixation titre of each monoclonal
antibody was recorded as the highest dilution which produced complete fixation
of complement. Controls for all reagents and test specimens were included in
each test.
e) Cytopathic effect neutralization test (CPENT)
The CPENT tests were based on the technique of Swanepoel et al (1986) using
flat-bottomed tissue culture microtitre plates (Sterilin), Two-fold dilutions of the
hybridoma-induced ascitic fluids were prepared in quadruplicate in the plates with
Leibovitz-If medium supplemented with 5% )C~. Uqu~l volumes of virus
containing 100 tissue culture infective dosesj, (100 TCIDso) as determined by
previous titration were added to each well and the plates incubated for 1 h at
37°C before seeding with 3 x 104 Vero cells per well. A concurrent titration of
the virus was performed to est.ablish that the test dose actually contained the
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calculated infective dose. The plates were incubated in a humidified container at
37PC and examined after 4 days for ability of the monoclonal antibodies to inhibit
cytopathic effect of the virus. Final readings were made on the sixth day and end
points recorded as the mean reciprocal of the highest dlutions which prevented
cytopathic effect. Complement-enhanced neutralization was determined by the
addition of 5% guinea pig serum as a source of complement to the virns-antibedy
preparat 1S prior to the 1 h incubation step.
f) Plaque reduction neutralization test (PRNT)
Assays were performed in duplicate on Vero cell monolayers in 24 well tissue
culture plates (Costar) essentially as described by Swanepoel et al (1986), The
wells were seeded with 2 x lOSVero cells in Leibovitz medium with 5% FCS,
incubated in a humidified container at 37°C and the monolayers used 24 h later.
Serial four-fold dilutions of heat-inactivated hybridoma ascitic fluids were
prepared in sterile tubes in the Leibovitz medium. An equal volume of virus
containing a calculated 80 plaque forming units (PFU) per 0,05 ml, was added to
each tube and the MAb-virus mixtures incubated for 2 h at 37°C. Medium was
removed from the monolayers and 0,1 ml of each mixture added to each well and
allowed to adsorb for 1 hat rt. The cells were then overlaid with Hanks-based
minimum essential amino acid medium (!IMEM) containing agarose at a final
concentration of 0,5% and 2% FCS. The cultures were incubated at 37°C for
two days, then st.ained with agarose overlay medium containing neutral ted at a
1:5000 dilution. Plaques were counted after a further 24 h incubation and MAb
neutralizing titres were recorded as the reciprocals of the highest dilutions which
produced an 80% reduction in the number of plaques relative to the virus
controls. The effect of complement CC') on the MAb neutralization titres was
investigated by adding guinea-pig serum at a 1:40 final dilution to the MAb-virus
mixtures prior to incubating and staining as above.
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2.2.3.4 MAb cross-reactivity
To assess whether the MAbs were cross-reactive with another member of the
phlebovirus genus, the hybridoma ascitic fluids were also tested by the indirect
immunofluorescence and HI assays against Gordil vi:v..s. For the
immunofluorescence tests, Vero cells infected with Gordil virus at mouse passage
11 and tissue culture passage 2 were used to prepare multitest slides as described
in 2.2.2.3b. The !FA assays were carried out with the RVF hybridoma ascitic
fluids at a 1:100 dilution in PBS. The HI tests were performed with sucrose-
acetone extracted Gordil virus antigen using the method outlined in section
2.2.3.3c.
2.2.3.5 Passive protection studies
The in vivo protective ability of the MAbs against RVFV was assayed in four
week old mice. The virus used in these experiments was stock tissue culture
virus (2.2.1.1) with a titre of 107/m1. In order to determine the LDso (50%
mortality endpoint) for mice, serial ten-fold dilutions of the stock virus were
prepared in serum-free EMEM. Groups of four mice were inoculated
intraperitoneally (i.p.) with 0,2 ml volumes of each virus dilution ranging from
10-3 to 10-6• The mice were monitored for three weeks and euthanased when
moribund. The LDso was calculated using the Karber method as described by
Hawkes (1979). The plaque forming units (PFU) were subsequently determined
for the virus dilution which corresponded to lOLDso by plaque assay as described
earlier (2.2.3.3 f).
For the protection studies, monoclonal antibody ascitic fluids were diluted 1:2 in
EMEM and 0,2 m1 volumes were inoculated i.p. into groups of five mice.
Twenty-four hours later, mice were challenged i.p. with lOLDso (360 PFU) of the
stock RVF virus diluted in EMEM while controls received virus only. The mice
were observed for three weeks as outlined above. Statistical significance of the
difference in the time of death between the test and control groups was assessed
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by the Student's t-test. The level of minimal significance was calculated using
both p <O~05 and p <0,01.
2.3 Results
2.3.1 Production of M..Abs
Screening of the hybridomas was performed by ELISA using the viral
glycoprotein at a dilution of 1:200 for the capture antigen. This corresponded to
the highest dilution which gave maximum absorbance (Table 1) and represented
a protein concentration of 8,5 ~g/well. By the screening ELISA, 23/273 (8,4%)
hybridoma clones were found to be excreting antibodies specifically against the
glycoprotein antigens. Six of these exhibited weak reactivity, but were confirmed
by means of the IFA test.
While a1123 hybridomas were successfully cloned and frozen stocks prepared, the
viability of the hybridomas varied considerably on resuscitation from liquid
nitrogen. Growth of the cells was greatly promoted by the addition of freshly
prepared macrophages or 5% macrophage extract. All 23 clones appeared to be
stable as they remained positive for RVFV antibody excretion.
Table 1. Titration of RVFV glycoprotein for use as capture antigen in ELISA
Antigen dilution! Optical density (405 nm)
50 2.000
100 2.000
200 2.000
400 1.757
800 1.254
1600 0.795
NoAg 0.054
I Dilutions expressed as reciprocals
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2.3.2 Characterization of MAbs
2.3.2.1 Determination of immunoglobulin isotype
The immunoglobulin subclasses of the 23 MAbs are shown in Table 2. The
majority of the antibodies were of the IgG 1 subclass.
Table 2. Immunoglobulin subclass of MAbs
MAb Subclass
3E5, 5E1, 3D2, 3Rl, 4B3, 5AI, IgG1
9E4, 5A6, 9C4, 7F2, 8C2, 7Fl,
4DlO, 8E6, 6ElO,5C12
5Ell, 8A3, 5E9, 8G2 IgG2a
5F2 IgG2b
1E4,8GlO IgM
i--.
2.3.2.2 Determination. of MAb speciflcity
The optimum period for radiolabelling the infected cells for the detection of the
virus-specific proteins by polyacrylamide gel electrophoresis (PAGE) was
investigated by labelling at various times post-infection (p.i.). Labelling for the
period 4-20 h poi. was found to be the most suitable and was used in subsequent
immunoprecipitation experiments,
By SDS-PAGE, polypeptides of the following molecular weights were detected
from infected cell .ystates which had been immunoprecipitated with RVFV
hyperimmune ascitic fluid: 65K, 56K, and 26K (Fig, 1 lane 2), The apparent
molecular weights of these bands correspond to the known weights for RVFV G1,
G2 and NC proteins respectively. The fact that similar polypeptides were not
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Fig.I. Immunoprecipitation of r:5S] methionine-labelled RVFV -specific proteins
by selected MAbs. Proteins were electrophoresed on a 12% SDS-polyacrylamide
gel. Lane 1, 14C molecular weight markers (Amersham); lane 2, RVFV-infected
ce111ysate immunoprecipitated with RVP polyclonal hyperimmune ascitic fluid;
lane 3, MAb 4B3; lane 4, MAb 3R1; lane 5, MAb 5EI; lane 6, MAb 3E5; lane
7, MAb 802.
detected in the uninfected cell controls (data not shown) indicates that these
proteins were indeed virus-specific.
The specificity of the MAbs is shown in Table 3. Fourteen of the MAbs
precipitated the G1 protein while the remaining nine were specific for the 02
protein. Examples ale shown in Fig. 1 (lanes 3-7). While the 02 polypeptide
was easily visible when immunoprecipitated by the polyclonal hyperimmune
ascitic fluid, the intensity of the G2 band when precipitated by the MAbs was
very weak. By increasing the concentration of the 35S label from 10 to 50 ftCilml
ann increasing the exposure time, the 02 band was detectable but still weak.
Table 3. Specificity of the RVFV MAbs as determined by the
radioimmune precipitation assay
MAb Specificity
3E5, SE1, 3D2, 3Rl, 4B3, 5Al, 01
9E4, 5Ell, 8A3, 5E9, 5F2, 5A6,
lE4,801O
9C4, 8G2, 7F2, 8C2, 7Fl, 4DlO, 02
8E6, 6EI0, 5C12
2.3.2.3 Serological reactivities
a) Enzyme-l1Lnked immunosorbent assay (ELISA) titres
Table 4 shows the results of the reactivity of the MAbs in the ELISA using either
purified whole RVFV or the extracted glycoprotein preparation as capture antigen.
The titre of most of the MAbs against the extracted glycoprotein antigen was one
to two logs higher than against the whole virus,
b) Indirect imm mofluorescence antibody titres
IFA titres of hybridoma ascitic fluids ranged from 1:1024 to 1:128 000 (Table 4).
For each individual MAb, the titres of different batches of ascitic fluids remained
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Table 4. Reactivity of the RVFV MAbs by indirect immunofluorescence
and ELISA
MAb Specificity !FA titre' ELISA titre?
Purified virus Glycoprotein
3ES G1 64 000 105 106
SEI G1 16000 104 105
3D2 G1 64000 105 107
3R1 Gl 32000 107 103
4B3 G1 128000 105 106
5A1 Gl 64000 106 107
9E4 Gl 8000 105 106
5Ell G1 16000 105 106
8A? Gl 32000 lOS 107
5E9 G1 64 000 104 106
5F2 G1 4096 103 105
SA6 G1 1024 103 104
lE4 Gl 16000 103 103
8G10 G1 64000 103 105
9C4 G2 128000 105 106
8G2 G2 64 000 105 106
7F2 G2 32000 105 105
8e2 G2 32000 104 105
7F1 G2 64000 105 106
"
4D10 G2 64000 104
I
106
8E6 G2 32000 1Q4 106
6ElO 02 4096 103 1tY
5C12 G2 64000 103 103
"".,...._ .........._---. --I-t~ -
1 Titres expressed as dilution reciprocals
2 Titres expressed as - loglOdilution reciprocals
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relatively constant. Differences in the intensity of the fluorescence induced by the
various MAbs were evident i.e. while the majority exhibited strong fluorescence,
several displayed a weaker intensity of fluorescence (5C12 and 5A6).
c) Haemagglutination-inhibition and complement-fixation activities
The biological activities of the MAbs in various serological tests are shown in
Table 5. Nine of the Gl-specific MAbs and four of the G2-r~.active MAbs
.displayed haemagglutination-inhibition (HI) activity, with titres ranging from weak
(1:20) to very strong (1:81920).
In the complement-fixation test, only four Gl- and G2-specific MAbs were
reactive. MAb 8A3 exhibited the highest activity, with a titre of 1:1024.
d) Neutralizing activities
Two MAbs (,E5 and 9C4) were able to neutralize RVFV in the CPENT (Table
5). Many of the others, however, appeared to delay the appearance of CPE and
were therefore tested by the more sensitive PRNT (Table 6). These assays
revealed that nine of the anti-G 1 MAbs neutralizeAi the virus in vitro in the
absence of C', with MAb 3E5 exhibiting the highest neutralization titre. When
C' was added, the majority of these antibodies neutralized to higher titres;
furthermore the remaining five non-neutralizing MAbs showed low level
neutralizing activity.
With regard to the G2-specific MAbs, three were able to neutralize the virus in
vitro without Ct. Of these, MAb 9C4 was strongly neutralizing whereas MAb
7F2 and 8G2 were much weaker. In the presence of C' the remaining anti-G2
MAbs, with the exception of MAb 5C12, were, able to neutralize at a low level.
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Table 5, Haemagglutination-inhibition, neutralizing and complement fixation
activities of the RVFV MAbs
.
I.
.....'#_~ IMAb Specificity HI CPENT CF-~
3E5 01 25601 4096 -
5E1 G1 - - -
3D2 G1 10240 - -
3R1 G1 81920 - -
4B3 G1 40960 - -
SAl G1 81920 - -
9134. G1 10240 - -
SEll G1 - - -
8A3 G1 - - 1024
5E9 G1 5 120 - 32
5F2 G1 - - -
5A6 G1 - - -
1E4 G1 5 120 - 512
8010 G1 10240 - -
9C4 G2 40960 1 024 -
8G2 G2 160 - 8
7F2 G2 40 - -
8C2 G2 - - -
7F1 G2 20 - -
4DlO G2 - - -
8E6 G2 - - -
6E10 G2 - - -
5C12 02 - .. -
1 Titres expressed as dilution reciprocals
39
Table 6. Neutralizing activity of the RVFV MAbs by the plaque reduction
neutralization tI.•Jt (PRNT)
MAb Specificity PRNT PRNT + C' ._
3E5 Gl 327681 262 144
5El G1 - 512
r
3D2 G1 32 256
3R1 G1 1024 16384
4B3 01 4096 8 192
5Al 01 1024 4096
9FA 01 128 2048
5Ell Gl - 128
8A3 G1 - 256
5E9 G1 1024 2048
5F2 G1 - 512
5A6 G1 - 512
lE4 G1 4096 524288
8GI0 G1 4096 16384
9C4 G2 8 192 65536
8G2 02 32 1024
7F2 G2 256 256
8C2 G2 ,. 128
7F1 02 - 128
4DlO G2 - 32
8E6 G2 - 128
6ElO G2 - 32
5C12 G2 - -....,
1 Titres expressed as dilution reciprocals
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2.3.2.4 MAb cross-reactivity
The results of the reactivity of the MAbs with Gordil virus by indirect
immunofluorescence are shown in Table 7. Three of the MAbs directed against
the G1 protein ie 4B3, 5AI and 9E4 reacted strongly; while the remaining
antibodies displayed weak or no reactivity.
With regard to the HI test using Gordil virus antigen, only the three Gl-specific
MAbs which fluoresced strongly against Gordil virus by IFA exhibited
haemagglutination-inhibition activity (Table 8). For each of these antibodies, the
HI titres against Gordil virus were lower than those for RVFV.
2.3.2.5 Passive protection
From the initial virus titration in mice it was established that a dilution of 104,5
of this particular batch of RVFV :,ielded the 50% mortality dose (LD50). The
lOLDso (10.3,5) used in the subsequent protection studies in turn corresponded to
360 PFU.
Due to constraints imposed by the University's Animal Ethics Committee, it was
not possible to test the in-vivo protective ability of all the MAbs. Instead, those
MAbs which exhibited the highest in-vitro ne1J'iralizing activity were examined,
as well as several non-neutralizing antibodies.
The Gl-reactive MAb 3E5, which exhibited the highest in-vitro neutralization
activity, provided complete protection from lethal RVF infection (Table 9).
Another G l-specific MAb which possessed a relatively high in-vitro neutralizing
titre, (MAb 3R1), protected 60% of the animals.
In the case of the MAbs specific for the G2 protein, MAb 9C4, a strong in...vitro
neutralizing antibody, provided complete protection from infection while MAb
7F1 protected 60% of the mice.
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Two other MAbs, 8A3 and 8G2, specific for G1 and G2 respectively,
significantly prolonged the mean survival time of the infected animals at the 99%
confidence level. The remaining antibodies tested were not able to significantly
delay death even at the 95% confidence level.
42
Table 7. Reactivity of MAbs with Gordil virus by indirect immunofluorescence
MAb RVFV AN l830 Gordil virus
3E5 + -
5El + -
3D2 + ±1
3Hl + ±
4B3 + +
5Al + +
9E4 + +
5Ell + -
8A3 + ±
5£9 + -
5F2 + -
5A6 ± +
1E4 + -
8G10 + -
9C4 + ±
8G2 + -
7F2 + ±
8C2 + ±
7F1 + ±
4DlO + ±
8E6 + ±
6ElO + -
5C12 ± ±
± = weak immunofluorescence
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Table 8, Haemagglutination-inhibition activity of the RVFV MAbs with Gordil
virus
MAb Specificity RVFV 1830 Gordil virus'"-r----"
3E5 G1 2560 -
3D2 G1 10 240 -
3Hl Gl 81920 -
4B3 Gl 40960 1280
SAl 01 81 920 5 120
9E4 G1 10240 1280
1E4 G1 5 120 -
8GlO I 01 10240 -
9C4 G2 40960 -
802 02 160 -
7F2 02 40 -
7F1 G2 20 -
"'","?i_
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Table 9. Protection of mice from infection with RVFV1 by passive administration
ofMAbs
MAb Specificity No.of survivors/ Mean day p3
No. tested of death'
"
Expt 1
NoMAb 0/5 3.2
3E5 G1 5/5 _4 < 0.01
5E1 01 0/5 2.8 > 0.05
9C4 G2 5/5 - < 0.01
71'''. G2 0/5 4.4 > 0.05
EX1.2t 2
NoMAb 015 2.8
(
lE4 G1 1/5 4.6 > 0.05
3H1 G1 3/5 8.8 < 0.01
7Fl G2 3/5 8.4 < 0.01
Expt;2
NoMAb 0/5 2.02
4B3 G1 015 4.2 > 0.05
8A3 G1 2/5 7.4 < 0.01
~G2 G2 2/5 7.D < 0.01 I_.
1 Virus 10LDso (360 PFU)
2 Mice euthanased when moribund
3 P values for the difference in death time between each test group and the
control group assessed by Students t-test
4 All animals survived > 21 days
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2.4 Discussion
The successful generation of hybridomas excreting specific monoclonal antibodies
depends on many factors, each of which plays a critical role at the various stases
of production (Fazekas de St. Groth and Scheidegger, 1980; GalfnS and Milstein,
1981; Lane, 1985; Oxford, 1982; Reading, 1982; Sinkovics and Dreesman, 1983;
Westerwoudt, 1985). The main factors, influencing the production of the RVFV
MAbs will firstly be discussed, and thereafter the characterization of the
antibodies with respect to their antigen s,},I_cificityand biological activities.
The first step for efficient production of Mab-secreting hybridomas generally
requires that the donor animal be well immunized against the antigen of irrerest
(Lane, 1985). Both virus-infected mouse brain and purified virus as antigen have
been used to elicit hybridomas specific for members of the Bunyaviridae family
(Arikawa et al, 1989; Gonzalez-Scarano et al, 1982; Pifat et al, 1988). Since in
the present study it was necessary ~ . tain a large number of MAbs directed
against the glycoproteins relative to .ghly immunogenic nucleocapsid protein,
a purified glycoprotei., preparation was the immunogen of choice. Extraction of
the glycoproteins from the RVF virion was performed using mild nonionic
detergent lysis since antigens prepared this way should not expose the epitopes
buried within the secondary or tertiary structures of the protein (Roehrig et al,
1982).
One reason for the success of the actual immunization protocol followed for
generating the RVFV hybridornas probably lay in scheduling two final booster
doses four and three days before explantation of the spleens, thus improving on
the single booster which reportedly increases the amount of hybridomas that
secrete antibody against the immunizing virus (Prabhakar et at, 1984; Sander and
Dietzgen, 1984), Another factor of paramount importance is choice of the parent
myeloma cell line for hybridization with the immune B lymphocytes since the
stability of the resrltiug hyLdds h in part determined by the myeloma cell type
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(Reading, 1982). The Fo myeloma cells, a fast-growing mutant clone of the
SP 2/0 line (Fazekas de st. Groth and Scheidegger, 1980) were chosen for the
production of the RVFV hybridomas as they have been shown to generate hybrids
which are more stable than those from the x63 Ag.8.653 line (Besselaar and
Blackburn, 1988).
One of the factors which is extremely crucial at the stage of cell fusion is the
exposure period of the cells to the fusing agent polyethylene glycol (Fazekas de
St. Groth and Scheidegger, 1980; Lane et al, 1986). A shorter fusion period than
the 90 seconds advocated by Fazekas de St. Groth and Scheidegger (1980) was
used here since exposure times longer than one minute appeared to have a
detrimental effect upon the fusion efficiency, possibly due to an increased
sensitivity of the newly formed hybrids to the cytotoxic effects of this chemical
(Lane, 1985).
Another critical step in the procedure for generating MAbs is the screening of
hybr.idoma cultures for those hybrids secreting the desired antibodies. Since
screening represents the stage C'''' hybridoma production which is extremely labour
intensive, an assay that is both rapid and sensitive is required so that an
immediate decision can be made as to whether or not to clone the hybridoma
(Goding, 1980), The choice of assay can moreover greatly affect the selection of
antibodies with different specificities (Prabhakar et at, 1984), Screening of the
RVFV antibody secreting clones by ELISA utilizing extracted glycoprotein as
antigen not only permitted the detection of MAbs specific for the envelope
proteins, but was rapid to perform. The confirmatory screening test by indirect
immunofluorescence, on the other hand, was particularly valuable for those MAbs
which reacted weakly in the ELISA.
In order to avoid contamination of the antibody-secreting hybridomas with clones
producing no globulin, it is advisable not to aim for a high multiplicity of hybrids
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in the fusion cups (Fazekas de St. Groth and Scheidegger, 1980). Since the
precursor parental cells forming hybrids are independently distributed throughout
the wells, the number of hybrids per well follow the Poisson distribution, thereby
allowing the lowest number of parental cells required to form hybrids to be
calculated (Cianfriglia et al, 1986). As the number of hybridomas formed
depends on the number of spleen cells and not on the number of myeloma cells,
the multiplicity of spleen cells used for fusion is critical (Westerwoudt, 1985;
1986). It is thus sound strategy to follow a method such as that of Fazekas de
St.Groth and Scheidegger (1980) where the spleen cell input (2,5 x lOs/well) has
been calculated to ensure that positive cultures arise predominantly from single
hybrids. This eliminates the need for stringent cloning. In most instances,
cloning one", by limiting dilution was found to be adequate for the RVFV
hybridomas, thereby having the added advantage of saving time, material and the
risk of contamination associated with increased cell manipulation.
During the stage of expansion of the RVF hybrid clones, one of the problems
experienced was that of fungal and yeast contamination of the cultures. Although
contamination of this kind is difficult to confinedue to the rapid spread of spores,
the inclusion of 0,8 mcg/ml Amphotericin B (Fungizone, Squibb, Princeton, NJ,
U.S.A.) in the culture medium helped to contain it without exerting any toxic
effects on the cells.
Another difficulty encountered at this stage was that of poor cell growth of some
hybrid clones. As has been reported by others (Fazekas de St. Groth and
Scheidegger, 1980; Galfre and Milstein, 1981; Prabhakar et al, 1984; Sanders and
Dietzgen, 1984; Sugasawara et al, 1985) the presence of either a peritoneal
macrophage feeder layer or macrophage conditioned medium greatly promoted
hybridoma cell growth. This was particularly evident for a few clones where, in
the absence of macrophages, a very low perc-entage of the original antibody-
secreting cells were recovered upon resuscitation from liquid nitrogen. This
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enhancing effect of the macrophages has been suggested to be due in part to the
production of monokines which are growth supporting for the hybridomas
(Reading, 1982; Westerwoudt, 1986).
With regard to the characterization of the MAbs, knowledge of antibody isotype
is important for the interpretation of various immunological assays such as binding
to protein A or complement, and for antibody competition (By et al, 1978;
Kronvall and Williams, 1969; Yewdell and Gerhard, 1981). Since, for example,
irimunoglobullns of IgGl subclass bind poorly to protein A (By et al, 1978;
Kronvall and Williams, 1969) it was necessary to "arm" the protein A with anti-
mouse immunoglobulin in the RIPA to ensure that it would react with the RVFV
MAbs of this isotype.
A major problem experienced during determination of the specificity of the MAbs
by the RIPA was that of poor labelling of the RVFV G2 protein. This
phenomenon has been reported by others for various Bunyaviridae (Bishop and
Shope, 1979; Gonzalez-Scarano et al, 1982). The weak reaction with G2 may
have been due to low affinity of the antibodies (Yolken, 1982), although it is
unlikely that all nine anti-G2 MAbs would possess similar poor antigen-binding
activity. A more probable explanation is that the poor reactivity could be due to
lack of stable antigen binding under the conditions of the assay (Fernie et al,
1982). MAbs are often sensitive to minor conformation changes (Carter and ter
Meulen, 1984; Lussenhop et al, 1988; Niesters et al, 1987) and consequently may
be adversely affected in the RIPA where the detergents necessary to prevent non-
specific contamination of the precipitate have some destabilizing effect on protein
structure (Yewdell and Gerhard, 1981).
The possibility that certain of the epitopes defined by these MAbs were more
conserved than others was examined by determining the cross-reactivity of the
antibodies with Gordil virus. The latter was chosen as it represents an African
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phlebovirus (Tesh et ai, 1976) which exhibits an antigenic relationship with
RVFVas established by various serological tests with RVF convalescent sera and
reference antisera (Shope et al, 1980; 1981; Swancpoel et at, 1986; Tesh et al,
1982). The strong reactivity of three of the G1-specific MAbs with Gordil virus
indicates that the antigenic determinants defined by these antibodies are not
specific for RVFV, but may be highly conserved in some other members of the
phlebovirus genus.
Examination of the serological reactivities of the RVFV MAbs revealed that some
MAbs directed against both G1 and G2 were capable of neutralizing virus in the
absence of C'. This suggests that their epitope specificities are localized to sites
which contribute to the role of the glycoproteins in virus infectivity. Of interest
was the fact that all the neutralizing sites identified by these antibodies also
demonstrated haemagglutination activity (RA). While several neutralizing
epitopes have been identified in ~_,'·:.erstudies on RVFV (Collett ei al, 1987;
Schmaljohn et al, 1989) no data regarding the HA of these antigenic sites has
been published. The findings here are similar to those reported to the phlebovirus
Punta Toro, where all except one of the neutralizing MAbs also had
haemagglutinarion-inhibition activity (Pifat et al, 1988). The close correlation of
neutralizing and HA responses stro.igly suggests that the RVFV Gl and G2
domains Which bind to erythrocytes also bind to receptors on virus-susceptible
cells in culture.
In addition to C'-enhanced virus neutralization exhibited by these in vitro
neutralizing antibodies, the majority of the non-neutralizing RVFV MAbs were
also able to neutralize virus in the presence of C'. C'-enbanced and C'-dependent
virus neutralization by MAbs is a well-documented phenomenon (Holland et al,
1983; Kimuro-Kuroda and Yashui, 1983; McCullough, 1986; Russell et al, 1983).
Both RVFV IgG and IgM subclass l\1Abs exhibited increased neutralization when
C' was added. In the case of IgG antibodies, C' may function together with
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immune IgG to lyze (Oldstone, 1974; Oroszlan and Gilden, 1970), aggregate
(Oldstone et al, 1974) or coat viruses (Linscott and Levinson, 1969), resulting in
destruction or inactivation. IgM also binds C' under certain conditions (Feinstein
et al, 1986). The addition of C' plus anti-viral IgM to the nairovirus Dugbe, for
example, increased neutralization 16-fo1d (Armstrong et al, 1990). It is possible
that those MAbs which are dependent on C' for neutralization cannot alone induce
sufficient conformational changes in the virus to effect neutralization
(McCullough, 1986).
The passive immunization studies clearly demonstrate that antibodies to individual
epitopes on both the RVFV G1 and G2 proteins can provide protection to
otherwise lethally infected mice, indicating that both envelope proteins play an
important role in virus infectivity and pathogenesis. This finding is of particular
interest since previously only anti-G2 or a mixture of anti-Gl and G2 antibodies
had been shown to be protective in vivo (Battles and Dalrymple, 1988).
Of the four MAbs capable of protecting mice from lethal RVFV infection to
varying degrees, three were also able to neutralize in vitro. The remaining
antibody (7F1) was, however, non-neutralizing in. vitro. A similar finding has
been shown for several other viruses (Boere et al, 1985; Schmaljohn et at, 1982).
A number of possible explanations for in-vivo protection by non-neutralizing
MAbs are apparent, including complement-dependent lysis or antibody-dependent,
cell-mediated lysis of virus infected cells (Boere ei al, 1985; Lefraccois, 1984;
Schmaljohn et al, 1982). Since MAb 7Fl was of the IgGl subclass, the
underlying mechan! sm for this phenomenon is unlikely to be C'<dependent
cytolysis (Spiegelberg, 1974). Similarly, enhanced uptake of virus in non-
permissive macrophages is not probable, as this is most likely to be mediated by
IgG2a subclass antibodies (Boere et al, 1985). The 7F1 antibody may instead
protect by inhibition of virus maturation (Boere et al, 1985) or antibody-dependent
cell mediated cytotoxicity (Stanley et al, 1986).
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In addition to the four MAbs that were able to protect at least 60% of the infected
animals, two other antibodies significantly prolonged the mean survival time of
the mice. The Gl-specific MAb 8A3 was non-neutralizing in vitro 'while the anti-
G2 MAb 802 exhibited very low level neutralizing activity in the absence of C'.
Since the in vitro neutralizing activity of both antibodies was potentiated by C',
the underlying mechanism for the prolonged survival time could be Ct-dependent
cytolysis mediated by the non-neutralizing antibodies as suggested by Schmaljohn
et al (1982~. Alternatively, as both antibodies are of the IgG2a isotype, the
partial protection might be due to the clearance of virus-antibody complexes in
nonpennissive ..nacrophages as suggested for Semliki Forest virus (Doere et at,
1985).
The results of th- characterization of the RVFV MAbs with respect to their
antigenic specificity and their biological acf +ties thus indicate that they are
involved in various biological functions. This in turn suggests that they are
directed against different antir~nic determinants on the G1 alJd G2 proteins. IAl
order to assess this, and to assign the protective, neutra'lzing and
haemagglutination functions to antigenic regions on the glycoproteins, it is
necessary to examine the topological relationship of the epitopes tP each other.
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3. EPITOPE MAPPING OF RVFV Gl AND G2
3.1 Introduction
The topological relationship of antigenic determinants to each other on the surface
of the virus protein molecule can be conveniently examined by utilizing MAbs in
a competitive binding assay (CBA) (Heinz, 1986; Stone and Nowinski, 1980;
Ycwdell and Gerhard, 1981). Competitive binding is frequently performed by
ELISA or radioimmunoassay, where one MAb is labelled with an appropriate
marker, and unlabelled antibodies are assessed for their capacity to inhibit the
c...npetition of the labelled antibody with antigen (Carter an" ter Meulen, 1984).
The definition of epitopes by CBA is based on the assumption that a MAb binding
to a specific site hinders the attachment of another antibody to the same or
proximal site (Stone and Nowinski, 1980).
CBA's with MAbs have been used to map the antigenic determinants of the
envelope glycoproteins of several members of the Bunyaviridae family (Arikawa
et al, 1989; Dantas et al,1986; Gonzalez-Scarano et at, 1932; Kingsford et all
1983; Najjar et al, 1985) including the phlebovirus Punta Toro (Pifat et al, 1988).
Epitope mapping studies on La Crosse virus (LACV) have, for example, revealed
the presence of eight ar.tigenic regions on the Gl glycoprotein (Kingsford et al,
1983). In the study by Arikawa et al (1989), nine distinct, partially-overlapping
antigenic sites, two on Gl and seven on 02, were demonstrated for Hantaan
virus. Monoclonal antibodies reactive with the Punta Toro G1 protein were
shown to bind to epitopes in two distinct topological sites (Pifat et at, 1988).
In contrast, a topographical analysis of the surface glycoproteins of RVFV has not
been undertaken to date. This may partly be due to the difficulty in generating
RVFV MAbs to the glycoproteins relative to the highly immunogenic
ucleocapsid (Pifat et al, 1988).
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The present objectives therefore are to use the RVFV MAbs prepared against the
South African AN 1830 strain to map the antigenic sites on G1 and G2. The
epitope mapping will be carried out using competitive binding ELlS As with MAbs
conjugated with an enzyme label. The biological functions of the MAbs will then
be assigned to the corresponding mapped domains.
~.2 Materials and Methods
3.2.1 Purification of virus for eBA
a) RVFV was PEG-precipitated and purified using esCl gradients as described
ill section 2.2.1.2.
b) Purification of RVFV using potassium tartrate-glycerol gradients (Robeson et
al, 1979) was also performed in an attempt to obtain a higher yield of intact virus
particles. The potassium tartrate-glycerol gradients were prepared by successively
layering 1,5 ml volumes of solutions A to G (Appendix C) in Beckman Ultra-
Clear centrifuge tubes. Two ml PEG-precipitated RVFV (2.2.1.2) was then
loaded over the combination equilibrium-viscosity gradients of glycerol and
potassium tartrate. The tubes were spun at 35 000 rpm (155 000 g) for 90 min
at 4°C in a SW 40 Ti rotor using a Beckman L8-60M ultracentrifuge. The visible
virus band in each tube was harvested by collecting 0,5 ml fractions using a 19
gauge needle. The fractions were tested for protein by measuring the absorbance
at 280 nm.
Positive fractions were pooled and dialyzed overnight against TSE buffer (0,01
M tris-hydrochloride buffer, pH 7,6, containing 0,15 M NaCl ai.d 0,003 M
EDTA, pH 7,4). The final protein concentration was determined
spectrophotometrically as above.
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3.2.2 Purification of MAbs
Prior to purification the monoclonal antibody rich ascitic fluids were treated with
Lipoclean (Behring, Hoechst, Germany) to remove any lipid-containing material.
The ascitic fluids were mixed with the Lipoclean reagent at a ratio of 1,5;1,
vortexed and clarified by spinning at 2500 rpm for 15 min in a Beckman TJM6
benchtop centrifuge. The top phase was carefully removed for antibody
purification.
IgG MAbs were purified from the clarified ascitic fluid by protein A-linked
agarose (Affi.-gel MAPS; Bio-Rad Laboratories, Richmond, CA, USA)
chromatography. Fractions of 1 ml were collected and tested for protein using
the Bio-Rad Protein assay (Bio-Rad Laboratories). Positive fractions were pooled
and concentrated by ultrafiltration using CX-10 ultrafiltration units (Millipore),
The antibodies were then dialyzed against 0,1 M phosphate buffer, pH 7,4 with
0,075 M NaCl and the resulting protein concentrations determined
spectrophotometricaUy at 280 nm.
MAbs of the IgM subclass were isolated by gel filtration on Ultragel AcA 34
(Spectrum Medical Industries, Los Angeles, CA, USA) using a 50 x J.,5 cm
column. The gel was equilibrated with 0,5 M NaCl buffered with 0,02 M
sodium phosphate buffer, pH 7,3. Clarified ascitic fluids (1 ml per run) were
applied to the column and eluted with the same phosphate buffer as above.
Fractions of 3 ml were collected and the protein contents checked using the Bio-
Rad Protein assay kit. The. fractions in the first peak were pooled, concentrated
by ultrafiltration and the protein concentrations determined at 280 nrn.
3.2.3 Determinatlon of MAb avidities
The abilities of MAbs to bind to solid-phase viral antigen were evaluated by
indirect ELISA using both purified virus and glycoprotein preparations ELISA
micro titre plates were coated overnight at 4°C with an optimal dilution of
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gradient-purified RVF virions or glycoprotein extract determined as in Section
2.2.2.3a. Non-specific binding was blocked by addition of 0,2 mllwell of 4%
BSA for 1 h at 37°C. Log., dilutions of purified MAbs adjusted to a starting
concentration of 0,1 mg/rnl were prepared and 0,1 ml volumes added to the wells
and incubated for 2 h at 37°C. The bound antibody was determined with anti-
mouse peroxidase conjugate as described for the screening ELISA (2.2.2.3a). To
provide an approximate comparison of MAb~binding properties, relative binding
avidity was defined as the amount of antibody (f.tg MAb protein) required to yield
an absorbance of 0,5 at 405 nm (Boere et al, 1984).
3.2.4 Peroxidase conjugation of MAbs
Antibodies were initially coupled to horseradish peroxidase (HRPO) (Sigma
Chemicals, St Louis, Mo, USA) by the method of Wilson and Nakane (1978).
Immunoglobulin fractions were isolated from ascitic fluids by ammonium sulphate
precipitation and dialyzed overnight against 0,01 M sodium carbonate buffer (PH
9,5), HRPO (10 mg) was dissolved in 2,5 ml distilled water and activated with
0,5 ml freshly prepared 0,1 M sodium periodate for 20 min at rt. The solution
was then dialyzed against 0,01 M sodium acetate buffer (PH 4,4). The pH of the
solution was then raised to 9,5 with 0,2 M sodium carbonate buffer (PH 9,5) and
4 mg immunoglobulin was incubated with the activated HRPO for 2 h at rt. After
the addition of 0,25 ml freshly prepared sodium borohydride solution (4 mg/ml),
the mixture was left for 2 h at 4°G, then dialyzed against PBS overnight at 4°G.
A modified peroxidase conjugation method in which ascorbic acid is used instead
of sodium borohydride as the reducing agent (Henning and Nielson, 1987) was
also assessed. The labelling procedure was identical to that above, with the
exception that 13,25 ml of ascorbic acid (4 mg/ml) was added to the HRPO-
antibody mixture instead of the sodium borohydride. The mixture was left at 4°C
for 24 h to stabilize and then sterilized by filtration through a Ot22 p..ffi filter
(Millipore Corp, Bedford, USA).
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To remove uncoupled IgG and free enzyme, peroxidase conjugates were purified
by gel filtration by the method of Nakane a.ndKawaoi (1974). Half the amount
of the HRPO-conjugates (2 mg protein) was chromatographed on a 85 x 1,5 cm
column of Sephadex G-I00 equilibrated in PBS. Fractions of 20 drops were
collected and their absorbances at 280 and 403 nm determined. The enzymatic
activity of the fractions were tested by ELISA (3.2.7) to detect the \If>JSenrLof
active conjugates. Positive fractions were pooled and conceatrates by
ultrafiltration. The purified conjuga.tes were then compared to the other half of
the non-purified conjugate for antigenic activity by ELISA (3.2.7).
;,'1.2.5 Biotin labelling of MAbs
\"
labelling of the MAbs with biotin was assessed using two methods:
a) Amersham biotinylation kit (Amersham Int., U.K.): MAb immunoglobulin
fractions (precipitated by ammonium sulphate) were dialyzed overnight against
0,05 M borate buffer (PH 8,5). The protein concentration of each sample was
adjusted to 2 mg/ml and 40 ILlbiotin was added for 1 h at rt with shaking. The
labelled preparation was then fractionated through the Sephadex G25 column
supplied and fractions of 0,5 ml were collected.
b) Biotinylation using the succinimide ester: Labelling of the MAbs with a biotin
ester (biotin-XX-NHS) which has an extra spacer arm interposed between the
reactive ester and the biotin molecule was also examined. Purified as well as
ammonium sulphate precipitated RVFV MAb immunoglobulins were adjusted to
2 mg/ml in 0,05 M borate buffer (PH 8,5). The biotin-XX-NHS (Calbiochem,
Behring, Hoechst, Germany) was prepared by dissolving 1 mg in 1 ml of
dimethylsulphoxide (DMSO). Fifty ILg and 250 ILgquantities of the biotin ester
were then added to duplicate 2 mg MAb immunoglobulin samples. These were
reacted for 4 h with shaking at rt followed by the addition of 20 ,,1 of 1,01\1
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ammonium chloride per 250 J.!.g biotin to block unreacted biotin ester. The
labelled preparations were then fractionated through Sephadex 025 as described
above.
3.2.6 Conjugation ofMAbs via their carbohydrate moieties
Conjugation of antibodies via their carbohydrate moieties using the hydrazide
derivatives of peroxidase and biotin was evaluated using RVFV hyperimmune
ascitic fluid (HAF) and several representative MAbs. The RVFV antibodies were
oxidized by mixing 2 mg of ammonium sulphate precipitated immunoglobulin
diluted in 0,5 ml of 0,1 M sodium acetate (PH 5)5) with 0,5 ml 0,01 M sodium
periodate for 20 min at rt. The mixtures were then dialyzed against 011 M
sodium acetate (PH 5,5).
a) Peroxidase-hydrazide
Crystalline horseradish peroxidase (5 mg) (HRPO, Sigma) was dissolved in 1 ml
of 0,15 M sodium chloride. To this was added 0,1 ml of a 0,5 M aqueous
solution of adipic acid dihydrazide (AADH, Sigma) adjusted to pH 5,0 with
1 N HCl, and 0,5 ml of a 0,1 M aqueous solution of l-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC, Sigma). The reaction
was allowed .to proceed for 6 h at rt at which time the solution was dialyzed
against 0,15 M sodium chloride and then against 0,1 M sodium acetate, pH 5,5.
After dialysis, the HRPO-hydrazide was mixed with oxidized RVFV
immunoglobulin at a protein ratio of 1: 1 and allowed to react overnight at rt.
b) Biotin-hydrazide
Solid biotin-hydrazide (Sigma) was added to 2 mg/ml of oxidized RVPV
immunoglobulin to yield a final concentration of 0,01 M. This was reacted for
2 h at rt with gentle shaking, followed by extensive dialysis against PBS.
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3.:2.7 Determination of the reactivity of the conjugated MAhs
a) To determine the efficiency of the labelling metbod, the enzymatic activity of
the conjugated MAbs Was tested by ELISA. The peroxidase conjugated
preparations were diluted 1:50 in ELISA coating buffer (pH 9,6) and serial two-
fold dilutions p1' pared in ELISA plates. Following overnight incubation at 4°C,
the wells were washed and blocked with 4% BSA for 30 min at 37°C. .t\fter
washing again, ABTS substrate was added and the absorbance read at 405 nm.
The reactivity of the biotin conjugated MAbs was determined in the same manner,
except: that peroxidase streptavidin (Amersham) at a dilution of 1:WOO was added
after the blocking step. Following an incubation period of 1 hat 3rC, the wells
were washed and the enzymatic activity detected with ABTS substrate.
b) The antigenic reactivity of the labelled MAbs was examined by adding serial
two-fold dilutions of the conjugated antibodies to ELISA plates coated with
extracted glycoprotein and whole virus antigen (3.2.3). After 1 h incubation at
37°C, the wells were washed and ABTS substrate added to the peroxidase
conjugated MAbs. For the biotin labelled MAbs, peroxidase streptavidin was
added instead and the ELISA carried out as described above.
3.2.8 Competitive bindlng assays
Competitive binding ELISAs were performed using ELISA plates which had been
coated with an optimal concentration of extracted RVFV glycoprotein (80,ug/ml)
and blocked with BSA as described in Section 2.2.2.3. Prior to carrying out the
actual competitive assays, the amount of each labelled MAb needed to give an
optical density (O.D,) of 0,5 to 1)0 in the absence of a second unlabelled antibody
(Lussenhop et al, 1988) was determined by titrating the conjugated antibodies.
A starting dilution of 1:25 was prepared in ELISA diluent for each enzyme-
labelled antibody, and 0,1 ml volumes added in duplicate to the coated and
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blocked ELISA plate wells. Serial two-fold rtHlItl(jnswere prepared in the plates
and incubated at 37°C for 1 h. The plates were washed, ABTS substrate added
and the absorbance values at 405 nm were read.
For the competitive binding assays, unlabelled purified MAbs were adjusted to
0,1 mg/ml in ELISA diluent and 0,1 ml volumes added in duplicate to the coated
plates. After incubation for 3 h at 37°C, the plates were washed and peroxidase-
labelled MAbs were added in duplicate (0,1 mliwell) for a further hour at 37°C.
After washing as before, the colour was developed by adding ABTS substrate and
the O.D. at 405 nm determined. Controls included antigen-coated wells without
any competing unlabelled MAbs) as well as homologous unlabelled antibody for
=ach respective conjugated MAb.
Percent inhibition ur enhancement due to the competing antibody was calculated
from average corrected absorbance readings using the formula described by
Lussenhop et al (1988):
[(% O.D'405 with competing antibody) - (% O.D'405 without competing antibody)]
x 100/(% O.D'405 without competing antibody).
Competition was rated strong if it was more than 75% and partial or intermediate
if it was more than 25% (Arikawa et al, 1989). An increase in binding to more
than 20% was considered significant enhancement.
3.3 Results
3.3.1 MAb avidities
The relative binding avidities of the MAb~, which serves to provide an
approximate comparison of MAb-binding properties, are shown in Table 10. The
MAb avidities differed greatly for the purified virus and extracted glycoprotein
antigens. In general, the amount of MAb protein which Was required 1:0 bird to
the intact virus in order to give an ELISA absorbance value of 0,5 was about
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Table 10. MAb relative avidities
Relative Avidity' (",g/ml)
l'
MAb Purified virus Glycoprotein.
3£5 25 15 x 10-3
9E4 1.6 1 x 10-3
5AI 1.7 1 x 10-3
4B3 3.8 1 x 10-3
3Rl 5 1 x 10-;)
3D2 22 2 x 10-3
5E9 0.8 1 x 10-3
8A3 14 2 x 10-3
5Ell >50 0.1
5El 7.6 27 x 10-3
5F2 33 0.3
5A6 >50 0.4
8GIO 34 7.2
1E4 20 7.4
9C4 7 5 x 10-3
7F2 2.5 2 x 10-3
7F1 2.9 6 x 10-3
8G2 3.2 17 ;t 10-3
8C2 0.4 25 x 10-3
4DlO 9.3 27 x 10-3
8E6 23 2 x 10-3
6EI0 12 0.2
5C12 5.8 3.8
1 Amount of antibody (p.g/ml) required to yield an absorbance of 0,5 at 405 nm.
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three logs greater than ibat for the glycoprotein antigen eg for MAb 3E5, 25
f.tg/rri1was needed to bind to the viral antigen compared to only 15 ng/ml for the
glycoprotein preparation. The individual MAbs furthermore varied in their ability
to bind to solid phase antigen, with relative avidities ranging from 1 x 1O-~to
7.4 f.tg/m1 in the case of the glycoprotein preparation.
3.3.2 MA.u labelling
Several different conjugation procedures were initially evaluated in order to
determine the optimum method for enzyme labelling of the RVFV MAbs.
Preliminary studies on peroxidase conjugation of the MAbs using the period ate
method.of Wilson and Nakane (1978) and the modified procedure of Henning and
Nielson (1987) yielded conjugates of similar reactivity. The latter method was
subsequently used as it was less toxic and generated conjugates with greater
stability on storage. Optimal coupling efficiencies were obtained using a ratio of
10 mg peroxidase conjugated with 4 mg of protein.
By this method, seventeen MAbs were successfully coupled to peroxidase. The
remaining six antibodies exhibited enzymatic activity, indicating that labelling
with peroxidase had occurred. However, the antigenic reactivity (ability to bind
antigen) of these conjugates was extremely weak. Purification of the peroxidase
labelled antibodies by gel filtration to remove uncoupled IgG did not improve the
activity of the conjugates.
With regard to biotin labelling, coupling of the MAbs using the biotin N-
hydroxysuooinimide ester (biotinlyation kit; Amersham) or the biotin-XX-NHS
(Calbiochem, Behring, Hoechst) yielded conjugates of comparable reactivity.
While the enzymatic activity of all the biotinylated antibodies was excellent, the
antigenic reactivity of the individual 1vIAbsvaried considerably. Several of the
biotinylated MAbs, eg 3E5 and 7Fl, exhibited a markedly reduced ability to bind
antigen compared to the same MAbs labelled with peroxidase. The six MAbs
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which displayed poor antigenic reactivity on coupling to peroxidase similarly did
not retain their binding capacity on bioti.iylation.
Conjugation of RVFV antibodies via their carbohydrate moieties using hydrazide
derivatives of peroxidase and biotin produced active conjugates as verified by
testing the enzymatic activity. The antigenic activity of the conjugates, however,
was very low compared to the other methods where labelling was performed via
the amino groups of the antibodies.
3.3.3 Competitive binding assays
The seventeen MAbs which retained their binding capacity after coupling to
horseradish peroxidase were USetJ in reciprocal competition assays (Tables 11, 12,
13, 14). With regard to the Gl-specific antibodies, MAbs 3ES and SE1 exhibited
complete, symmetrical inhibition, indicating that they recognized identical or
overlapping sites (Table 13). As the antibodies displayed different serological
behaviour, the epitopes were considered to be overlapping rather than specific for
the same epitope,
Partial symmetrical competition between various MAbs was also observed. Here
differences in the degree of blocking efficiency between antibody pairs was seen
despite having comparable avidities eg MAb 3Rl competed fully with MAl) 3])2-
and 3D2 only partially competed with 3Rl. MAb 4B3 exhibited partial reciprocal
binding with MAbs 3R1 and 3D2, as well as MAbs SAl and 9E4. As such
partial competition may be due to a low degree of structural overlap of
determinants, the epitopes identified by these five antibodies were consic l to
be closely adjacent and were assigned to the same antigenic domain (G1 II).
A similar competition pattern was observed for MAbs SEil and 8A3 (01 Illa and
IIIb), while MAl) 5E9, which did not show any reciprocal competition with the
other MAbs, was assigned to domain IV. Besides competition, enhancement was
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also observed, MAb 9E4 (G1 IIe) induced enhanced binding of MAhs 3.£5 (G1
Ia) and 5Ell (GI rna) but not vice versa (Fig. 2).
The competition assays with the G2-specific MAbs showed that none of the MAbs
displayed complete, symmetrical competition with any of the other antibodies and
thus appeared to recognize different epitopes (Table 14). MAb 7F2 had the
unique ability to compete fully or partially with all the other labelled G2 MAbs.
In tum, 7F2 was partially blocked by only one MAb (8C2) which suggested that
these two antibodies bound to closely adjacent epitopes in the same antigenic
region (G2 Ie and Id).
Asymmetrical inhibition occurred between MAbs 9C4 and 8G2 ie 9C4 blocked
the binding of 8G2 by 100% but 8G2 did not compete with 9C4 at all. A similar
pattern of one-way inhibition was seen for MAbs 7F2 and 8G2 where 7F2
blocked 8G2 by 95% but 8G2 only blocked 7F2 by 10%. Since this type of
competition could be explained by the lower avidity of 8G2 relative to that of 9C4
and 7F2, the epitope recognized by 8G2 was assigned to the same domain as the
9C4 and 7F2 determinants (G2 la, Ib, Ic), No two-way competition was observed
for MAbs 7F1, 4D10 and 8E6 which were thus placed in different domains. In
addition, reciprocal enhanced binding was seen for MAbs 7F1 and 8C2, 7Fl and
4DIO, 7FI and 8G2, 4D10 and 8C2, 4DIO and 8G2, and 8C2 and 8G2 (Fig. 3).
Data from CBAs performed with competitor Gl-specific MAbs against labelled
anti-G2 MAbs and vice versa revealed that none of the anti-Gl MAbs competed
with the G2-specific antibodies for binding to the G2 protein. In the reverse
situation, MAbs 8G2, 7F2 and 8e2 (mapping to G2 I) competed with the Gl-
specific MAbs for binding to domain G1 II (Table 15),
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Table 11. Percentage inhibition of binding of labelled MAbs by unlabelled antibodies determined by competitive binding assay
forRVFV Gl
Antigenic Unlabelled HRPO Labelled MAb
Domain MAb
3E5 5EI 3D2 3Hl 4B3 5Al 9E4 5Ell 8A3 5E9
Gl Ia 3E5 100 91 - 9 0 17 - 7 - 1 - 8 6 - 3
Ib 5El 75 100 9 0 4 -13 1 4 12 3
ITa 3D2 41 46 100 56 43 1 5 26 3 - 14.L
IIb 3Rl 71 2 100 ioo 27 -13 -10 0 82 -13
0\
Ul ITc 4B3 58 46 59 49 100 93 91 0 - 1 - 14
IId 5Al 65 23 2 - 2 36 100 100 - 2 11 -17
TIe 9E4 -94 26 - 15 - 8 25 54 100 -56 60 - 14
IlIa 5Ell 45 30 - 7 14 23 - 15 1 100 36 - 7
IIIb SA3 39 1'7 7 3 14 6 4 57 100 .rLT - - - - 0
IV 5E9 9 47 - 9 - 16 1 - 8 - 6 5 15 100
- - enhanced antibody binding
Table 12. Percentage inhibition of binding of labelled MAbs by unlabelled antibodies determined by competitive binding assay
for RVFV G2
Antigenic Unlabelled HRPO labelled MAb
domain MAb
9C4 8G2 7F2 8C2 7F1 4DlO 8E6
0\ G2 Ia 9C4 lDO 100 2 19 - 98 - 186 3
0\
b 8G2 20 100 15 - 13 -74 - 81 - 1
c 7F2 65 95 100 58 64 68 43
d 8C2 - 5 - 104 26 100 - 59 - 82 8
IT 7Fl 24 - 39 15 - 90 100 - 72 10
ill 4D10 - 90 - 256 -3 - 146 - 62 100 14
rv 8E6 3 20 1 - 14 18 4 100
- - enhanced antibody binding
Table 13. Competitive binding assay mapping of RVFV G1 glycoprotein epitopes based on patterns of antibody
binding inhibition
Antigenic
domain
Unlabelled
MAb
HRPO labelled MAb1
3E5 5El 3D2 3Hl 4B3 5Al 9E4 5Ell 8A3 5E9
01Ia 3E5 ++ ++
Ib 5E1 ++ ++
IIb 3D2 + + ++ + + +
IIb 3Rl + ++ ++ +
lIe 4B3 + + + + ++ ++ ++
IId 5A1 + + ++ ++
ile 9E4 0 + + + ++ 0 +
IlIa 5Ell + + ++ +
Illb 8A3 + + ++
IV 5EY + ++ I
1 Binding inhibition of labelled MAb by unlabelled antibodies as defined by
++, >75% competition; +, 25 to 75% competition
0, one-way enhancement more than 20%
Table 14. Competitive binding assay mapping of RVFV G2 glycoprotein epitopes based on patterns of antibody binding
inhibition
Antigenic
domain
Unlabelled
MAb
HRPO labelled MAbl
9C4 8G2 7F2 8C2 7Fl 4DIO 8E6-------------~--------
0\
00
G2 Ia 9C4 I ++ ++ 0
b 8G2 ++ R R
c 7F2 + ++ ++ + + + +
d 8C2 0 + ++ R R
II 7Fl R R ++ R
ill 4DlO 0 R R R 1 -l-T 1
IV 8E6 ++ I
1 Bindinginhibition of labelled MAb by unlabelled antibodies as defmed by:
++,>75% competition; +,25 to 75% competition
0, one-way enhancement more than 20%; R, reciprocal enhancement more than 20%
Table 15. Percentage inhibition of binding of labelled Gl-specific MAbs by unlabelled G2-specific antibodies determined by
competitive binding assay
Antigenic Unlabelled HRPOMAb
domain MAb
3D2 3Hi 4B3 1::'.\1 9E4In....
(Gl IIa) (Gl IIb) (Gl IIc) (Gl TId) (Gl TIe)
Cl\
\0 G2 Ia 9C4 2 32 0 7 6-
G2 Ib 8G2 37 52 82 83 100
G2 Ie 7F2 70 77 35 26 40
G2 Id 8C2 67 50 98 85 100
G1 II
G1 IV G1 III
Fig. 2. Diagrammatic representation of the antibody interactions between the
epitopes on the RVFV 01 glycoprotein. Circles represent epitopes recognized by
each MAb. Overlapping circles indicate competition between MAbs. The
unfilled arrows show unidirectional enhanced antibody binding.
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G21
G2 II G2 Iii G2 IV
Fig. 3. Diagrammatic representation of the antibody interactions between the
epitopes on the RVFV 02 glycoprotein. Circles represent epitopes recognized by
each MAb. Overlapping circles indicate competition between MAbs. The
unfilled arrows show unidirectional enhanced antibody binding. The solid arrows
indicate bidirectional augmented antibody binding.
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3.4 Discussion
The CBA utilizing MAbg is a powerful technique for the topographical analysis
of antigens (Heinz, 1986; Roehrig et al, 1982; Stone and Nov ~:lski, 1980).
While this type of study can be conveniently performed by BLi3A using enzyme
labelled MAbs (Carter and ter Meulen, 1984), it is necessary to establish optimal
conditions for the assay. Firstly, a uniform preparation of purified antigen
suitable for. use in the eBA is essential (Engvall, 1980), It is also critically
important to determine the best method for enzyme conjugation of the MAbs
(Howard et al, 1985; O'Shannessy and Quarles, 1985; O'Sullivan and Marks,
1981). Additionally, the avidities or binding strengths of the antibod es for the
viral antigen have to be taken into consideration so as not to misim zrpret the
results of the CBAs (Stone and Nowinski, 1980).
With regard to the preparation of antigen, purification of RVFV led to substantial
losses of intact virus particles. The problem encountered here in maintaining the
structural integrity of the virus particles 11:.\8 been reported for various members
of the Bunyaviridae family (Obijeski ePal, 1976; Robeson et 0.1,1979). Although
this can reportedly be overcome using potassium tartrate-glycerol gradients
(Robeson et al, 1979), low yields of intact RVFV were still obtained by this
method. In contrast, high yields of a purified glycoprotein preparation were
produced by extraction of the surface glycoproteins from the RVF virion using
mild nonionic detergent lysis.
Preliminary studies using some of the higher avidity MAbs in parallel with
purified virus and glycoprotein as the solid phase antigen gave virtually identical
competition results. The latter was used in subsequent competitive binding assays
since the MAb avidities for the purified viral antigen were in general much
weaker than for the glycoprotein extract. This weak reactivity in the ELISA may
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have been due to disintegration of the virus or "deformation" of antigenic
determinants. during the purification procedure (Boere et al, f984; Robeson et at,
1979).
While many procedures have been described for enzyme-antibody conjugation,
their efficiencies differ greatly (Jeanson et at, 1988; O'Sullivan and Marks, 1981).
A method widely used for enzyme-labelling of MAbs is the periodate-oxidation
technique developed by Nakane and Kawaoi (1974)J whcr; 'Y horseradish
peroxidase is coupled to amino groups of the immunoglobulins. Nevertheless,
since labelling with an enzyme such as peroxidase may cause loss of antigen-
binding capacity due to the higher molecular weight of the conjugate (Boersma
and Kalsbeek, 1975), it may be valuable to use a low molecular weight marker
such as biotin instead (Simkins. et al, 1989). However, these types of amino-
directed labelling procedures can also result in the destruction of antigen binding
activity (Howard et al, 1985; O'Shannessy et ai, 1984). TIns can reportedly be
overcome using a method based on coupling the enzymes to the carbohydrate
moieties of immunoglobulins (O'Shannessy and Quarles, 1985») as the latter are
not involved in the antigen binding site.
Of the various enzyme coupling procedures investigated in the present study,
labelling using the HRPO-periodate method yielded MAb conjugates with the
highest antigenic reactivity. A ratio of HRPO to immunoglobulin of 2,5: 1 was
found to be optimal, which is similar to the optimal ratio of 2,3: 1 reported by
Nakane (1979). While unconjugated IgG may reduce assay sensitivity by
competing with labelled antibody for binding to antigen (Porstmann et al, 1981),
the activity of the RVFV MAb conjugates was not increasedby purification. A
similar finding has been reported by Jeanson et al (1988) who carried out a
comprehensive comparison of conjugation procedures for the preparation of MAb-
enzyme conjugates.
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In contrast to the amino group labelling procedures in which active conjugates
were obtained for the majority of the MAbs, conjugation of the antibodies via
their carbohydrate moieties was completely unsuccessful. Several other studies
have reported that in the case of MAbs, this method of conjugation was inferior
to cenjugation via amino groups (Gretch et al, 1987; Jeanson et al, 1988). This
in tum may possibly be due to the destruction of the sugar moieties of the
ar tibodies caused by the treatment conditions being too severe (Jeanson et al,
1988).
The fact that antigenically reactive conjugates could not be prepared. for six of the
MAbs by any of the methods used suggests that the activity of these antibodies
was .lowered Of destroyed by these coupling procedures. This loss of reactivity
may have been due to the modification of amino acid residues involved in the
antigen binding site (Ohose et al, 1983). Alternatively, since these particular
MAbs all hac law avidity, enzyme labelling may have further lowered their
affinity for the antigen, resulting in increased antibody displacement from the
antigen solid phase in the ELISA.
With regard to the CBA itself, while this type of assay is undoubtedly a powerful
technique for epitope mapping (Heinz, 1986; Roehrig et al, 1982; Stone ano
Nowinski, 1980), interpretation of competitive binding data is not without some
difficulties (Cepica et al, 1990; Henchal et al, 1985; Shaw et al, 1986). The
definition of epitopes by this type of blocking assay is based on the assumption
that a MAb binding to a specific site hinders the attachment of another antibody
to the same or proximal site (Stone and Nowinski, 1980). However, the
possibility tnat blocking may result from positionally unrelated steric hindrance
cannot be disregarded. Moreover Stone and Nowinski (1980) have shown that if
the CBA was performed with two antibodies of similar specificity, but of different
avidities, the competition reactions invariably favoured the binding of the antibody
with higher avidity. Taking this into consideration, the RVFV MAbs of low
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avidity were not used in the CBA. Avidity effects were also minimized by
preincubating the antigen for 3 h with an excess of competitor antibody before the
addition of the labelled antibody.
Another difficulty in the interpretation of CBA results lies in the fact that there
is no standard cut-off percentage for what is representative of significant
competition. In this study competition was (;efi.ned as complete, partial or
negative if the unlabelled antibody prevented attachment of labelled antibody by
>75%, 25-75% or <25% respectively (Arikawa et al, 1989) when the
competitor was used at 100 IJ.g/ml.
Analysis of the competitive binding data using the above criteria revealed the
presence of four antigenic domains on both the Gl and G2 proteins of RVFV.
In the case of the G 1 protein, if it is assumed that the partial competition observed
between the MAbs binding to GIl with MAbs recognizing each of the other
domains is due to steric hindrance, the results can be interpreted to indicate that
the four Gl regions are overlapping or adjacent to each other, forming a slagle
antigenic domain of interlinked epitopes. However, because of the possibility that
partial or asymmetrical competition is due to allosteric prevention of binding, the
domains might be located on various parts of the glycoprotein and share a
functional spatial relationship by virtue of higher protein structure.
With regard to the epitopes comprising domain G2 I, if the asymmetrical
competition observed between the MAbs defining sites G2 Ia, Ib and Ic is due to
avidity differences, then these epitopes may be clustered and form part of a single
large antigenic region on the G2 spike. The complete asymmetrical inhibition
which occurred between epitopes G2 lb and Ia, and lb and Ic, but not Ia and Ic
could then be interpreted to indicate that Ia and Ic are located 011 opposite sides
of lb.
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The G2 domains II, Ill and IV, on the. other hand, were defined by MAbs which
displayed no reciprocal competition with any of the other antibodies. Based on
the partial one-way competition exhibited by the MAb recognizing G2 Ic with all
the other G2-specific MAbs, it might be argued that all four areas are linked to
form a single antigenic domain similar to the G1 protein. However, this
asymmetrical competition is most likely due to allosteric phenomena rather than
steric hindrance, since this particular antibody was shown to also partially inhibit
binding of some of the MAbs specific for G1. The observation that a limited
number of pairs of G1 and G2-specific MAbs were capable of compe.ing for
binding is of interest, demonstrating that these antibodies can induce
conformational changes in an entirely different viral protein. To our knowledge
there is no published data regarding epitope mapping studies on the effect of
binding of GI-specific MAbs on the G2 protein and vice versa for any other
phleboviruses. Conformational changes in the PE2 protein induced by the binding
of a MAb specific for the envelope E1 protein have nevertheless been shown for
Sindbis virus (Clegg et al, 1983).
The unidirectional and bidirectional enhancement observed between various
antibody pairs here has been reported for many other viruses (Boere et al, 1984;
Burns et al, 1988; Cecilia et al, 1988; Heinz et al, 1984; Kingsford, 1984;
Lubeck and Gerhard, 1981). This phenomenon is thought to be due to a change
in the conformation of the antigen brought about by the binding of the first
antibody (Lubeck and Gerhard, 1981), Antibody interaction with critical buried
residues in one site, for example, may help to induce side-chain adjustments in
adjoining sites (Getzoff et al, 1987), making the binding of additional antibodies
more favourable (Heinz et al, 1984; Lubeck and Gerhard, 1982). Studies have
furthermore shown that MAbs which enhanced the binding of other antibodies in
the CBA system can have a synergistic effect on the neutralizing activity of such
antibodies (Anderson et al, 1988; Chanas et al, 1982; Dubuisson et al, 1990;
Kingsford, 1984; Russell, 1986; Van Drunen Littel-van den Hurk et al, 1985;
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Volle et al, 1982). The increased antibody binding which occurred between
various RVFV MAb pairs in the CBAs here may thus have important biological
consequences in terms of neutralization of RVFV and will be further investigated.
By correlating the data of the competitive binding and serological assays, it was
possible to assign functional properties to the mapped regions. The epitope
recognized by MAb 3E5 (Gl Ia) appears to define a biologically important area
on the G1 protein since it had very potent neutralizing and significant HI activity
and was also associated with complete protection to otherwise lethally infected
mice. The fact that the epitopes assigned to the G1 domains II and IV also
exhibited virus neutralizing as well as haemagglutination activity, indicates that
these sites, like Gl la, are accessible to antibody on the intact virion" These
domains therefore are likely to be located in the hydrophilic portions on the outer
surface of the folded G1 polypeptide as shown for the neutralizing ~1lr;;;~ on many
other viral glycoproteins (Eisenberg et al, 1985; Nowak and Wengler, 1987;
Pellet et al, 1985; Wiley and Skehel, 1987).
Of interest is the finding that the three MAbs earlier shown to cross-react with
Gordil virus all mapped to closely adjacent sites (01 IIc, IId and IIe), indicating
that this particular region on the Gl protein is more highly conserved than the
epitopes defined by the other antibodies.
\S in the case of the G1 protein, the epitope G2 Ia defined by the G2-reactive
MAb 9C4 exhibited very high neutralization as well as haemagglutination activity.
Since this site was also involved in protection of mice from virulent RVFV
infection, it must represent an immcnolog.cally significant area on the G2 protein,
similar to the G1 determinant dehned by MAb 3E5. In contrast to the G1
glycoprotein, however, only one domain (G2 I) was associated with significant
neutralizing activity. As the remaining G2 domains only displayed low level C'-
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dependent neutralization, these may be less accessible than G2 I for antibody
binding.
These CBAs with peroxidase labelled RVFV MAbs have thus permitted the
topographical analysis of ten of the G1 epitopes and seven of the 02 antigenic
sites. Four heterogeneous antigenic regions which may be interlinked were
identified on the G1 protein, while four distinct domains on the G2 were defined.
The collinearity of the epitopes defined by the mapping studies; however, do not
necessarily imply sequence collinearity on the Gland G2 viral protef ..i. While
the relationships between the epitopes may be linear, the antigenic sites may share
spatial relationships by virtue of tertiary protein folding. To clarify this, further
characterization will be undertaken by ELISA studies using denatured viral
proteins.
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4. STRUCTURAL ANALYSIS OF EPI'fOPES
4.1 Introduction
Since antigenic determinants in proteins are often complex co.formations
dependent on the tertiary folding of the protein chain (Crumpton, 1974; Getzoff
et al, 1987; Geysen et al, 1987b; Sela, 1969), the linear arrangement of epitopes
mapped by CBAs does not necessarily reflect sequence collinearity along the viral
polypeptide chain (Coe and Meengeling, 1990). Both conformation-dependent as
well as conformation-independent antigenic sites have been identified on the
envelope proteins of various viruses (Cybinski et al, 1990; Eiiot et al, 1990; Hall
et al, 1990; Heinz et al, 1983; Niesters et all 1987),
Furthermore, conditions which destroy the tertiary structure of the protein usually
result in a large reduction in reactivity of antibodies to the native protein
(Crumpton, 1974; Sela, 1969). MAbs against the glycoproteins of various
viruses, for example, have revealed that certain neutralizing sites are found only
on the native viral protein and not on the denatured protein (Brioen et al, 1982;
Cybinski et al, 1990; Eliot et at, 1990; Heinz et al, 1983; Niesters et al, 1987).
Thus not only the position but also the conformation of the antigenic determinant
may be important for antibody binding and the expression of functional activities
at the epitope level (Berzofsky and Berkower, 1989; Carter and tel' Meulen, 1~84;
Hall et al, 1990; Jackson and Nestorowicz, 1985; Pollock et al, 1984).
In order to further characterize the structural properties of the RVFV G1 and G2
epitopes, the reactivity of the MAbs with viral antigen that has been denatured
will be assessed to establish whether the antigenic determinants are linear or
conformation-dependent. This will be investigated by firstly examining the
sensitivity of MAb interactions to conformational changes generated by disruption
of noncovalent bonds of the viral protein. Further conformational changes will
then be generated by reducing disulphide bonds and determining the effect these
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changes have on the antibody interactions. By combining the CBA data with the
results of the conformational studies, a diagrammatic representation of the
conformation and topography of the RVFV glycoprotein epitopes can be
constructed. The structural analysis will also help to elucidate the role of
conformation of the RVFV envelope proteins in antibody attachment and other
functional activities.
4.2 Materials and Methods
4.2.1 MAb reactivity with heat denatured viral antigen
The structural properties of each epitope were assessed by analysing the'.effect of
heat denaturation of the native viral protein on the antigenic reactivity of each
MAb. The method used was based on that described by Eliot et al (1990).
Purified stock viral glycoproteins (17 mg/ml, section 2.2.1.2) were diluted 1:50
in PBS and denatured by heating for 3 min at 100°C with or without 2,5% B-
mercaptoethanol (ME), The treated antigens and untreated glycoprotein (control
antigen) were diluted in carbonate-bicarbonate coating buffer (PH 9,6) (2.2.2.3)
to yield a final dilution of 1:200 (85 .tg/ml). Microtitre plates (Nunc Immuno II,
As/Nunc, Roskilde, Denmark) were coated in parallel with 0,1 ml/weu of the
treated and control antigens. After overnight incubation at 4°C, the wells were
saturated with 4% BSA for 30 min at 37 °C, Serial dilutions of MAbs in ELISA
diluent were added for 1hat 37t>C, followed by anti-mouse peroxidase conjugate
and substrate as outlined earlier (2.2.2.3).
4.2.2 MAb reactivity with reduced and alkylated viral antigen
Reduction of the disulphide bonds in the viral glycoproteins was performed by the
method of Karl et al (1986). Purified stock extracted viral glycoproteins (17
mg/ml; section 2.2.1.2) were prepared for reduction by diluting 0,05 ml in 5 ml
TN buffer (0,02 M Tris-hydrochloride buffer, pH 7,8, containing 2,5 mM NaC!
and 0,1 % Nonidet P40) adjusted to pH 8,0, containing 8 M urea. Dithiothreitol
(DTT; Sigma Chemicals) was added to the viral antigen to a final concentration
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of O,OlM. The reaction was allowed to proceed at rt overnight with constant
stirring. Alkylation was performed by adding 9 mg of iodoac=tamide and
allowing the reaction to proceed at rt for an additional 2 h. Samples were then
dialyzed to remove excess reagents. The reduced and alkylated viral proteins
were then diluted in carbonate-bicarbonate buffer (pH 9,6) to give a final
concentration of 85 JLg/ml. Untreated viral glycoproteins were used as control
antigen at the same protein concentration as the treated antigen. ELISA plates
were coated with the reduced and alkylated viral antigen in parallel with the
control antigen and the reactivity of each MAb with the viral proteins was
examined by ELISA as described above.
4.3 Results
4.3.1 Heat denatured antigen
With the exception of MAb lE4, none of the Gl-specific MAbs bound to the heat
denatured antigen as indicated by the extremely low D.D. readings « 0.200)
obtained in the ELISA. With regard to the MAbs specific for the G2
glycoprotein, the reactirities of MAbs 8C2 and 7Fl (G2 Id and G2 II) were
unaffected by heat or mercaptoethanol treatment (Table 16). The remaining anti-
G2 MAbs did not react with antigen that had been denatured by heat.
4.3.2 Reduced and alkylated antigen
Of the three MAbs which recognized heat denatured viral glycoprotein (1E4, 8C2,
7Fl)) the Gl-specific MAb 1E4 was unable to bind to antigen that had been
subjected to conditions which disrupted the polypeptide disulphide bonds (Table
16). The reactivities of MAbs 8C2 and 7F 1, on the other hand, were not affected
by this treatment as evidenced by strong positive readings in the ELISA.
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Table 16. Reactivity of MAbs in ELISA with RVFV antigen which had been
denatured by various treatments
Reduction! Enhanced
MAb Domain Heat He.a.t/MEI alkylation antibody
binding
3E5 01Ia 82 S E4
5El Ib S S
3D2 IIa S 8
3Hl lIb S S
4B3 lIe S S
5Al IId S S
I IS9B4 IIe S S I
I
I5Ell lIla S S I It
8A3 IIIb S S I I
5E9 IV S S
5F2 ? S S
8GlO ? S S
1E4 ? R3 R S
5A6 ? S S
9C4 G2Ia S S I
8G2 Ib S S E, I
7F2 Ic S S
8C2 Id R R R B, I
7Fl II R R R E, I
4DIO III S S E, I
8E6 IV S S
6ElO ? S S
5C12 ? S S
1 ME::::: B-mercaptoethanol 2 S = epitope sensitive to denaturation
3 R := epitope resistant to denaturation 4 E = exhibits enhanced binding
5 I ::::;induces enhanced antibody binding to other sites
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4.3.3 Diagrammatic representation of topography
By combining the data from the CBAs with the denaturation studies, it was
possible to construct a diagrammatic representation of the conformation and
topography of the G1 and G2 epitopes here (Figs 4 and 5). Fig. 4 clearly shows
that the G1 domains I to IV are comprised of epitopes which are homogeneous
regarding their sensitivity to denaturation and thus all map to a conformation-
dependent portion of the protein. In contrast, the site defined by MAb 1E4 is not
destroyed by heat denaturation and therefore has been depicted as lying in a
different region of the glycoprotein.
The majority of the G2 antigenic sites likewise map to a conformationally-
dependent area on the envelope protein (Fig. 5). Bpitopes G2Id and 02 IT, on
the other hand, are completely resistant to denaturation and thus comprise a
portion of the G2 protein that is conformationally more stable.
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Denaturation-sensitive
Reductlon-
sensitive
It:HA
~E4
l
Epitopes associated with the following functions:
P = protection HA = haemaggiutination
N = neutralization C'N = complement-dependent.neutralizvtion
Fig. 4. Diagrammatic model of the proposed spatial arrangement, conformational
and biological properties of the epitopes on the RVFV 01 protein recognized by
the MAbs. Overlapping or closely adjacent epitopes are indicated by overlapping
lines in the figure, as defined by mutual inhibition of antibody binding.
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Denaturation-
sensitive I Reduction-
resistant
N/HA I -r
1e'N HA/C'NP/N/::~ . / \
'\.2 bC~ "Tia
Denaturation-
sensitiver
C'N
\
Epitopes associated with the following functions:
P = protection HA = haemagglutination
N ::: neutralization C'N = complement-dependent neutralization
Fig. 5. Diagrammatic model of the proposed spatial arrangement, conformational
and biological properties of the epitopes 011 the RVFV G2 protein recognized by
the MAbs. Overlapping or closely adjacent epitopes are indicated by overlapping
lines in the figure, as defined by mutual inhibition of antibody binding.
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4.4 Discussion
All the antigenic sites comprising domains I, II, ill and IV on the RVFV G1
glycoprotein appear to be strongly dependent on the native conformation of the
protein as shown by their sensitivity to heat denaturation. These epitopes thus
probably represent discontinuous determinants which are formed as loops or clefts
in the folded native structure stabilized by hydrophobic interactions (Atassi, 1980;
Crumpton, 1974). The fact that all the G1 domains I to IV are conformation-
dependent supports the eBA data that these are situated in close proximity to each
other on the G1protein. The low level C'-dependent neutralization exhibited by
epitopes G1 Ib, G1 Illa and 01 IIIb in turn suggests that these sites are less
accessible for antibody binding than those comprising the epitopes involved in
haemagglutination and potent neutralization. These particular antigenic
determinants (ie 01 Ib, 01 lIla, 01 IIIb) may therefore be located in areas or
pockets of the 01 polypeptide which are more folded than those comprising the
more functionally active epitopes.
The Gl-specific epitope defined by MAb lE4, on the other hand, lies in a region
of the protein that resists heat and mercaptoethanol denaturation. The
involvement of disulphide bridges in stabilizing the native conformation of this
antigenic site is suggested by the loss of antigenicity upon reduction and
alkylation. While this epitope could not be mapped due to the weak avidity of
MAb 1E4 in the ELISA, it probably corresponds to an independently folding
region within the 01 compared to the domains I to IV.
As in the case of the 01 protein, most of the G2 determinants including the
neutralizing epitopes G2 Ia, Ib and Ic, appear to be dependent on the tertiary
protein structure. These antigenic sites thus map to an area of the 02 protein
which is conformation-dependent, and most likely represent discontinuous
determinants which are assembled from residues from several different portions
of the polypeptide chain.
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The G21d determinant, on the other hand, which is associated with C'-dependent
neutralization, is resistant to denaturation. Epitope G2 II, although non-
overlapping with G2 Id, similarly maintained its antigenic structure under
conditions which destroy disulphide bonds. This could be interpreted to indicate
that these epitopes represent conformation-independent, sequential antigenic sites.
This is somewhat unexpected since the antibodies to these sites exhibited enhanced
binding when mixed with certain MAbs. Synergistic binding of this nature is
usually interpreted to be due to an allosteric rearrangement which permits easier
access for the MAb to its conformational epitope (Heinz et al, 1984; Kingsford,
1984). A possible explanation for this phenomenon may be that although G2Id
and G2 II are linear sequential sites, they are partially hidden in the native
structure of the protein by loops or folds comprising other sites. The enhanced
binding which occurs in the presence of other specific antibodies may be due to
allosteric changes which are induced in areas of the viral polypeptide close to the
G2 Id and G2 II epitopes, which result in better exposure of these sites for
antibody binding.
Alternatively, these antigenic sites may in fact be conformational, but owe their
resistance to denaturation on the presence of the carbohydrate side chain which
serves to Shield these sites from the action of reducing agents. This has, for
example, been shown for several epitopes on tick-borne encephalitis virus
(Guirakhoo et al, 1989). Studies to determine whether the antigenic reactivity of
these epitopes is abolished by deglycosylating tbe G2 protein might help to
elucidate this. In contrast to the G2 Id and G2 II determinants, all the other
epitopes which were involved in enhanced antibody binding appear to be
discontinuous sites which is consistent with the general interpretation of this
phenomenon.
With regard to the role of conformation of the RVFV envelope proteins in
antibody attachment, it is evident that the native protein structure is required for
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recogrution and expression of functional activities of all the MAbs in this study
which ate involved in neutralization and haemagglutination-inhibition, Of interest
is that despite the fact that extensive disulphide formation has been predicted for
the RVFV envelope proteins (Ihara et al, 1985), only one epitope defined by these
particular MAbs appears to be dependent on disulphide bridges for conformation.
Together, the eRA and structural analyses have permitted the probable spatial
location and structure of these epitopes to be defined. Further localization c.'f the
epitopes will require other approaches, such as by the expression of rmall
fragments of recombinant DNA clones, to map these sites to the gene coding
regions and the corresponding predicted amino acid sequences on the polypeptide
chain as has been performed by Keegan and Collett (1986). However, due to the
discontinuous conformational nature of the majority of these determinants,
mapping using the above method would be difficult. A possible alternative
approach would be to analyse the amino acid changes associated with mutants (eg
neutralizing escape mutants) which exhibit an altered pattern of reactivity with the
MAbs. The precise localization of discontinuous epitopes nevertheless would
require a knowledge of the complete three-dimensional structure of the RVFV
envelope proteins, similar to that acquired for the influenza haemagglutinin (Wiley
and Skehel, 1987; Wilson et al, 1981),
The topological studies have thus revealed not only that the spatial conformation
of the RVFV glycoproteins plays a decisive role in determining the antigenic
specificity of these particular sites, but that some MAb mixtures exhibit enhanced
binding to certain conformational epitopes. As this may have important biological
consequences in terms of virus neutralization, the possibility that such co-
operative effects may potentiate the neutralizing activities of the MAbs will be
investigated.
88
5. NEUTRALIZATION
5.1 Introduction
Glycoproteins of many enveloped viruses have been reported to play important
roles in the adsorption and penetration of the virus (Choppin and Scheid, 1980)
and are also the targets of the immune response to infections (Dimmock, 1987;
Sarmiento et al, 1979). The neutralization of virus infectivity by antibodies has
been proposed as a major mechanism of immunological defence against virus
invasion (Dimmock, 1984; 1987; McCullough, 1986). Several mechanisms of
virus neutralization have been described for other viruses, including cross-linking
of virus particles by antibody (Emini et al, 1983), inhibition of virus binding,
virus internalization and uncoating (reviewed by Dimmock, 1984; 1987; Iorio,
1988). Complete neutralization may moreover require synergistic enhancement
of neutralization by pairs of antibodies to different antigenic sites (Gehrz et al,
1992; Kingsford, 1984; Lussenhop et al, 1988). It hac recently become apparent
that there is no mechanism of neutralization specific for all viruses (Kingsford et
al, 1991; Outlaw and Dimmock, 1991).
With regard to RVFV, several neutralizing epitopes on the glycoproteins have
been identified by monoclonal antibodies (Collett et al, 1987; Schmaljohn et al,
1989). The neutralizing antibodies have also been used to analyse antigenic
determinants of vaccinia virus- or baculovirus-expressed RVFV glycoproteins
(Collett et al, 1987; Dalrymple et al, 1989; SCh •')hu et al, 1989) and to
investigate the potential efficacy of a recombinant ie (Saluzzo and Smith,
1990). However, there is little published informaticn regarding the mechanisms
of neutralization of RVFV.
The majority of the RVPV MAbs produced in this study exhibited neutralizing
activity, suggesting that they will be useful for examining the mechanisms of
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inhibition of virus infectivity. The MAbs were therefore used to analyse the
mechanisms involved in the antibody-mediated r -utralization of RVFV, including
possible synergistic neutralization by mixtures of antibodies.
5.2 Materials and Methods
5.2.1 CPEN'l'tests with mixed MAbs
MAb pairs were tested using both uninactivated and heat inactivated (56°C for 30
min) ascitic fluids. These were diluted 1:4 in Leibovitz medium supplemented
with 5% PCS and 0,3% gentamicin antibiotic. Volumes of 50 polof each MAb
pair were added to the first well of a microtitre plate to give a 1:8 dilution for
each antibody. Serial two-fold dilutions of each MAb mixture were then made,
followed by the addition of an equal volume of virus (100 TCIDso) to yield final
initial dilutions of 1:32 for each MAb. The plates were incubated for 2 h at 37°C
in a humidified container, then seeded with cells and incubated as outlined in
section 2.2.3.3 e. Each MAb pair was tested in duplicate and end points recorded
as the mean reciprocal of the highest dilutions which prevented CPE.
5.2.2 PRNT tests with mixed MAbs
MAbs which did not neutralize individually but which neutralized when used in
combination in the CPENT were further tested by PRNT. The method used was
based on that of Lussenhop et at (1988) with the exception that MAb ascitic fluid
was used instead of purified antibody preparations, and no C1 was added. Each
combination was tested with one MAb at a fixed concentration, mixed' ...1serial
fourfold dilutions of the second MAb and vice versa. The dilution used for the
MAb at fixed concentration was that which yielded a 50 % PRNT titre. Assays
were performed in duplicate on Vero cell monolayers in 24 well tissue culture
plates essentially as described in section 2.2.3.3f. The neutralization titres were
recorded as the reciprocals of the highest dilutions which gave an 80% reduction
in the number of plaques relative to the virus controls.
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5.2.3 Blocking of MAb neutralization
Those MAbs which competed for binding of the strongly neutralizing MAbs 3E5
and 9C4 to RVF antigen in the CBA (Section 3.3.3) were tested for their ability
to inhibit the neutralizing activity of the latter two antibodies. This was carried
out using a modification of the CPENT described above. Briefly, the competing
MAbs at 10.1 and 10.2 in Leibovitz medium were preincubated with 100 TCID50
virus for 1 h at 37°C before serial two-fold dilutions ofMAbs 3ES and 9C4 were
added. The plates were incubated :for a further hour at 37°C, followed by the
addition of the cells. After 6 days at 3~°C, the wells were examined for the
pres ence of CPE.
5.2.4 Post-adsorption virus neutralization tests
Post-adsorption neutralization tests were performed as described by Highlander
et al (1987) with slight modifications. RVFV was diluted to ± 800 PFU/ml in
Leibovitz medium and aliquoted in 0,4 ml volumes. Dilutions for each MAb
were prepared so that approximately 80% of the input virus would be neutralized.
Vero cell monolayers in 24-well plates were prechilled for 1 h at 4°C. One set
of virus samples was mixed with an equal volume of the MAbs for 2 h at 37"C.
The second set of virus samples was added directly to the individual monolayers
for 1 h at 4°C and unadsorbed virus was removed by washing the cells with
phosphate buffered saline with magnesium chloride (PBS~MgC10. Bound virus
was incubated with the individual MAbs for an additional 2 h at 4°C. Virus
control samples were plated for 1 h at 4°C, washed and incubated an additional
2 h at 4°C without antibody, In all three cases, the monolayers were again
washed twice, overlaid with agarose, stained, and the plaques counted as for the
PRNTs. Neutralization before and after virus adsorption for each sample was
compared to that of the virus control without antibody and expressed as a ratio.
Post-adsorption neutralization assays were also carried out with C'-dependent
MAbs; here C' was added to the MAb dilutions to y;eld a 1:4) final concentration
of C'.
91
5.3 Results
5.3.1 CPFNT with MAb pairs
'The effects on the neutralizing activity of MAbs 3E5 (G1 Ia) and 9C4 (G2 Ia)
when mixed witt. other MAbs which were non-neutralizing in the CPENT ate
shown in Table 17. Only those MAb pail's which resulted in enhanced
neutralization or binding in the CBA with either MAb 3E5 or 9C4 are shown.
The neutralizing activity of Ml\b 3E:5 (G1 Ia) was increased two to almost eight-
fold when mixed with MAbs binding to domains G1 II as well as MAbs 1E4 and
aG10. The sites recognized by the latter could not be mapped due to the weak
avidity of these entlbodies in the CBA. MAb 9E4, which resulted in augmented
binding of 3E5 in the CBA, on the other hand, did not increase the neutralizing
titre of 3E5. Of the two MAbs which caused increased binding of MAb 9C4 (G2
Ia), only MAb 6.810 brought about synergistic neutralization of 9C4. Enhanced
neutralization of MAb 9C4 also occurred when mixed with another of the G2-
specific MAbs (7F1, mapping to G2 II) as well as some antibodies specific for the
G1 protein.
Tables 18, 19 and 20 show the results of mixing all the RVFV MAbs in various
combinations in the CPENT. Many of the pairs of the G l-specific MAbs were
able to neutralize the virus when tested as uninactivated ascitic fluid, but only four
of these retained their neutralizing ability once inactivated (Table 18). None of
these neutralizing antibody pairs exhibited augmented binding in the CBA as
determined previously.
In contrast to the Gl-specific MAb pairs, only one of the mixtures of the G2-
reactive MAbs (8C2 and 7Fl mapping to G2 Id and II) resulted in synergistic
neutralization (Table. 19). This particular MAb pair had previously been shown
to display bidirectional enhanced binding in the CBA. A number of the mixtures
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Table 17. Effects on neutralizing activity of MAbs 3E5 and 9C4 by mixing with other MAbs
Increased neutralization ratio!
G1 protein G2 protein
CBA Ia TIa TIb TIc TId TIe ? ? Ia II ill ?
domain
MAb 3E5 3D2 3Rl 4B3 5Al 9FA 8G10 lE4 9C4 7F1 4DlO 6EI0
3E5 1 5.5 2 2.7 2.7 1 5.5 7.8 3.1 1 1 1
\0 9C4 3.1 1 8 4 8 1 1 1 1 4 1 2.8~
1Neutralization ratio = neutralization titre of mixtures
mean of expected neutralization titre
Table 18. Neutralizing activity of paired Gl-specific MAbs
Neutralization titre'
eBA domain 1 Ib ITa IIb ITc TId TIe IJla TIIb IV ? t ?
MAb 5El 3D2 3Rl 4B3 5Al 9E4 5Ell 8A3 5£9 5F2 8GI0 lE4
Ib 5El _2 128
ITa 3D2
IIb 3Rl 128 -~ 128
ITc 4B3 128 128 128~
\0 TId 5Al 128 - 128
.t:::-
Ile 9E4
rna 5Ell 128 128
fib 8A3
IV 5E9 128~
? 5F2 128
? 8GlO
? lE4
1
2
Neutralization titre in CPENT
No neutralization
Inactivated MAb ascitic fluido
Table 19. Neutralizing activity of paired G2-spec1fie MAbs
Neutralization titre'
Ib Ie Id IT III IV ? ?
SG2 7F2 8C2 7F1 4DlO 8E6 6EIO scrz
_2
--,
- I 2561
CBA domain
:MAb
Ib 8G2
Ie 7F2
Id gC2
\0
IT 7FlVI
m 4DIG
IV 8EE"
? 6EIG
? 5C12
1 Neutralization titre in CPENT
2 No neutralization
o Inactivated MAh ascitic fluid
of Gl and G2-specific MAbs neutralized when tested as uninactivated ascitic fluid,
but upon inactivation only three pairs still exhibited synergistic neutralization
(Table 20).
5.3.2 PRNT with mixed MAbs
The combinations of MAbs which exhibited synergistic neutralization in the
CPEN I's were further tested by PRNT. When the antibodies were tested
individually, neutralizing activity was seen with Gl-specific MAbs 3Rl, 4B3,
5Al, 5E9, 8GI0 and the G2-specific 7F2 at antibody concentrations ranging from
1:256 to 1:8000 using a 80% plaque reduction endpoint. MAbs 8C2 (G2 Id) and
7Fl (G2 II), on the other hand, did not neutralize RVFV at the 80% plaque
reduction level even at a concentration of 1:128.
By combining mutually enhancing pairs of antibodies eg 8C2 + 7FI j 8G10 +
7Fl and 4B3 + 7F2, strong neutralizing effect was seen. The combination of
MAbs 8C2 + 7Fl (Fig. 6a), both of which were individually non-neutralizing
at the 80% plaque reduction level, resulted in neutralization up to a dilution of
1:64000. The MAb pairs 8010 + 7Fl (Fig. 6b), 4B3 + 7F2 (Fig. 6c) and 5E9
+ 8G10 (Fig. 60) all neutralized with an 80% PRNT titre of 1:128000. An 80%
PRNT titre of 1:256000 was obtained for the MAb pairs 3Rl (G1 Ilb) + 5E9
(Gl IV) (Fig. 6e) and 5Al (G1 IId) + 8GI0 (G1?) (Fig. 6t). The MAb
combination of 4B3 (G1 IIc) + 8010 (Fig. 6g) neutralized at the 80% plaque
reduction level up to a dilution of 1:1024000, while the neutralizing titre for 5E9
(Gl IV) + 7Fl (G2 II) was 1:64000 (Fig. 6h). For each MAb pair, the
synergistic neutralization obtained by mixing a fixed concentration of one antibody
with serial dilutions of the second antibody, and vice versa, was almost identical.
The only exception was the MAb pair 4B3 + 8GlO, where mixing varying
dilutions of 4B3 with a constant amount of 8G10 gave a titre of 1:1024000
compared to 1:32000 when the antibodies were mixed the other way around, The
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Tabl- 20. Neutralizing activity of paired Gl and G2-specific MAbs
Neutralizing titre 1
CBA domain GlIb ITa ITb ITc lId TIe rna 1IIb IV ? ? ?
MAb SEI 3D2 3Rl 4B3 SAl 9E4 SEll 8A3 5E9 SF2 8GlO lE4
G2Ib 8G2 _2 128 32
Ic 7F2 128 [iliJ 128
Id 8C2
II 7FI 64 128 128 32 128
\Q
<a
III 4D10 32 :i2 128
N 8E6 32 64
? 6EI0 32
? Se12
1 Neutralization titre in CPENT
2 No neutralization
o Inactivated MAb ascitic fluid
7F1(v) + 8C2(C)
20 -e- MAb 8C2
-r- MAb 7F1
OL-~·~~~L-~~~~~WW~~~~~~~.~
2 3 4 5 7
Fig. Sa MAb dilutions (10910 )
-e- MAb 8Gi0
-r- MAb 7F1
4 5
MAb dilutions (log )
10
6 7
Fig. 6. Plaque reduction neutralization test (PRNT) using MAb pairs.
(a) PRNT with a combination of two non-neutralizing G2-reactive MAbs (8C2
+ 7Fl) which exhibited reciprocal augmented binding in the CBA. The
synergistic neutralization obtained by mixing fl. constant (c) amount of 8C2 (G2
Id) and varying (v) dilutions of 7Fl (G2 IT) is shown. (b) PRNT with a mixture
of Gl and G2-specific MAbs (8Gl0 + 7Fl). The enhanced neutralization
observed by mixing a constant (c) amount of 7Fl (G2 IT)with varying (v)
dilutions of 8GlO (Gl 1) is shown.
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4B3(v) .. 7F2(c)
20 -e- MAb 4f\3
-+- MAb 7F2
20 -e- MAb 8G10
-+- MAb 5E9
O~~~llW~~~~ __ ~~~~_L~~_~-4!·~I!~"~II!
2 4 6 6 7
Fig. 6e1 MAb dilutions (iOg1o )
Fig. 6. Plaque reduction neutralization test (PRNT) using MAb pairs.
(c) Potentiation of the ;neutralizing activity of MAbs 4B3 (01 IIc) and 7F2 (02
Ic) when us..... ". combination by mixing a constant (c) amount of 7F2 with
varying (v) dilutions of 4B3. (d) The enhanced neutralization obtained by mi'·1.ng
a constant (c) amount of MAb 5E9 (Gl IV) with varying (v) dilutions of 8GI0
(01 ?).
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Fig. 6. Plaque reduction neutralization (PRNT) using MAb pairs.
(e) PRNT with a combination of two Gl-reactive MAbs (3Hl + SE9). The
enhanced neutralization observed by mixing a constant (c) amount of 5E9 (G1 IV)
with varying (v) dilutions of 3R1 (G1 fib). (f) Potentiation of the neutralizing
activity of MAbs 8GlO (01 'I) and 5Al (Gl TId) when used in combination by
mixing a constant (c) amount of SAl with varying (v) dilutions of 8GI0.
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Fig. 6. Plaque reduction neutralization test (PRNT) using MAb pairs.
(g) The synergistic neutralization obtained by mixing a constant (c) amount of
8Gl0 (G1 1) with varying (v) dilutions of 4B3 (G1 TIc). (h) Pru~T with a
mixture of Gland G2-specific MAbs where a constant (c) amount of 5E9 (G1 IV)
was added to varying (v) dilutions of 7Fl (G2 II).
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greatly enhanced percentage in plaque reduction achieved by combining the MAbs
could not be explained by adding the percentage of plaque reduction contributed
by each antibody tested individually.
5.3.3 Inhibitlon of neutralizing activity of MAbs
Those MAbs which had partially inhibit d the binding of MAb 3E5 (G1 Ia) and
9C4 (G2 Ia) in the CBA were examined for the ability to inhibit the neutralizing
activity of the latter two antibodies. None of the antibodies were found to affect
the neutralizing titre of MAbs 3E5 and 9£:4.
5.3.4 Pest-adsorption neutralization tests
The MAbs which exhibited neutralization activity independent of C' in the PRNT
were tested for their ability to neutralize the virus once it had attached to the cells
(Table 21). Some of the MAbs specific for G1 and G2 were found to neutralize
adsorbed virus as efficiently as pre-adsorbed virus eg those mapping to GIla, JIb,
IId and G2 Ia. Several antibodies directed against G1 neutralized the adsorbed
virus to lower titres than before virus adsorption (MAbs 4B3, 8GIO, 5E9) while
one of the anti-G 1 MAbs, 9E4, and two of the anti-G2 MAbs (mapping to G2 Ib
and 02 Ie) were unable to neutralize the attached virus. None of the MAbs
requiring complement for neutralization were able to neutralize cell-adsorbed
virus.
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Table 21. Neutralization by RVFV MAb treatment of virus before or after adsorption
MAb Antigenic domain Neutralization' Neutralization
Preadsorption Postadsorption ratio?
3E5 G1Ia 32768 32768 1.00
3R1 GIUb 1024 1024 1.00
4B3 G1 IIc 16384 4096 0,25
5Al G1 TId 1024 1024 1.00
)-4 9E4 G1 TIe 1024 0.00
0
u:>
5E9 G1 IV 128 0.1251024
lE4 G1? 4096 512 0.125
8G10 G1? 4096 512 0.125
9C4
8G2
7F2
G2Ia
G2 Ib
G2 Ie
32768
2048
2048
32768 1.00
0.00
0.00
1 80% PRNT
2 Ratio of neutralization after virus adsorption to neutralization before virus adsorption
5.4 Discussion
Studies on the neutralization of various enveloped viruses suggest that antibodies
binding to different sites on a viral protein neutralize. by different mechanisms allr~
also that a single MAb can neutralize by a number of alternative procedures
(Dietzschold et al, 1987; Dimmock, 1987; Dubuisson et al, 1990; Fuller et al,
1989; Gollins and Porterfield, 1986a; Kingsford et al, 1991; Okazaki et al, 1986;
Roehrig et al, 1988; Taylor et al, 1987). Synergistic effects which potentiate the
functional activity ofMAbs have been demonstrated with many viruses, including
La Crosse virus (Kingsford, 1984), Newcastle disease virus (Russell, 1986),
respiratory syncytial virus (Anderson et 01, 1988), bovine herpes virus (Dubuisson
et al, 1990) and cytomegalc .. irus (Gehrz et al, 1992; Lussenhop et al, 1988).
The mechanisms involved in the antibody-mediated neutralization of RVFV were
analysed here using the panel of MAbs. Since several of the MAbs were. found
to augment the binding of other antibodies in competitive binding assays, an
important aspect of the study was examining the possibility that mixtures of the
antibodies could have a synergistic effect on RVFV neutralization.
Individually, nine MAbs mapping to ~he G1 domains I, II and IV, and three
MAbs specific for the G2 I domain, were able to neutralize RVFV in vitro
without C', while the remaining antibodies required C' for neutralization. On
mixing all combinations of these antibodies, synergistic neutralization was
observed for many MAb pairs, The fact that some of these antibody pairs were
no longer capable of achieving this synergy when tested after heat-inactivation
emphasizes the important role of C' in this particular aspect of RVFV
neutralization.
However, even in the a1,,)fence of C', various different mixtures of MAbs
exhibited enhanced neutralization; these could be divided into three categories.
In the first instance, synergistic neutralization occurred for two of the MAb pairs
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that showed augmented binding for 02 in the binding assay ie 9C4 + 6ElO and
8C2 + 7Fl. The former pair comprised one neutralizing MAb (mapping to G2
Ia) and a non-neutralizing antibody. This probably presents an example of
conformational changes by one MAb altering epitope expression by the virus so
that the second MAb binds or neutralizes more efficiently (Clegg et al, 1983;
Kingsford, 1984; Lubeck and Gerhard, 1982). The other MAb pair (8C2 + 7F1)
which exhibited synergistic neutralization were both individually non-neutralizing
at the 80% plaque reduction end-point, Here neutralization could be due to the
combined mass of both antibodies binding which could interfere with the process
of cellular attachment and fusion by steric hindrance as suggested for
cytomegalovirus (Lussenhop et al, 1988). Alternatively, increased neutralization
could be due to combined conformation changes brought about by both antibodies
binding, The fact that this MAb pair displayed reciprocal enhanced binding in the
competitive binding assay favours the latter explanation,
The second category of synergistic neutralization occurred between combinations
of MAbs for which increased binding had not been detected, indicating that
enhancement of RVFV neutralization must involve more than just an increase in
the amount of neutralizing antibody bound to the virus. Synergy of this type was
seen between MAbs directed against closely adjacent epitopes eg 3E5 (G1 Ia) and
3R1 (Gl lIb) as well as distant epitopes eg 3R1 (G1 IIb) and 5E9 (G1 IV). The
enhanced neutralization in the latter case is most likely the result of
conformational changes in sites critical for virus infectivity which do not lead to
extra antibody binding to the virion surface as indicated by the binding assays.
In contrast, the increased neutralizing activity obtained by mixing MAbs against
overlapping or closely adjacent epitopes may either be due to a more efficient
blocking of critical sites on the surface of the virion (Russell, 1986; Van Drunen
Littel-Van den Hurk et al, 1985) or to allosteric phenomena (Gehrz et al, 1992;
Kingsford 1984).
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Lastly, mixtures of MAbs reacting with the Gland G2 RVFV proteins were also
capable of enhancing neutralization, supporting the findings in the binding studies
that some antibodies can induce conformational changes in an entirely different
viral protein.
The data from these in-vitro neutralization assays thus suggest that synergistic
neutralization between various antibodies directed against different antigenic
determinants on the RVFV Gland 02 proteins is a common phenomenon. This
may be of considerable immunological relevance with respect to the functional
activity of a polyclonal immune response to infection with RVFV.
In order to further elucidate the mechanisms of antibody-mediated RVFV
neutralization, post-adsorption neutralization tests were performed. If RVFV
neutralization primarily involves the inhibition of virus attachment, adsorbed
virions should be resistant to neutralization. In contrast, if the process involves
the blocking of some steps subsequent to virus adsorption, the antibodies should
neutralize cell surface-bound virions as shown for example for rabies virus
(Dietzschold et al, 1987), herpes simplex virus (Fuller and Spear, 1985),
transmissible gastroenteritis coronovirus (S:1.m6 et al, 1990) and bovine herpes
virus (Okazaki et al, 1986).
The results obtained revealed not only that the RVFV MAbs exhibited different
mechanisms of neutralization, but that antibodies mapping to a single antigenic
domain (eg G1 II) do not neutralize in an identical manner. Some of the
antibodies specific for Gland G2 neutralized rell-attached virus as efficiently as
unadsorbed virus, thereby indicating that they can neutralize by inhibiting the
infection process after virus attachment. Both the Gland G2-specific MAbs
previously shown to be highly protective in. vivo (3E5 and 9C4) exhibited this type
of neutralization.
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While a relationship of both the RVFV envelope proteins to infectivity has been
established (Battles and Dalrymple, 1988; Collett et al, 1987; Dalrymple et al,
1989; Keegan and Collett, 1986; Schmaljohn et al, 1989) the exact role played
by either of the glycoproteins in viral penetration has not yet been directly
demonstrated. The findings here that MAbs directed against both G1 and G'.!,
neutralize virus that has already bound to cells strongly suggests that both the
RVFV envelope proteins are responsible for penetration of the virus.
Other MAbs, eg those mapping to Gl Ile, G2 Ib and G2 Ic, on the other hand,
did not exhibit any post ...adsorption neutralizing ability, suggesting that these
antibodies may neutralize by preventing virus attachment to cells. The RVFV
MAbs requiring C' for virus neutralization likewise may effect neutralization by
preventing virus attachment, possibly by enhancing aggregation of virus-antibody
complexes (Oldstone et al, 1974).
The remaining MAbs specific for the G1 protein displayed a certain degree of
post-adsorption neutralizing activity. These antibodies may be capable of
inhibiting RVFV infectivity in several ways, as reported for certain poliovirus
MAbs (Emini et al, 1983). The mechanism of neutralization may be partly
dependent on the isotope of the antibody (Dimmock, 1984; 1987). In the case of
the two IgM antibodies lE4 and 8GiO, neutralization is most likely effected by
both prevention of virus attachment as well as virus internalization, as shown for
IgM neutralization of influenza virus (Taylor and Dimmock, 1985). The IgG
MAbs defining sites Gl Ilc and Gl IV, on the other hand, could possibly
neutralize by inhibiting any of the various stages of virus infectivity i.e.
attachment, penetration, uncoating or replication.
The post-adsorption studies also help to further elucidate the mechanism
underlying the enhanced neutralization which occurred between the pairs ofMAbs
which map to the closely adjacent Gl I and Gl II domains. The fact that, for
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example, MAbs 3E5 (G1 Ia) and 3Rl (Gl lIb) can neutralize virus that is already
cell-attached, indicates that the increased neutralization is not due to a more
efficient blocking of sites involved in virus attachment as has been suggested for
Newcastle disease virus (Russell, 1986).
The data obtained from these neutralization assays thus provide evidence for an
interaction between the RVFV Gl and G2 proteins by showing that antibodies to
one of the envelope glycoproteins can cause a conformation change resulting in
an altered antigenicity in the other glycoprotein. The findings furthermore
suggest that inhibition of virus attachment is not the principal means of antibody-
mediated RVFV neutralization. Instead such neutralization is most likely the
result of several different processes, including synergistic neutralization by
combinations of different antibodies, prevention of virus attachment and inhibition
of steps subsequent to virus adsorption. To clarify the neutralization mechanisms
further, possible interference by the MAbs of various stages of virus infectivity
such as virus attachment and penetration will be examined in more detail.
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6. RVFV ArrACHMENT
6.1 Introduction
The early events in the infection process of RVFV and other members of the
Bunyaviridae are not well defined (Schmaljohn and Patterson, 1990). As with
other enveloped viruses, attachment of RVFV to host cells is a critical first step
to infection mediated by the interaction between one or both of the viral envelope
glycoproteins and cell surface receptors (Choppin and Scheid, 1980; Lentz, 1990).
While the cell receptors involved in binding have not been identified thus far for
any member of the Bunyaviridae family (Wang et al, 1991), the viral attachment
proteins have been examined indirectly using MAbs (Arikawa et al, 1989; Dantas
et al, 1986; Gonzalez-Scarano et al, 1982; Grady et al, 1983; Keegan and Collett,
1986; Kingsford et aI, 1983; 1991; Ludwig et oi, 1939; 1991; Pifat et ai, 1988).
Antibodies against the region of the viral coat proteins thought to be involved in
binding have been shown to block the attachment of virus (Dietzschold et al,
1987; Dimmock, 1987; Dubuisson et al, 1990; Massey and Schochetman, 1~t1;
McCullough, 1986; Roehrig et al, J.988). Inhibition of virus binding by
antibodies in fact represents one of the classic explanations of virus neutralization
(Mandel, 1967). Blocking of virus attachment may be effected through the
binding of antibody at or near the cell attachment site on the virus, "bridging" of
this cell hinding site through the MAb reacting with epitopes on either side of it,
saturation of' the virion surface by antibody, or aggregation of virus particles to
form virus/antibody complexes (reviewed by McCullough, 1986). In addition to
these inhibitory effects on virus binding, some MAbs have been identified which
neutralize by preventing internalization of the adsorbed virus (Armstrong et al,
1990; Sune et al, 1990; Taylor and Dimmock, 1985).
With regard to the Bunyaviridae family, virus attachment and MAbs which inhibit
such binding have recently been examined in some detail for the burvavirus La
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Crosse virus (LACV)(Kingsford et al, 1991; Ludwig et al, 1991). The findings
of these and earlier studies (Gonzalez-Scarano et al, 1982; Kingsford and Hill,
1981; 1983; Kingsford et al, 1983) suggest that the LACV Gl protein is more
actively involved in binding to vertebrate host cells than G2.
Unlike LACV, comprehensive analyses on the viral proteins involved in
attachment of RVFV have not been performed to date. In contrast to the situation
for LACV, however, the presence of neutralizing and haemagglutination sites on
both the RVFV Gl and G2 proteins (Keegan and Collett, 1986) indicates that both
envelope glycoproteins may be involved in attachment, either directly or by
conformational requirements (Schmaljohn and Patterson, 1990).
'The neutralization studies undertaken here have revealed that some MAbs were
unable to inhibit RVFV infectivity once virus had already attached to cells. This
suggests that these particular antibodies may effect neutralization by either
preventing virus from binding to cells or by inhibiting the adsorbed virus from
entering the cell. To further identify the stage of the virus cycle interrupted by
the neutralizing antibodies, the effect of the MAbs OU virus binding and
internalization will thus be examined. An investigation of this nature may also
help to identify the site(s) on the RVFV Gl and G2 glycoproteins which are
involved in virus attachment.
6.2 Materials and Methods
6.2.1 Preparation of purified radiolabelled virus
esS] Methionine-labelled virus was prepared as outlined below. Vero cell
monolayers in 75 em' flasks were infected with RVFV (TC3) at a multiplicity of
infection (m.o.i.) of 10. After adsorption of virus for 1 h at 37°C, 10 ml of
serum-free EMEM was added to each flask for a further 2 h at 37°C. The
medium was then removed and replaced with 10 ml of methionine-free EMEM
(Flow Laboratories, Irvine, U.K.). Following incubation for 1 h at 37°C, [35S]
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methionine (sp.act 1000 Ci mmol, Amersham International, U.K.) was added. to
give a final concentration of 50 ,uCi/ml. Virus was harvested at 48 h post-
infection and clarified by centrifugation at 7000 g for 30 min at 4°C it'! a
Beckman J2-21 centrifuge.
Radiolabelled virus was purified based on the method of Kingsford and Hill
(1983) with the exception that DMSO w. not included in the gradient, Clarified
virus (20 ml) was layered onto a discontinuous sucrose gradient comprising 20%
(w/v) sucrose in 0,01 M Tris, 0,1 .l ~I~ EDTA and a 65% sucrose cushion in the
same buffer. The tubes were spun for 21/Z h at 26 000 rpm at 4°C in a SW 28
rotor in a Beckman L8-60 M ultracentrifuge. Fractions of 0,5 ml from the
sucrose-sucrose interphase were harvested and aliquots assayed for infectivity by
titration in 96 well microtitre plates as described in 2.2.1.1. Infectious fractions
with the same titres were pooled, a" . -ted and stored at -70°C. Prior to use in
the attachment assays, one amp fTC' ' ::h batch of labelled virus was thawed in
order to determine the PFU/ml by means of the plaque assay as described in
section 2.2.3.3f, using 24 well plates.
6.2.2 Efficiency of virus attachment
Several control experiments were initially carried out in parallel to assess the
efficiency of virus attachment. In the first instance, virus inoculated cells were
incubated for 6 days to check for CPE as evidence for productive infection.
Purified [35S] methionine ..labelled virus (6,5 x 107 PFU/ml) was diluted 1';20,40,
100 and 500 in PBS-MgC12 and chilled on ice for 15 min. Aliquots of 0,4 ml
were then added in triplicate to confluent Vero monolayers (1 x 106 cells/well) in
6 well plates (Cel-Cult, Sterilin Ltd., Hounslow, U.K.). Following adsorption
for 2 h at .+"C with gentle rocking, the inoculum was removed, the cells washed
and medium replaced with Leibovitz containing 5% pes and antibiotics (2.2.1.1).
The plates were incubated at 37°C for 6 days, then read for CPR
111
Secondly, the amount of infectious virus which had not bound to the cells was
examined by titrating the supernatant inoculum after a 2 h adsorption period.
Labelled virus at the same concentrations as above was adsorbed to cell
monolayers for 2 h at 4°C. The inoculum was removed and used for titration in
96 well microtitre plates as described in section 2.2.1.1. The cells were washed
three times with cold PBS and lysed with 1 m1 of 1% SDS in distilled water. Cell
lysates were transferred to liquid scintillation vials containing 5 ml of scintillation
fluid (Ultima-Gold XR, Packard Instruments, U.S.A.). Radioactivity of these
samples was determined by liquid scintillation spectrometry using an LKB 1217
Rackbeta liquid scintillation counter.
6.2.3 Inhibition of.virus attachment
The effect of MAbs on virus attachment was determined based on the procedure
of Dietzschold et al (1987) with some modifications. Purified RVFV was
preincubated with various dilutions of MAb ascitic fluids for 2 h at 37°C. T!1e
final concentration of virus was 5 x 106 PFU/ml. The mixtures were then chilled
on ice prior to addition to the cells. Confluent Vera monolayers in 6 well plates
were washed three times with cold PBS and incubated with 1 ml/well of 1%
ovalbumin (Sigma Chemicals) in PBS for 15 min at 4°C to prevent non-specific
binding. The ovalbumin was then removed and aliquots (0,4 ml containing 2 x
106 PPC with an activity of 10 000-15 000 c.p.m.) ofthe virus-antibody mixtures
were added to the monolayers, Following incubation for 2 h at 4 <:'Con ice with
gentle rocking, the cells were washed, lysed and the cell-associated radioactivity
determined as in 6.2.2.
The fraction of input counts for each sample of virus specifically bound to cells
in the presence of antibody was then compared with the average amount bound
when no antibody treatment was given. As a negative control, a MAb ":irecte.d
against West Nile virus (Besselaar and Blackburn, 1988) was used. RVFV
hyperimmune ascitic fluid was included as a control for polyclonal immune IgG.
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6.2.4 Effect of temperature on virus binding
Confluent monolayers of cells in three sets of six well plates were inoculated with
the same concentrations of virus-antibody mixtures as in 6.2.3. One set of plates
was incubated at 4°C on ice for 2 h with gentle rocking. The remaining plates
were incubated in parallel at rt under the same conditions. The cells from the
plates kept at 4°C and one of the sets held at rt were washed, lysed and the bound
radioactivity determined as outlined above. The remaining plates were used to'
test for neutralization of virus infectivity by the PRNT method as described in
section 2.2.2.3f.
6.2.5 Distlnguishlng between cell bound and internalized virus by proteolytic
digestion
The method used to' distinguish between virions adherent to' the cell surface and
endocytosed virus was modified from that of Gollins and Porterfield (1984) using
the proteolytic enzyme proteinase K. Binding and internalization assays were all
done using Vere cell suspensions (2 x 106 cells/ml) in sterile centrifuge tubes
(Falcon, Bector Dickinson & CD, New Jersey, U.S.A.). Binding studies were
carried out ill a cold room, while internalization assays were performed in a 37°C
incubator. Leibovitz medium containing 0,5 % BSA, pH 7,0, was used as the
assay medium.
a) Determination of total cell-associated radioactivity
TO' determine the binding of labelled virus to' cells in the absence of the
proteolytic enzyme, 0,5 ml of two different titred batches of [3sS] methionine-
labelled purified RVFV (6.2.1) was added to' 0,5 ml volumes of the cell
suspensions to' yield a m.o.i. of 2 and 0,02 respectively. The tubes were
incubated at 4°C with gentle shaking fer 2 h, and the cells were then washed
using the following standard procedure: 3 ml of assay medium was added to' each
tube and the cells pelleted at 1000 rpm for 6 min in a refrigerated centrifuge
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(Beckman J-6B). The cells were then washed twice more with 2 ml assay
medium.
For determining cell-associated radioactive c.p.m., the final cell pellet was
resuspended in 0,5 ml PBS and added to scintillation vials containing 0,1 rnl1.0%
SDS in distilled water. Five ml of Ultima Gold XR scintillation fluid was then
added and the radioactivity determined as in 6.2.2 to give a value for total virus-
specific radioactivity (i.e, protease-resistant + protease-removable c.p.m.).
b) Determination of protease-resistant radioactivity
To determine irreversibly cell-bound virus, the protease-resistant radioactivity
associated with cells was measured by means of virus binding assays followed by
treatment with proteinase K. These experiments were carried out in parallel with
the above virus attachment assays in which no enzyme was added. Virus was
allowed to adsorb to the cells as above. The effect of the MAbs was tested by
preincubating the virus with hybridoma ascitic fluids at a final dilution of 1:100
for 2. h at 37°C. The virus-antibody mixtures were then chilled on ice for 15 min
prior to adding to the cell suspe.isions for 2 h at 4°C. Following washing of the
cells by the standard procedure, the cells were resuspended in 5 ml PBS and
0,1251'111of a stock solution of proteinase K (Boehringer, Mannheim, Germany)
in PBS added. The protease stock solution was prepared fresh prior to use, at a
concentration of 0,5 mg/ml, The mixture was then incubated for 40 min on ice
with constant gentle shaking. The cells were washed once in PBS containing 10%
horse serum and twice in PBS with 0,2 % BSA. The final cell pellet was lysed
with 10% SDS as above and the c.p.m, determined. This was taken to represent
the protease-resistant radioactivity, which in turn was considered to reflect either
irreversibly cell-bound virus or endocytosed virus. Two replicates were included
for each experimental point and all experiments were performed at least twice.
With scintillation determinations, the average c.p.m, was calculated for replicate
vials.
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6.2.6 Effect of MAbs on virus internalization
The possible inhibition of virus internalization by MAbs was examined by shifting
the cell-attached virus to 37°C to allow substantial penetration to occur prior to
protease degradation.
Synchronized internalization of RVFV at 37°C was performed by prebinding
labelled virus to Vero cells at 4°C in the presence or absence of the MAbs under
identical conditions as in 6.2.5b, with the exception that the cell suspensions were
shifted to 37°C for the second hour. Following the temperature shift, the cells
were washed and proteinase K added as described earlier to remove any bound
virus that had not yet been endocytosed, The virus-specific counts bound in the
absence of antibody were taken to represent 100% internalization of the virus, and
the counts obtained with the antibody-treated virus were calculated relative to this.
To control for any possible inhibition of binding, the proportion of virus bound
in the presence of the MAbs after 2 h at 4°C without enzyme treatment was
determined in tAfallel to the internalization assays.
6.3 Results
6.3.1 Efficiency of virus attachment
Monolayers which had been infected with purified labelled virus and incubated for
6 days at 37°C showed CPE at all the virus concentrations used. The fact that
productive infection had occurred suggested that the virus had attached efficiently.
The results of the titration of virus present in the supernatant inoculum following
the 2 h adsorption period are shown in Table 22. The extremely low titres of
infectious virus remaining in the supernatant after adsorption confirmed the above
findings that the majority of the added virus had bound to the cells at this time.
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Table 22. Titre of infectious RVFV remaining in the supernatant following virus
adsorption to cells for 2 h at 4°C
Virus concentration in Titre of infectious virus Cell-associated
inoculum' in supernatant" radioactivity (o.p.m.)"
10 x lOS 2,5 X 101 24240
5 x 105 2,5 X 101 10746
2 x lOS 1,0 X 101 4500
0,4 X 105 - 786
1 Concentration of [3581methionine labelled RVFV added per 105 cells
2 Titre of infectious RVFV remaining in the supernatant after adsorption of
virus to cells for 2 h at 4 oC
3 Radioactivity associated with the cells after removal of the inoculum
6.3.2 Effect of MAbs on virus attachment
Initial experiments were performed using radi:olabelled RVFV preincubated with
the West Nile virus MAb at concentrations of 1:4 to 1:500 of the hybridoma
ascitic fluid to determine if any non- specific inhibition of virus attachment
occurred with non-immune antibody. Table 23 shows the percent inhibition by
this negative control, as well as by the RVFV polyclonal HAF. Non-specific
inhibition of virus binding by the unrelated MAb was observed at a concentration
of 1:50 and below. At high concentrations the RVP HAP prevented virus
adsorption substantially but at a 1:500 dilution there was only an 18% reduction
in bound virus. 111 the presence of 20% PCS, the amount of bound virus was
reduced by 52% .
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Table 23. Effect of different concentrations of immune and non-immune
antibody on the attachment of RVFV to Vero cells
Antibody'
dilution
~, __ %_'O_In_hi_'_bi_tion of virus 2 attachment
WNMAb RVF HAp3
63 70
56 68
49 65
30 42
0 22
0 18
0 7
--.----------------~r--------
1:5
1:10
~:20
1:50
1:1JO
1:500
1:1000
1 Ascitic fluid
2 Purified [35S]methionine labelled RVFV (5 x 106 PFU/ml with an activity of
±lS 000 c.p.m per well)
3 RVFV polyclonal hyperimmune ascitic fluid
Based on these results, the effect of the RVFV MAbs on virus attachment was
examined using the hybridoma ascitic fluids at a final dilution of 1:100. Some of
the MAbs were also tested at a final dilution of 1:500. All the MAbs exhibited
negligible inhibitory effects on virus binding when the virus was used at 5 x 106
PFU/ml (Table 24). Since this corresponded to a virus concentration ± 6 x 103
times greater than that usee for the neutralization tests, attachment assays with
lower tltred virus (1500 PFU/ml) were subsequently performed to determine if the
MAbs could prevent virus binding under these circumstances. The results showed
that even at low virus concentration, none of the MAbs were a' '0; to significantly
inhibit attachment (Table 24). The PRNTs performed concurrently nevertheless
confirmed that the antibodies were neutralizing the virus.
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Table 24. Effect of neutralizing MAbs on attachment of RVFV at a high and low
multiplicity of infection
MAbl Antigenic % inhibition of attachment %
domain neutralization
(PRNT)4
H' h . 2 T • 319 m.o.i, LOW m.o.i,
/irus only - 0 0 0
3E5 G1Ia 0 2 99,0
3Rl G1 IIb 1 1 98,7
4.133 01 lIc 8 9 96,5
5Al Gl IId 12 11 96,5
9E4 G1 IIe 5 10 96,3
5E9 G1 IV 3 8 98,7
1E4 01? 0 8 95.8
8G10 G1? 5 7 98,0
.9C4 G2Ia 6 5 99,9
8G2 G2 Ib 2 5 93,8
7F2 G2 Ie 3 4 97,0
Controls:
5Ell G1 nr, ntS 25 < 50,0
8A3 G1 IIIb 0 ° < 50,08C2 G2Id 2 8 < 50,0
4DI0 G21TI nt 26 < 50,0
8010 + C' G1? 77 71 99,3
RVFV - 18 22 99,9
HAP
WNMAb - 0 0 0
MAbs used at 1:100
2 Purified labelled RVFV (5 x 106 PFU/ml)
Purified labelled RVFV (1500 PFU/ml)
4 PRNT performed in parallel to attachment assays with RVFV at low m.o.i,
J Not tested
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6.3.3 Effect of temperature on. virus attachment
With the lower titred virus, the bound radioactivity measured at 4°C was
relatively low (± 6000 c.p.m. per well). Attachment studies were therefore also
carried out in parallel at rt in order tv increase the efficiency of virus binding.
At room temperature, the radioactivity specifically bound to the cells in the
absence of antibody approximately doubled compared to that obtained for virus
binding at 4°C. No Significant blocking of virus attachment I)y the MAbs was
observed in these experiments.
6.3.4 Effect of MAbs on stability of virus binding at 4°C
To distinguish between virions adherent to the cell surface and endocytosed virus,
inoculated cell cultures were treated with the proteolytic enzyme proteinase K to
remove putatively attached virus. By this means it was possible firstly to
determine if preincubation of RVFV with the MAbs at 4 °C influenced the stability
of virus binding to the cell surface. Secondly, by shifting the inoculated cultures
to 37°C, it was possible to examine if antibody-coated bound virus was prevented
from penetrating the cell (6.3.5),
To determine the optimum concentration of protease to use for the removal of cell
bound virus, two different concentrations of proteinase K were initially tested
(Table 25). In the absence of antibody, both concentrations of enzyme removed
approximately 81% of the c.p.m, bound to the cells which had been incubated
with labelled virus at 4°C for 2 h. The remaining c.p.m. (19%) were considered
irreversibly bound and probably represented virus which had fused to the cell
surfaces and was no longer susceptible to the enzymatic activity of the J_Jroteinase
K. As proteinase K concentrations greater than 0,5 mg/ml are reportedly toxic
to cells (Gollins and Porterfield, 1984), the protease was used at 0,5 mg/ml in
subsequent experiments to avoid any possible detrimental effects on the cultures.
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Table 75. Percentage irreversibly bound virus to cells after digestion with
different concentrations of the proteinase K enzyme
Input virus' % binding? at 4°C
(m.o.i.) NopK; + PK (0,5 mg/ml) + PK (0,25 mg/ml)
0,02 100 19,1 18
2,0 100 18,4 nd
1 Purified [35S] methionine-labelled RVFV
2 Based on cell-associated radioactivity
3 Proteinase K
In the presence of RVF hyperimmune ascitic fluid, a greater proportion of cell-
bound virus was removed by protease digestion relative to the virus without
antibody (Table 26). In contrast, preincubation of the virus with MAbs 8A3 (01
Illb) and 8C2 (02 Id), which served as controls for non-neutralizing antibodies
in the absence of C I, had no effect on the amount of virus that remained cell
bound.
In the case of the neutralizing Gl-specific MAbs 3E5 (01 Ia), 3Rl (GIIIb), 4B3
(01 lIc) and 9E4 (G1 IIe), approximately the same proportion of antibody-treated
virus was removed from the cell surface as uncoated virus. In the presence of the
other neutralizing Gl-reactive MAbs (51.1, 5E9, lE4, 8GlO) and the MAbs
defining the neutralizing G2 1 domain (9C4, 8G2, 7F2), on the other hand, more
cell-bound virus was removed compared to the untreated virus as shown by the
reduction in cell-associated radioactivity,
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Table 26. Percentage irreversibly bound virus after 2 h adsorption to cells at
4°C and proteolytic digestion with proteinase K
Antibody Antigenic % irreversibly bound virus
domain
r---'----
Virusl only (_PK)2 10(f' Na4
Virus only(+PK) 19 wOS
3E5 G1 Ia 19,4 102
3Hl Gl lIb 18,2 96
4B3 Gl Ilc 17,9 94
5Al G1 IId 14,9 78
9E4 Gl IIe 18,0 95
8A3 GIIIIb 19,7 104
5E9 Gl IV 9,9 55
1E4 G1? 9,4 49
8GlO Gl? 11,0 58
9C4 02Ia 11,4 60
8G2 G2 Ib 10,3 54
7F2 G2 Ie 12,0 63
8C2 G2Id 19,7 103
RVFV HAF - 12,8 67
1 Input virus = purified [358] methionine labelled RVFV (3 x lQ3PFU/ml)
2 Proteinase K
3 Virus specific counts in the absence of protease were taken to represent 100%
attached virus and the counts obtained with the protease-digested virus were
calculated relative to this
4 Not applicable
5 The non-neutralized virus-specific counts after protease treatment were taken
to represent 100% irreversibly bound virus and the counts obtained with the
antibody-treated virus were calculated relative to this
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6.3.5 Effect of neutralizing MAbs on virus internalization at 37.:1C
Synchronized internalization of RVFV at 37°C was performed by prebinding
labelled virus to Vero cells at 4°C in the presence or absence of the MAbs, then
shifting the cell-bound virus to 3rC for 1 h. This was followed by digestion
with proteinase K to remove any remaining putatively attached Vir!.IS, thr~rebv
permitting the exclusive determination of penetrated virus only. For the p.rrposes
of comparison of antibody-coated virus with untreated virus, the total amount ul
radioactivity internalized for virus prebound in the absence of antibody was taken
to represent 100% penetration.
Tb.edata for the binding assays (2 h at 4°C without enzyme digestion) which were
carried out in parallel to the internalization studies are shown in Table 27. The
results were similar to those obtained for virus attachment to cell monolayers
(6.3.1) and confirmed that none of the MAbs significantly prevented binding.
The effect of the MAbs on the internalization of RVFV is also shown in Table 27.
Premixing the virus with the polyc1onal hyperimmune ascitic fluid prevented 18%
of the virus from binding and resulted in an overall reduction of 29 % internalized
virus. This indicated that a proportion of the virus that managed to attach was
prevented from penetrating the cell. Preincubation of the virus with the control
MAbs 8A3 and 8C2, both of which are non-neutralizing without C' , had no affect
on the amount of internalized radioactivity.
In contrast to the non-neutralizing MAbs, the amount of internalized virus-specific
radioactivity was reduced considerably when virus was treated with the anti-Gl
neutralizing MAbs 5AI, 1E4 and 8G10, and the G2-specific MAbs 9C4, 8G2 and
7F2. In these cases, therefore, a substantial proportion of the attached virus was
prevented from entering the cell. Preincubation of the virus with the neutralizing
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Table 27. Effect of neutralizing MAbs on virus internalization at 37°C~
determined after protease removal of exposed virus
Antibody Antigenic % virus-specific counts at time after
domain shift to 37°C
o min (-PKY 60 min (+PK?
Virus' only - 1004 1005
3E5 01Ia 104 102
3R1 oi ne 102 98
4B3 01 lIc 98 94
5Al GIIId 86 66
9E4 Gl fie 98 95
8A3 01lITb 103 105
5E9 01 IV 103 87
1E4 G1? 105 60
eoio G1? 94 64
9C4 02Ia 103 60
802 02Ib 97 68
7F2 02Ib 96 70
8C2 02 Ic 104 102
RVFVHAF - 82 71
1 No proteinase K digestion
2 Proteinase K digestion after temperature shift
3 Input virus = purified [35S] methionine labelled RVFV (3 x lQ3PFU/ml)
4 The non-neutralized virus-specific counts at 4°C were taken to represent 100%
binding to cell and the counts obtained lith the antibody-treated virus were
calculated relative to this
5 The non-neutralized virus-specific counts at 37°C were taken to represent 100%
penetration and the counts obtained with the antibody-treated virus were
calculated relative to this
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MAbs binding to the G1 domains I and II (3E5, 3R1, 4B3, 9E4), on the other
hand, did not affect the percentage of internalized virus-specific counts, indicating
that virus penetration was not being blocked by these antibodies.
6.4 Discussion
Prior to examining the possible inhibition of virus attachrrent by the RV.IV
MAbs, various experimental parameters were initially assessed. The
concentrations of both antibody and virus suitable for use in the binding studies
were investigated, as well as the efficiency of virus attachment. As the inhibition
of RVFV infectivity by neutralization mechanisms independent of C' were of
particular interest here, the attachment assays were performed using heat-
inactivated antibodies.
Firstly, since immunoglobulin at high concentrations may interfere non-
specifically with virus binding as has been demonstrated usint.\ non-immune
antibody (Fuller and Spear, 1985; Kingsford et al, 1991) it was important to
establish the concentration of antibody which would reflect only specific inhibition
of attachment. The resulting data revealed that non-specific reduction in virus
binding did indeed occur at high antibody concentration, thereby necessitating
using a minimum dilution of 1:100 of hybridoma ascitic fluid.
Another important aspect of antibody concentration is that the density of
neutralizing antibodies on the virus surface may influence virus attachment
(reviewed by Outlaw and Dimmock, 1991). It has, for example, been shown for
influenza virus that higher concentrations of IgG result in a. closer packing of IgG
molecules on the virus surface, thereby reducing the mobility of the antibodies
which is necessary to prevent virus attachment to cells (Armstrong et al, 1990;
Taylor and Dimmock, 1985). The relatively small decrease in the proportion ot
bound virus which was seen with the RVF polyclonal hyperimmune ascitic fluid
at a 1:100 dilution was unlikely to have been due to too high a density of
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antibodies on the virus surface, however, since lower antibody concentrations did
not have an increased inhibitory effect.
Unlike the situation with the immune antibodies, virus attachment was
considerably reduced in the presence of a high concentration of FeS. A similar
phenomenon has been reported by Passi-Fihri et al (1990) for concentrations of
FeS of 5% or greater. The decreased binding in the presence of high serum
concentrations, might be due to the formation of large viral aggregates which are
more easily removed from the cell surface during the washing procedure than
single viral particles.
'yv'ith regard to the optimum virus concentration, virus attachment is traditionally
examined using high multiplicities of infection. In the present study, no inhibition
of virus attachment by the heat-inactivated MAbs was observed using a high input
multiplicity of virus. Since this was possibly due to the fact that the latter virus
concentration was far greater than that used in the PRNTs, attachment assays
were also carried out with lower titred virus. In these experiments, virus binding
was shown to be highly efficient as indicated by the low level of infectious virus
remaining unattached after the adsorption period, as well as by the subsequent
productive infection of the inoculated cell monolayers,
With the lower virus concentration, inhibition of attachment by the MAbs was still
negligible, even though virus infectivity was neutralized by 94 to 99,9 %. Despite
their large size, the two IgM M.A.b::i lE4 and 8G10 did not reduce the binding of
neutralized virus, suggesting that the prevention of virus attachment by sterie
hindrance doe!' not play an essential role in the neutralization mechanisms
involved in these particular instances.
In contrast to the lack of inhibition which occurred with MAb 8G1\) in ~.~e
absence of C. virus attachment was reduced significantly when the virus was
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mixed with this antibody with added C'. The inhibitory effect in these
circumstances may have been due to aggregation of the antibody-coated virions
(sensitized virus), resulting in a reduction in the number of infectious units
(Oldstone et al, 1974). Alternatively, the C' may have 'blanketed' or coated the
sensitized virus, thereby interfering with binding to the cellular receptors (Beebe
et al, 1983).
Unlike the situation with the neutralizing MAbs, RVFV attachment was blocked
to a certain degree by two of the MAbs which are non-neutralizing in the absence
of C' under normal conditions of PRNT assays i.e, SEll (Gl rna) and 4D10
(G2 III). everal non-neutralizing MAbs directed against the LACV Gl protein
have also been found to reduce virus binding (Kingsford et al, 1991). This
phenomenon may be due to lack of stability between the antibody-coated virus and
the cell receptor site, and thus removal of the treated virus by the extensive
washing procedures used in the assay.
The fact that the neutralizing MAbs specific for the G1 domains I, II and IVana
the G2 I domain inhibit virus haemagglutination, yet do not prevent binding of
virus, strongly suggests that the epitopes they define are spatially separate from
the site(s) responsible for virus attachment to the cellular receptor. These
antibodies thus must neutralize by mechanisms other than inhibition of attachment.
As one of the possible mechanisms may be the prevention of virus entry into the
cell, it was important to determine whether or 110tthe neutralized virus was being
internalized. This was measured by resistance of the virus to removal from the
cells by the proteolytic enzyme proteinase K.
The resulting data revealed that certain of the neutralizing MAbs directed against
both RVFV envelope proteins prevented virus internalization substantially. The
fact that these particular MAbs also caused more of the putatively attached virus
at 4°C to be proteolytically removed from the cell surface than uncoated virus
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suggests that they interfere' with the stability of virus binding. Thus the apparent
interference by these MAbs with the internalization of virus at 37QC may partly
be due to the inability of the virus to bind as firmly to the cell surface as it would
in the absence of such antibodies.
While all the neutralizing MAbs directed against the G2 I domain (9C4, 8G2,
7F2) exhibited this type of inhibition, the G 1-specific MAbs that prevented virus
entry mapped to various different sites i.e. Gl IId, GI N and the unmapped
epitopes recognized by MAbs t£4 and 8GlO. The fact that only one of the five
MAbs defining the Gl IIdomain interfered with virus internalization while the
others had no affect, supports the earlier post-adsorption findings that the MAbs
binding to this domain neutralize by different mechanisms.
In all cases, however, virus internalization by these MAbs was not totally
prevented, The fact that the remaining bound virus entered the cell, and y,~twas
still almost completely neutralized, indicates that blocking of virus infectivity must
also occur at another stage of the virus life-cycle.
Of some interest was the finding that RVFV antibodies of both the IgM and IgG
isotype appeared to neutralize in a similar fashion i.e. by inhibiting internalization
of a proportion of the attached virus. The situation here is thus different to that
reported for influenza virus where the mechanism of neutralization appears to be
partly dependent on the isotype of antibody (Armstrong et ai, 1990; Dimmock,
1984; 1987; Taylor and Dimmock, 1985).
In contrast to the various MAbs which substantially blocked virus uptake into the
cell, with the exception of 5AI, all the MAbs directed against the neutralizing
epitopes comprising the GIL and G1 II domains had no influence on virus
internalization, indicating that the inhibition of virus infectivity must be effected
at an intracellular stage of viral replication. Neutralization of this nature may be
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due to conformational changes induced by antibody binding which prevent the
virus from undergoing a subsequent replication step.
Thus, although the RVFV G1 and G2 antigenic sites involved in virus attachment
could not he identified with these particular MAbs, the data from the binding and
internalization assays nevertheless have helped to elucidate the mechanisms of
antibody-mediated neutralization of the virus. The results indicate that while one
of the mechanisms involves the inhibition of virus internalization, additional
modes of action must involve some step(s) later in the virus infectious cycle such
as interference with the rate of virus penetration or neutralization of virus after
penetration. As the virion-cell fusion event leading to the release of the viral
genome may be particularly sensitive to inhibition by neutralizing MAbs (Fuller
and Spero, 1987) the sensitivity of the MAbs to pH-induced conformational
changes in the RVFV glycoproteins also requires investigation.
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7. PENETRATION
1.1 Introduction
As with all viruses, infection of host cells by RVFV is largely dependent on the
ability of virus to penetrate the cell and release the genome into the cytoplasm
(Choppin and Scheid, 1980; Dimmock, 1982; Lenard and Miller, 1982; Marsh
and Helenius, 1980; 1989; Schmaljohn and Patterson, 1990; White et al, 1983).
With enveloped viruses, this process occurs by fusion of the virus and lipid
membranes of the target cells, induced by the viral envelope proteins (Marsh,
1984; Marsh and Helenius, 1980; 1989; White et al; 1981; 1983).
Depending on the pH threshold, the membrane fusion event may either occur on
the plasma membrane, or in the acidic vacuoles of the endocytic pathway (Lenard
and Miller, 1982; White, 1990; White et al, 1983.) In the latter case, the rniloly
acidic pH (PH 5,0 - 6,0) in the endosomal compartment (Tycko and Maxfield,
1982) triggers a conformational change in the glycoproteins on the virion surface,
causing exposure of a. hydrophobic portion of a virion surface protein (Subbaroa
et al, 1987; reviewed in White, 1990). This hydrophobic region promotes fusion
between the virion envelope and the vesicle membrane (Marsh, 1984; Matlin et
al, 1981; White, 1990; White et al, 1981; 1983). Such acid-induced changes in
the tertiary structure of the envelope proteins are believed to be an important part
of the mechanism by which the viral nucleocapsid is discharged into cell
cytoplasm, thereby initiating the process of replication (Lenard and Miller, 1982;
Marsh, 1984; Marsh and Helenius, 1989; Matlin et al, 1981; White et al, 1981;
1983).
With regard to RVFV, very little is currently known about the actual mechanisms
by which the virus gains access to the cell cytoplasm (Ellis et al, 1988;
Schmaljohn and Patterson, 1990). Studies on some of the ( er Bunyaviridae
have shown that at acidic pH values, the envelope glycoproteins undergo a
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conformational change and induce cell fusion (Arikawa et al, 1985; Gonzalez-
';c",7ano, 1985; Gonzalez-Scarano et al, 1984; Wang et al, 1991). This pH-
G:ej?endentmembrane .usion suggests that they rely on endocytic uptake and that
their fusion activity ii) triggered by the low pH of the intracellular vesicles
(Gonzalez-Scarano et al, 1984; Marsh, 1984; Mar~h and Helenius, 1980; 1989).
Direct evidence for this process with RVFV, however, has not yet been obtained
(Schrnaljohn and Patterson, 1990). It is furthermore unclear at this stage whether
one or both of the envelope glycoproteins are necessary for fusion.
As a step towards the understanding of the fusion mechanism of RVFV, the
MAbs will be.used to investigate the sensitivity of the viral glycoprotein epitopes
to pH-induced conformational changes. Since the fusion event presents a. point
at which penetration can be blocked (Dietzschold et al, 1987; Gollins and
Porterfield, 1986a; Marsh and Helenius, 1989) these studies may also indirectly
help to ascertain if any of the MAb:swhich appear to neutralize intracellularly do
so by interfering with this step,
The route of RVFV entry and penetration will be examined further by testing the
possible inhibition of viral uncoating by the Iysosomotropic agent ammonium
chloride which acts to raise endosomal pH. In addition, the kinetics of resistance
of penetrated virus to neutralization by the MAbs will also be investigated.
7.2 Materials and Methods
7.2.1 Th1Abreactivity with antigen exposed to different pH's
Analysis of the antigenic reactivity of the MAbs with virus preparations exposed
to different pH's was carried out using the method of Guirakhoo et al (1989).
Stock RVFV extracted glycoproteins (17 mg/m1; section 2.2.1.2) were diluted
1:100 in TAN buffer (0,5 M triethanolamine, 0,1 M NaCl) which had been
previously adjusted to pH's ranging from 7,5 to 4,0 using Hel. After incubation
at rt for 30 min, the pH's of the antigen samples were all readjusted to pH 8,0
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with 1,0 M NaOH. The samples were then diluted in carbonate-bicarbonate
ELISA buffer (PH 9,6) to yield a final concentration of 80 ",g/m1. Volumes of
0,1 ml were added to wells of ELISA microtitre plates and incubated overnight
at 4°C. The plates were washed and blocked. with 4% BSA as described in
section 2.2.2.3a. Reactivity of the MAbj with the acidified antigens was
determined by adding 0,1 ml aliquots of each lVIAb (diluted 1:200 in ELISA
diluent) to duplicate wells against each of the different pH-treated antigens. After
incubation for 211 a, 37°C, the wells were washed and incubated with peroxidase
conjugated anti-mouse immunoglobulins (2.2.2.3a) for a further hour at 3TC.
The colour reaction was measured at 405 nm following the addition of ABTS
substrate. The unmapped G1-specific MAbs 1E4, 8GlO, 5F2, 5A6 and G2-
specific MAb 5C12 were not tested due to their very weak avidities in the ELISA.
7.2.2 Determination of virus uptake and uncoating
The uncoating of virus was determined by measuring the appearance of acid-
soluble material in supernatant fluids following shift of infected cells from 4°C
to 3rc based on the method of Kennedy-Stoskopf and Narayan (1986). The
possible inhibition of virus uncoating by raising endosomal pH was examined
using ammonium chloride at a final concentration of 0,05 M as described by
Gollins and Porterfield (1984).
Confluent monolayers of Vero cells in 6-well tissue culture plates (Cel-Cult;
Sterilin Ltd, Hounslow, U.K.) were incubated with 0,4 ml [35S] methionine-
labelled RVFV (250 PFU/ml; 15 x 1()3c.p.m.zml) for 2 h at 4°C. Cultures were
then washed three times with cold PBS and replenished with 0,5 ml of Leibovitz
medium (PH 8,0) in the presence or absence of 0,05 M ammonium chloride. The
plates were shifted to 37°C for various incubation times. At each stage, the tissue
culture supernatants were collected and the cells washed with PBS, then lysed
with 1 ml of 1% SDS. The cell lysates were transferred to scintillation vials
containing 5 ml Ultima-Gold XR and analysed by liquid scintillation spectrometry,
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To determine the acid-soluble radioactive material, 0,1 m1 of the collected tissue
culture supernatant was precipitated with perchloric acid. This was carried out
by adding 1 ml of 0,01 M sodium pyrophosphate and 1 ml of 3,5% perchloric
acid in 0,01 M sodium pyrophosphate sequentially to each tissue culture
supernatant aliquot at 4°e. The samples were mixed by vortexing and incubated
on ice for 30 to 50 min. The precipitates were collected by vacuum on glass-fibre
filters using a Millipore sampling manifold unit. The precipitates were rinsed
with 5 ml of 0,01 M sodium pyrophosphate and 0,1 M HCI, then with 95%
ethanol to facilitate drying. Filters were dried and placed in scintillation vials to
which 3 ml of Ultima-Gold Xl< was added. Counts quantified in the liquid
scintillation counter represented acid-precipitable radioactivity. Add-soluble
radioactivity was determined by subtracting acid-precipitable c.p.m. from the total
radioactivity of a 0,1 1111 sample in liquid scintillation fluid. All experiments were
performed in duplicate.
7.2.3 Neutralization of penetrated virus
The method used to determine whether the MADSmediated virus neutralization
when virus had penetrated cells at various time intervals was based on that of
Roehrig et aZ (1988) with some modifications. RVFV was diluted in Leibovitz
medium and 0,4 ml (200 PFU) was adsorbed onto Vero cell monolayers in six
well plates (Cel-Cult; Sterilin Ltd., Hounslow, UK) for 1 h on ice at 4°C. Each
plate was independently shifted to 37°C for 1, 5, 10, 25, 45 and 60 min. After
the appropriate time interval, the cells were shifted back to 4°C, washed and
incubated in the presence of 0,4 ml of MAb diluted in Leibovitz medium for 15
min. Each MAb was tested at the antibody concentration corresponding to the
80% PRNT titre obtained in the post adsorption PRNTs (5.3.4).
The medium was removed and the cultures either overlaid directly with agarose
as described in 2.2.3.3f, or were washed three times with PBS-MgC12prior to the
overlay. No antibody was added to the virus controls; instead, the extracellular
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virus was inactivated with citrate buffer (0,04 M citric acid, 0,01 M KCl, 0,135
M NaCl, pH 3,0) for 1 min, followed by three washes with PBS-MgC1:z. The
medius: was removed and the cultures overlaid with agarose. The number of
viral PPU surviving acid treatment after a 60 min time shift to 37°C was
considered to represent 100% penetration, and the fraction of intracellular virus
at any givea time was calculated relative to this.
7.3 Results
7.3.1 lVIAb reactivity with RVFV exposed to low pH
The reactivities of the MAbs with RVFV glycoprotein antigens treated at different
pH's as.measured by the ELISA are depicted in Figs 7a to 7f. One of the anti-Gl
MAbs (3E5) exhibited comparable levels of binding to acidified viral antigen
compared to the untreated control antigen as indicated by the relatively constant
C.D. levels over the entire pH range tested (Fig. 7a).
MAbs 5E1 (G1 Ib) and 5Ell (Gl Illa) showed a marked increase in binding to
viral antigen exposed to pH values ranging from 6,5 to 5,5 relative to the
untreated control (Figs 7a, 7c). Maximum binding occurred at pH 5,5. At pH
5,0, the increased binding was no longer evident, as reflected by the similar
absorbance levels obtained at this pH compared to that at pH 7,5.
The remaining MAbs directed against the G1 protein showed a reduction in
binding to antigen that had been exposed to pH values of 5,0 and lower (Figs 7a-
c). The greatest reduction in reactivity occurred with MAb 9E4, corresponding
to a 77% decrease in binding compared to that obtained with antigen at neutral
pH, Over the mildly acidic pH range ie pH 5,5 and pH 6,0, however, there was
only a slight reduction in the proportion of bound antibody. Unlike the situation
with the G1 protein, the activity of the G2-specific MAbs was not affected
substantially by low pH exposure of the virus (Figs 7d to 7f).
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Fig. 7. MAb reactivity with RVFV glycoprotein antigens treated at different pHs
as measured by the ELISA. Optical density (O.D.) was read at 405 nm,
(a) Reactivity of MAbs 3E5 (01 Ia), SE1(01 Ib) and 3D2 (Gl IIa).
(b) Reactivity of MAbs 3Rl (G1 lib») 4B3 (G1 nc), SAl (01 lId) and 9E4
(01 lie).
(c) Reactivity of MAbs SEll (Gl IlIa), 8A3 (01 lIIb) and 5E9 (Gl IV).
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The sensitivities of the individual glycoprotein epitopes to mildly acidic 9H was
examined by comparing the reactivities of all the MAbs with RVFV antigen
exposed to pH 5,5. The latter pH was chosen as this firstly corresponds to the
mid-pH value found within endosomes (Tycko and Maxfield, 1982) and secondly
was the pH at which maximum changes in antibody reactivity with several G1
epitopes (Gl Ib and G1 Illa) were seen. The percentage binding of the 01- and
G2-specific MAbs to their corresponding epitopes which occurred on antigen
exposure to pH 5,5 is shown in Figs 8a and 8b respectively. The maximum level
of each antibody which reacted with antigen at pH 7,5 was taken to represent
100% binding) and the amount of antibody which bound to antigen treated at pH
5,5 was calculated relative to this.
The :> epitopes comprising the GIl domain exhibited widely varying
sensitivities to mildly acid pH as reflected by the different reactivities of the
antibodies which defined these sites (Fig. 8a). While comparable levels of
antibody attachment to G1 Ia occurred at both pH 5,5 and pH 7,5, enhanced
binding corresponding to 153% was seen for epitope G1 Ib at the lower pH.
With regard to the G1 II domain, the Gl IIa and G1 IIb epitopes were relatively
resistant to exposure to pH 5,5, while the remaining three determinants appeared
to be slightly more sensitive as seen by the lowered reactivities of the antibodies
recognizing these sites.
As in the case of the G1 I domain, at mildly low pH, increased antibody binding
(172%) occurred for one of the G1 III epitopes (Gl IlIa), while the other
determinant, Gl IUb, was fairly resistant to pH treatment. The antigenic
reactivity of the G1 IV domain was adversely affected at mildly acidic pH as
indicated by the 35% reduction in bound MAb 5E9.
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'With regard to the G2 domains, all the epitopes were relatively resistant to
exposure to low pH as shown by the comparable antibody binding levels obtained
with antigen at both pH values (Fig. Bb).
7.3.2 Effect of ammonium chloride on viral nncoatlng
In the absence of ammonium chloride, shift of the esS] methionine-labelled RVFV
inoculated cells from 4°C to 37°C resulted in a steady decline in the amount of
cell-associated radioactivity over the 2112 h period (Fig. 9al. The percentage of
cell-associated c.p.m, measured at the 21hh shift interval an the presence of
ammonium chloride, on the other hand, was much higher ie 74% compared to
only 48% for the untreated RVFV.
Fig. 9b shows the rise in acid-soluble o.p.m. which occurred shortly after shift
of the inoculated cells to 37°C. In the absence of ammonium chloride, there was
a sharp increase in acid-soluble counts between a penetration time of 15 to 60
min, after which the c.p.m. levelled off. In the presence of ammonium chloride,
however, the acid-soluble radioactivity measured in the supernatant at each given
time interval was markedly lower than that of the control virus.
The results of the PRNTs performed in parallel to the uncoating experiments
revealed a 79 % reduction in the number of viral plaques formed when RVFV
virus was treated with ammonium chloride compared to untreated virus.
7.3.3 Ability of MAbs to neutralize penetrated virus
The kinetics of penetration of RVFV in the absence of antibody were examined
by infecting cells at 4°C, followed by a shift to 37°C to allow virus to penetrate
cell membranes. Inactivation of the extracellular virus at different times after
138
100
E
480c
"0
'* 60'0
o
~ 40
til
..L
~ 20
.~o
O~--L---~--~--~~~--~---_L_~
o
Fig. 9a
20 40 60 80 100 120 140 160
Time (m in)
""'"*- Vi r us on Iy -9- VI r us + AO
50
E 40
ci.
d
Q) 30:a
:::J
l20
"0
'0
« 10
";j.
~~~~~--~--~----~~~---~~~
20 40 60 80 100 120 140 160
Fig. 9b Time (min)
--*- Vir uS 0 III Y --8- Vir Us + AO
Fig. 9. Effect of raising endosomal plf with ammonium chloride (AC) on the fate
of f5s] methionine labelled RVFV after synchronized infection of Vero cells.
Labelled RVFV (250 PFU/ml; 15 x 103 c.p.m.Zml) was bound to cell rnonolayers
for 2 h at 4°C. Cultures were washed with PBS and replenished with Leibovitz
medium (PH 8,0) in the presence or absence of 0,05M ammonium chloride. The
cells were shined to 37°C for various times to allow virus penetration to occur.
At each time interval, the cell-associated radioactivity and acid-soluble counts
were measured. (a) The percentage radioactivity associated with the cells
determined for each time point were 100% represents the total c.p.m, bound
initially to the cells prior to virus internalization. (b) The acid-soluble
radioactivity present in the supernatant determined by subtracting acid-precipitable
c.p.m. from the total radioactivity of an aliquot of supernatant.
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shift with a low...pH buffer permitted the exclusive determination of intracellular
virus. In these experiments, penetration was operationally defined as the loss of
sensitivity to acid inactivation, where the number of viral plaques which ~vrmed
subsequent to a 60 min incubation period at 37°C represented 100% penetration
or infectivity, The fraction of intracellular virus at any given time shift was
c......culated relative to this. The kinetics of resistance of penetrated virus to
antibody-mediated neutralization was exams-ed in parallel by treating the infected
cells after each given time shift with various neutralizing MAbs prior to addition
of the agarose overlay.
The penetration kinetics of RVFV in the absence of antibody as measured by
plaque formation are shown in Fig. 10. The proportion of virus that entered the
cell increased rapidly after a shift period of 10 min at 37°C. After 45 min, the
rate of viral penetration decreased as shown by the levelling off of the curve.
The results of the resistance of penetrated virus to neutralization by the MAbs
were similar for all the neutralizing antibodies tested. No significant reduction
in infectivity was observed when the antibodies were added after viral penetration
at each time period and subsequently removed prior to the overlay (Fig. lOa). No
neutralization occurred even when immunoglobulin concentrations greatly
exceeding the 80% PRNT titres under normal PRNT conditions were tested.
Those MAbs which had previously been shown in the post-adsorption
neutralization tests to efficiently neutralize cell-bound vii IS, ie MAbs 3E5, 3Rl)
5Al and 9C4, were also tested for their ability to inhibit the infectivity of
penetrated virus if they were allowed to remain in contact with the infected cells.
The antibodies were used at the dilutions corresponding to the 80% PRNT titres
obtained in the post-adsorption neutralization assays.
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The results of these experiments are shown in Figs lOa and lOb. A 60%
reduction in viral infectivity was observed with MAb 3E5 (01 Ia) even after 60
min internalization of RVFV prior to exposure to the antibody (Fig. lOa). By
increasing the immunoglobulin concentration, neutralization of penetrated virus
was more efficient eg the addition of MAb 3E5 at a dilution of 1:1024 after 60
min virus internalization resulted in an 83% reduction in plaques (data not
shown). The latter antibody concentration represented a 32-fold increase over the
antibody dilution which gave an 80% neutralization titre under normal PRNT
conditions.
The neutralizin.g MAb 3Hl (Gl IIb) substantially inhibited plaque development
of RVFV that had internalized at any given interval (Fig. lOb). Even after a
penetration period of 60 min, there was a 69% reduction in plaques which
formed. In contrast, while RVFV infectivity was reduced to a certain extent on
exposure to MAb 5Al (Gl lid) during the early stages of viral internalization,
once the virus had penetrated the cells for 25 min, it was resistant to
neutralization (Fig. lOb). The G2-specific neutralizing MAb 9C4 (G2 Ia) had no
effect on virus infectivity at any stage of viral penetration.
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Fig. 10. Kinetics of resistance of penetrated RVFV to neutralization by MAbs.
Vero cell monolayers were infected with RVFV at 4°C, then shifted to 37°C for
various times to allow synchronized. viral penetration to occur. After each shift
interval, the cells were treated with a low-pfl buffer to inactivate any extracellular
virus (virus controls) or were treated with the neutralizing MAbs at the
concentrations which corresponded to the previously determined 80% post-
adsorption PRNT titres. The number of plaques which formed following viral
penetration for 60 min in the, 'rus control wells represented. 100% infectivity.
(a) Percentage infectivity following treatment with MAb 3E5 (GIla) which was
either washed off after 15 min or left in contact with the cells ( unwashed) prior
to the addition of the agarose overlay. (b) Percentage infectivity after the
addition of MAbs 3Rl (Gl IIb), 5Al (Gl lIc) and 9C4 (02Ia) which were left
in contact with the infected cells.
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7.4 Discussion
While the entry process of RVFV into cells has been studied at the ultrastructural
level by electron microscopy :'Ellis et al, 1.988)~the actual mechanisms involved
in RVFV penetration have not been clearly defined to date. Studies on several
of the other Bunyaviridae members suggest an entry route involving pH-dependent
fusion with acidic intracellular vesicles, which IS associated with concomitant
specific conformation changes in one or both of the viral envelope proteins
(Arikawa et al, 1985; Gonzalez-Scarano, 1985; Gonzalez-Scarano et al, 1984).
The various methods used to examine fusion directly all have sev e drawbacks
(Gallaher et al, 1980). Detailed study of viral fusion with intracellular
membranes by electron microscopy (Matlin et al, 1982), for example, is
impractical as the fusion process is so rapid (Pobjecky et al, 1986).
Demonstra.tion of t~e fusion function by fusing cells that are undergoing an active
infection by exposing them to acidic pH (fusion from within) or adsorbing virus
to cells and then acidifying them before infection (fusion from without) is very
laborious. Not only do both techniques necessitate the counting of large numbers
of nuclei within the fused cells, but the latter method also requires an extremely
high m.o.i. (± 2000 PFU/cell) for optimal fusion (Gonzalez-Scarano et at, 1984;
Pobjecky et al, 1986; Summers ( '1, 1989).
Since activation of the fusion function is accompanied by conformat ,•.ial changes
of the fusion protein (Marsh, 1984; Matlin et al, 1981; White, 1990; White et al,
1981; 1983) an alternative means to obt.in insight into the viral fusion mechanism
is to '.n.~MAbs to investigate the location of any changes induced by acidic pH
(Gonzalez-Scarano, 1985; Guirakhoo et al, 1989). The MAbs were therefore
used in this manner to examine the possibility that entry of RVFV and penetration
of the viral nucleocapsid into the cytoplasm involves an acid-catalyzed fusion
reaction in the intracellular compartments.
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Exposure of RVFV to low pH appears to induce a conformational change in the
GI surface protein as revealed by the altered binding of some of the G l-specific
MAbs to acidified antigen. The fact that the changes in antibody binding
persisted, in spite of readjusting the pH to neutral after acidification, :,i.ows that
the conformational changes are irreversible once established.
The increased binding by MAbs 5EI and 5EIl to their respective epitopes GlIb
and GI lila at mildly acidic pH suggests that at neutral pH these sites may be
partially hidden on the virion surface. This is consistent with the earlier
suggestion that these determinants are not as accessible for antibody binding as
epitopes which are involved in C'<independent neutralization and
haemagglutination, The enhanced antibody hinding of MAbs 5EI and 5E1l at
mildly acidic pH is probably due to a rearrangement of the G1 polypeptide which
results in greater exposure of these particular sites. A similar phenomenon has
been reported for viruses such as Sindbis virus (Schmaljohn et al, 1983) and the
well-studied influenza virus (Jackson and Nestorowicz, 1988; Kostolansky et al,
1988). These results are in keeping with the idea that treatment of a surface
fusion protein to mildly acid pH results in the subsequent exposure of a
hydrophobic face (Subbarao et al, 1987) which may play an important role in the
initiation of the fusion reaction (reviewed in White, 1990). The biological
significance of the pfl-dependent irreversible conformational changes in these G1
epitopes thus may wt111:e in the proposed endosomal route of RVFV entry into
the h08. cell cytoplasm.
Unlike the RVFV Gl protein, the G2 glycoprotein epitopes appear to be resistant
to low pH. This is similar to the situation for LACV, where the G1 undergoes
a conformational change at acidic pH (Gonzalez-Scarano et al, 1984) while the
G2 protein is resistant to low pH (Gonzalez-Scarano, 1985; Kingsford and Hill,
1981). Since the induction of membrane fusion may involve multiple interactions
between various virus components (Fuller and Spear, 1987), the conformational
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change undergone by RVFV G1 at acidic pH may possibly expose other sites on
the G1 molecule which comprise the actual fusogenic sites. Alternatively 1 the
allosteric changes in the G1 protein may serve to expose the G2 protein, thereby
facilitating involvement of the 02 protein in the physical event of RVFV fusion,
as has been suggested for LACV (Ludwig et al, 1989; Pobjecky et al, 1989).
Thus, while the actual fusogenic determinants have not been conclusively
identified here, the pll-induced changes in the RVFV G1 protein implicate
involvement of acidic endosomes in the entry process of the virus.
The dependence on endocytosis and subsequent exposure to acid conditions for
viral fusion and release of the nucleocapsid into the cytoplasm presents a point at
which penetration can be blocked (Dimmock, 1987; Marsh and Helenius, 1989;
Outlaw and Dimmock, 1990). Neutralization of West Nile and rabies virus by
antiviral antibody, for example, has been shown to be due to the inhibition of the
intraendosomal acid-catalyzed fusion step (Dietzschold et al, 1987; Gollins and
Porterfield, 1986a),
Analysis of the neutralizing activities of the RVFV MAbs earlier suggested that,
although neutralization can be mediated by inhibition of virus entry, other
mechanisms involving interference at an intracellular stage must also be involved.
While the inhibition of the fusion step by these MAbs has not been directly
examined, the fact that none of the antibodies exhibited drastically reduced
binding to antigen exposed to mildly acidic pH suggests that they do not neutralize
by binding to sites directly involved in the fusion event. Nevertheless, binding
of certain of these antibodies to their respective epitopes could conceivably inhibit
fusion by inducing a conformational constraint within the glycoprotein, thereby
preventing the allosteric change necessary to expose the actual hydrophobic
fusogenic region.
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The means by which RVFV penetrates cells was further investigated by examining
the sensitivity of the early stages of RVFV infection to the efff>r~1'jof the
lysosomotropic agent ammonium chloride. The latter, which is a weak base, acts
by raising the pH of acidic intracellular vesicles (poole and Okhuma, 1981), and
if they contain virus entering by endocytosis, it blocks the stage of membrane
fusion required for viral nucleocapsid release into the cytoplasm (Marsh and
Helenius, 1989; Marsh et al, 1983; White et al, 1983). Consequently,
progression of viral synthesis is prevented.
The postulated acid-catalized fusion of RVFV with acidic intracellular vesicles
was supported by the results of the uncoating experiments performed with
ammonium chloride. In the present study, ammonium chloride was used at 50
mM, as concentrations between 10-100 111M hale been shown by other workers
to inhibit viral replication without any direct virucidal activity or effect on virus
adsorption to cells (Glushakova et al, 1989; 1990; Gollins and Porterfield, 1986b;
Helenius et al, 1982).
In the absence of ammonium chloride, the sharp rise in acid-soluble radioactivity
present in the cell supernatant indicated that the labelled RVFV surface proteins
had undergone degradation to acid-soluble material via the lysosomal
compartments (Gollins and Porterfield, 1984; Kennedy-Stoskopf and Narayan,
1986). As the percentage of degraded protein released into the supernatant fluids
increased rapidly after only 15 minutes at 37°C, uncoati-ig of the RVF virion
appears to occur shortly after viral internalization. The kinetics of RVFV
uncoating thus seem to be similar to those of the alphavirus Semliki forest virus,
where uncoating was shown to take place within 5~7 minutes of entry and passage
to lysosornes was observed after 15 minutes (Marsh and Helenius, 1980).
In contrast to the above situation, the marked reduction in the acid-soluble
material which occurred when RVFV was treated with ammonium chloride,
146
clearly showed inhibition of proteolytic digestion of the viral proteins, which in
turn indicates that viral uncoating had been prevented. This finding was
supported by the demonstration that RVFV replication, as measured by reduction
in plaque formation, was inhibited by treatment with ammonium chloride. The
data from these experiments thus confirm the role of endosomal uptake and pH ..
dependent fusion for release of the RVFV genome and subsequent replication.
<Withregard to the kinetics of resistance of penetrated RVFV, the infectivity of
virus that had penetrated at any given time point was. not reduced by subsequent
brief exposure to any of the neutralizing MAbs. Intt!ra.crinj) between antibody and
virus prior to internalization is therefore nee .';t for intracellular
neatralizatien to occur. Since it had earlier bee'. .' .LJ1istR, J virus infectivity
can be efficiently inhibited "'y some .)1' the ~{'tibodlt:s if the latter are added after'
virus was already ...ell-bound, such an Interaction would appear to have to take
place at the cell surf ....\,.- prior to viral entry.
Of interest were the differences in neutral' .....ion of penetrated RVFV which
resulted when the MAbs were allowed to remain in contact with the infected cells.
The uncoating studies had earlier shown that extensive proteolytic degradation of
the viral glycoproteins had taken place following the shift of RVFV inoculated
cells for 1 hour at 37()C, Thus any reduction in plaque formation which occurred
after a 1 hour penetration period prior to the addition of immunoglobulin must be
due to recognition and binding of the antibodies with newly synthesized RVFV
glycoproteins.
In the case of viruses which mature at the plasma membrane, neutralization can
occur as a result of the binding of specific antibodies directed against a viral
antigen expressed on the surface of infected cells (Fujinami and Oldstone, 1979;
Navarro et al, 1992; Old stone et al, 1980; Roth and Compans, 1980). Fujinami
and Oldstone (1979), for example, showed that measles antibody can bind to viral
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proteins expressed at the cell membrane and not only strip off the surface
determinants, but also alter viral polypeptides found inside the cell not associated
with the plasma membrane.
The site of virus maturation in the Bunyavuidae family takes place predominantly
at the Golgi complex, with release of mature virions at the cell surface by
exocytosis (Matsuoko et al, 1991; Murphy et al, 1983; Smith and Pifat, 1982).
In the case of RVFV, however, it has been suggested that the site of viral
maturation varies as a function of both the strain of virus and the cell type used
to support the replication of the virus (Anderson and Smith, 1987). The Lunyo
strain of RVFV, for example, was shown by these workers to mature at the
plasma membrane of infected Vero cells as well as internally. Furthermore, in
hepatocytes, replication of both the ZH501 and Lunyo strains was associated with
maturation at cellular surface membranes in addition to the intracellular locations.
In a more recent study, the glycoproteins of recombinant RVF viruses were found
to be present both intracellularly as well as on the surface of infected Spodoptera
frugiperda insect cells (Takehara et al, 1990). With regard to the AN 1830 strain
of RVFV, where the site of maturation in infected cells has not been studied to
date, it is thus possible that in addition to intracellular maturation, some surface
expression of the viral glycoproteins may occur at the plasma membrane.
As a result of these different possible sites of virus maturation, the reduction in
RVFV plaque formation by the neutralizing MAbs 3E5 (G1 Ia) and 3Hl (G1 JIb)
may reflect neutralization of virus which has been released from the cells and/or
the interaction with cell surface-expressed G1 glycoprotein. In the former
instance, such neutral'zation may be effected by the coating of virus by the
antiviral antibodies present in the intercellular spaces as has been demonstrated
by electron microscopic studies with several phleboviruses (Smith and Pifat,
1982). In this way, the RVFV MAbs would prevent spread of virus from infected
to neighbouring uninfected cells, a process which would normally give rise to the
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development of localized foci of lysed cells. On the other hand, should some
RVFV maturation occur at the cell surface, neutralization may also possibly occur
as a result of the binding of these specific antibodies to their respective epitopes
on plasma membrane-expressed RVFV G1 protein.
The inability of MAbs SAl (01 IId) and 9C4 (G2 Ia) to inhibit plaque
develonment once virus had already penetrated is of particular interest. The
results confirm the earlier data that these antibodies neutralize 'RVFV by a
different mechanism to that of MAbs 3B5 (GIla) and 3Hl (01 Ilb). Unlike the
latter antibodies, MAbs 5A1 and 9C4 bad previously been found to substantially
block viral entry into the cell. These findings are thus similar to those for the
unrelated herpes simplex virus (HSV) type L, where some MAbs directed against
the surface glycoprotein B interfered with plaque development by preventing cell-
to-cell spread of the virus while several others that blocked viral entry did not
inhibit plaque formation (Navarro et al, 1992).
The actual mechanism underlying the resistance of newly released virus to
neutralization by MAbs SAl and 9C4 is unclear, but is conceivably related to the
fact that they ate directed against epitopes which are involved in viral entry into
the cell. Should these particular determinants occur in a relatively high
concentration on the RVFV glycoproteins, antibody concentrations which would
neutralize 80% of input virus under normal PRNT conditions may not be
sufficient to bind to the numbers of progeny virus released from the infected cells.
Moreover, should some surface expression of the viral glycoproteins occur in
addition to intracellular maturation, a proportion of the antibodies may recognize
and bind to the epitopes on the surface expressed glycoproteins. This could serve
to further reduce the number of antibodies available for interacting with the
mature virions which are subsequently released from the cells. While the
mechanisms outlined above are speculative, the differences in the ability of the
various MAbs to neutralize penetrated RVFV suggest that although the processes
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of cell-to-cell spread of RVFV and viral internalizauon are related, they are not
identical.
In summary, therefore, specific conformational changes in the RVFV G1 protein
were shown to take place at endosomal pH values. Such alterations are
irreversible once established and result in the increased accessibility of two
antigenic sites which may in turn play an important role in the initiation of the
viral fusion reaction. These plf-dependent allosteric changes which occur in the
G1 glycoprotein, together with the results of the uncoating assays, strongly
suggest that the route of entry and penetration of RVFV into the host ceil involves
the endosomal pathway.
With regard to the further analysis of antibody-mediated neutralization of RVFV,
cell-penetrated virus was found to be resistant to neutralization by several G1 and
G2-specific MAbs which had earlier been shown to block virus internalization.
The fact that other antibodies inhibited the infectivity of penetrated virus by
preventing the spread of progeny virus to neighbouring cells suggests that While
the processes of cell-to-cell spread of RVFV and viral entry are related, they are
not identical. The data moreover supports the earlier suggestion that certain
antigenic sites on both the RVFV G1 and G2 proteins which are involved in virus
entry into the cell are important in vim} pathogenesis.
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8. GENERAL DISCUSSION
8.1 MAb production and functional activities
Knowledge of the structural, functional and antigenic properties of the envelope
proteins is an essential requirement for the understanding of RVFV infection as
well as the host immune response to such infection (Keegan and Collett, 1986;
Parsons on and McPhee, 1985). At the time this study was undertaken, the
antigenic determinants on the RVFV Gl and G2 glycoproteins involved in viral
pathogenesis had not been .ully characterized. Since the analysis of viral epitopes
can be exquisitely performed by means of monoclonal antibodies (Carter and ter
Meulen, 1984; Heinz, 1986), this was considered to be an ideal approach for such
an investigation. MAbs were therefore generated specifically against the surface
glycoproteins and used to analyse the topological and functional properties of the
epitopes on the G1 and G2 proteins. Furthermore, in order to gain a better
understanding of the role of the RVFV envelope proteins in infection and
pathogenesis, the mechanisms of antibody-mediated neutralization of the virus
were examined, as well as the function of the glycoproteins in viral attachment
and penetration.
The successful generation of twenty three hybridomas which excreted antibodies
specific for the RVFV envelope proteins was due in part to the use of a purified
glycoprotein preparation as the immunogen. Another contributing factor was the
development of an antibody screening assay that permitted the rapid detection of
antibodies directed against the viral surface proteins.
Serological characterization of the resulting MAbs permitted the functional
activities of the corresponding epitopes on the RVF viral surface proteins to be
defined. While it is common knowledge that the RVFV envelope proteins elicit
neutralizing and haemagglutination-inhibition antibodies (Battles and Dalrymple,
1988; Keegan and Collett, 1986; Shope et al, 1980), there has been no published
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data regarding the possible correlation of these two functions for the several
neutralizing epitopes identified by other workers (Collett et al, 1987; Schmaljohn
et al, 1989). The present findings that all the 01 and G2 neutralizing sites also
demonstrated a haemagglutination function are similar to those reported for the
phlebovirus Punta Toro, where all except one of the neutralizing MAbs also had
haemagglutination-inhibition activity (Pifat et al, 1988).
Several antibodies directed against both the G1 and G2 glycoproteins were not
only associated with neutralization and haemagglutination-inhibition, but also with
protection of mice against virulent RVFV infection. The demonstration that
antibodies to a single epitope on each of the RVFV glycoproteins can provide
complete protection to otherwise lethally Infected mice suggests that both envelope
proteins playa critical role in virus infectivity and pathogenesis. This finding is
of particular significance, since previously only anti-G2 or a mixture of anti-Gl
and G2 antibodies had been shown to be protective in vivo (Battles and
Dalrymple, 1988).
8.2 Topographical, structural and functional analyses of epitopes
The topological relationship of the antigenic determinants to each other on the
envelope proteins was examined using competitive binding assays as this method
has been widely used for many viruses, including some members of the
Bunyaviridae (Arikawa d al, 1989; Dantas ei al, 1986; Gonzalez-Scarano et al,
1982; Kingsford et al, 1983; Pifat et ai, 1988). Having taken into consideration
all the various factors regarding possible misinterpretation of the competitive
binding data (Cepica et al, 1990; Henchal et al, 1985; Shaw et al, 1986; Stone
and Nowinski, 1980), the topologica11ocalization of ten of the G1 epitopes and
seven of the G2 antigenic sites was achieved. As one of the major drawbacks of
the CBA is that ar+ibodies with weak avidity are unsuitable for use in this method
(Stone and Nowinski, 1980; Yewdell and Gerhard, 1981), the epitopes recognized
by the remaining six low avidity MAbs could not be mapped.
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With regard to the RVFV Gl protein, four antigenic domains comprising clusters
of overlapping or closely adjacent epitopes were identified. Based on the
competitive binding patterns, these domains appear to be adjacent to each other
and may even be interlinked. to form one large antigenic region. The premise that
these are in close proximity to each other on the G1 protein is further supported
by the fact that they all appear to comprise an area on the glycoprotein that is
highly conformational. In contrast, the unmapped GI-specific determinant defined
by MAb lE4, which was more resistant to denaturation, probably corresponds to
an independently folding region within the G1 protein. It is of some interest t'iat
although extensive disulphide formation has been predicted for the RV.2V
envelope proteins (Ihara et al, 1985), this was the only determinant recognized by
the MAbs which appears to be dependent on disulphide bridges for conformation.
Correlation of the biological activities and epitope specificities of the MAbs
against G1 showed that the antigenic domains I, II and IV were involved in virus
neutralization and haemagglutination, indicating they are accessible to antibody
on the intact virion. These domains, therefore, are likely to be located in the
hydrophilic portions on the outer surface of the folded G1 polypeptide as shown
for the neutralizing sites on many other viral glycoproteins (Eisenberg et al, 1985;
Novak and Wengler, 1987; Pellett et al, 1985; Wiley and Skehel, 1987). Since
one of the epitopes within the GIl domain (G1 Ia) was also associated with
complete protection of mice against virulent RVFV infection, this region in
particular appears to represent a biologically important area. In contrast, the low
level C'-dependent neutralization exhibited by the epitopes comprising the G1 III
domain suggests that this region is less accessible for antibody binding than those
involved in haemagglutination and neutralization and may therefore be located in
areas or pockets on the G1 polypeptide which are more folded.
In the case of the G2 protein, four antigenic domains were identified, but unlike
the closely adjacent Gl domains, these appear to be spatially distinct. One of the
153
domains (G2 I) comprising a cluster of four sites was associated with significant
neutralizing and haemagglutination activity. In addition to these functions, the
epitope G2 Ia was shown to be a protective determinant, suggesting that it
represents an immunologically important area on the G2 protein. Domain G2 II,
on the other hand, was involved in weak haemagglutination and C'-dependent
neutralization, while the other two G2 regions had no haemagglutination function
and neutralized to a low level only in the presence of C'. These regions may
therefore be less accessible for antibody binding than the G2 I domain.
The observation that several of the antibodies directed against the G2 protein were
also capable of competing with GI-specific MAbs for attachment to certain sites
on the G1 protein demonstrates that these antibodies can induce conformation
changes in an entirely different protein. This finding is of particular interest since
there have been no other reports regarding epitope mapping studies on the effect
of binding of Gl-specific MAbs on the 02 protein and vice versa for any other
phleboviruses.
While the combined data from the topographical and structural analyses permitted
the probable spatial location end structure of these determinants to be defined,
actual epitope arrangements will require physical mapping to the Gland G2
genome sequences and the corresponding regions on the polypeptide chains. The
only mapping data published to date for RVFV utilizing the latter technique is that
of Keegan and Collett (1986) for three neutralizing -nd one non-neutralizing
determinants on the G2 protein of the Egyptian ZH ~. in. The discontinuous
nature of the determinants comprising the neutralizing Gi. I domain defined here
suggests that they occur on a different area of the G2 protein to the sequential and
continuous neutralizing sites identified by Keegan and Collett (1986). As the
latter were shown to map to amino acid sequences 258-291 (epitope I), 280-299
(epitope IV) and 382-392 (epitope II), the epitopes in this study are most likely
comprised of amino acid residues on the G2 polypeptide other than these.
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Determination of the actual gene coding regions of the discontinuous antigenic
determinants in the present study would require an alternative approach to that
used for th..~ mapping of the sequential G2 sites by Keegan and Collett (1986).
Moreover, since discontinuous epitopes cannot be predicted by computer analysis
(Becker, 1992), use of the hydrophilicity profiles of the RVFV glycoproteins
(Collett et al, 1985) to localize the probable regions on the G1 and G2
polypeptides that these epitopes map to would also not be effective. The precise
localization of the discontinuous epitopes would in fact require a combination of
various complex approaches (Burnens et al, 1987; Geysen et al, 1987a; Horsfall
et al, 1991) and knowledge of the complete three-dimensional structure of the
RVFV envelope proteins, similar to that acquired for the influenza haemagglutinin
(Wiley and Skehel, 1987; Wilson et aI, 1981).
Another aspect of the conformational nature of the RVFV determinants is that the
native protein structure of both the Gl and G2 proteins is clearly requited for the
recognition and expression of the functional activities of all the antibodies in this
study. The finding that the protective determinants G1 Ia and G2 Ia are
discontinuous has considerable implications with regard to the possible
development of a sub-unit vaccine. While knowledge of the positions of
protective epitopes could contribute significantly to the development of a RVFV
sub-unit vaccine (Keegan and Collett, 1986), the construction of synthetic
immunogens having a structure resembling the G1 Ia and G2 Ia topological
determinants would represent a difficult immunochemical problem. TI could
nevertheless possibly be approached by the 'surface simulation synthesis'
technique as outlined by Atassi (1980) and Geysen et al (1987a).
).3 Antlbody-medlatedneutralizationmechanisms
In addition to the functional and topographical analyses of the RVFV envelope
proteins, the mechanisms involved in antibody-mediated neutralization were
examined. The C' -enhanced and C'<dependent neutralization exhibited by the
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MAbs, while emphasizing the important role of C' in the inhibition of RVFV
infectivity, is a phenomenon that has been well-doctaecnted for many other
viruses (reviewed by McCullough, 1986). Of particular concern in this study
were the modes of action of the MAbs which neutralized the virus efficiently in
the absence of ct.
An important mechanism of neutralization of RVFV appears to be that of
synergistic neutralization between various antibodies directed against specific
antigenic determinants on the Gland G2 pr oteins. Such enhanced neutralization
does not seem to be directly correlated with increased binding of the antibodies
to their respective epitopes, but rather appe.ars to be the result of complex
conformational changes in the glycoproteins induced by antibody attachment. A
similar phenomenon has been reported for LACV (Kingsford, 1984).
Furthermore, the increased neutralization which occurred with certain
combinations of anti-Gl and G2 MAbs supports the evidence from the competitive
binding assays for an interaction between the two surface proteins of RVFV.
The demonstration that synergistic neutralization could even take place on
combining two antibodies which were non-neutralizing individually suggests that
the various types of co-operative effects between antibodies seen here may well
have considerable relevance with respect to a polyclonal immune response to RVF
infection.
A further neutralization strategy employed by certain MAbs was that of inhibition
of virus entry into the cell. Antibodies directed against the G1 IId, Gl IV and the
unmapped G1 epitopes defined by MAbs 1E4 and 8G10 displayed this type of
neutralizing activity. The G2 -specific neutralizing MAbs mapping to G2 Ia, Ib
and Ic likewise substantially prevented virus internalization. However, as viral
entry was not completely blocked, and yet subsequent plaque formation was
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inhibited, interference by these antibodies at a later stage in the viral life cycle
must also be involved.
In addition to these antibodies which appear to neutralize by two different
mechanisms, some MAbs had no effect on viral attachment or internalization, but
still inhibited viral plaque development effectively. These antibodies, which
included the strongly neutralizing and protective MAb mapping to site Gl la,
must thus neutralize solely at an intracellular stage. The fact that the MAb
defining the G1 IId epitope substantially prevented viral internalization while the
antibodies recognizing the closely adjacent Gl IIb, Ilc and lIe sites had no effect
on virus entry indicates that -teutralizing antibodies mapping to a specific domain
do not necessarily inhibit infectivity in an identical manner. Considering that the
phlebovirus cross-reactive epitopes G1 Ilc, IId and IIe are highly conserved, the
heterogeneous neutralization mechanisms displayed by the,antibodies recognizing
these determinants comprising the G1 II domain is even more interesting.
One of the intracellular stages which may be particularly sensitive to inhibition
by neutralizing antibodies is that of the virion-cell fusion event leading to the
release of the viral genome (Dietzschold et al, 1987; Dimmock, 1.987;Marsh and
Helenius, 1989). Gonzalez-Scarano (1985) has furthermore shown that at the pH
that activates the fusion function of LACV, the G1 protein undergoes a
conformational change which results in the reduced binding of several neutralizing
MAbs. Thus, while the inhibition of the RVFV fusion step by the MAbs was not
examined directly, such interference was looked at indirectly by ascertaining if the
attachment of any of these antibodies to acidified antigen was adversely affected,
Similar to the situation reported for the LACY G1 glycoprotein. The fact that
none of the antibodies exhibited drastically reduced binding to RVFY antigen
exposed to mildly acidic pH suggests that they do not neutralize by binding to
sites directly involved in the fusion event. Nevertheless, binding of certain of
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these antibodies to their respective epitopes could conceivably inhibit fusion
indirectly by preventing the allosteric change necessary to expose the actual
fusogenic region of the glycoprotein(s). Additional modes of action may involve
a step later In the virus infectious cycle such as interference with viral uncoating
as shown for West Nile virus (Gollins and Porterfield, 1986a) or by blocking viral
transcription as reported for influenza virus (Rigg et al, 1989).
8.4 Role of the RVFV glycoprotein epltopes ill virus attachment and
penetration
While a relationship of both the RVFV envelope proteins to infectivity has been
established (Battles and Dalrymple, 1988; Collett et al, 1987; Dalrymple et al,
1989; Keegan and Collett, 1986; Schmaljohn et al, 1989), the exact role played
by either of the glycoproteins in viral attachment and penetration has not been
directly demonstrated.
Based on the fact that both RVFV envelope proteins elicit neutralizing and
haemagglutination-inhibition antibodies} it has been suggested that the
glycoproteins may both be involved in virus attachment, either directly or by
conformational requirements (Schmaljohn and Patterson, 1990). In the present
study, the concordance of neutralizing and haemagglutination activities associated
particularly with the GIl and G2 I domains would seem to implicate these as the
possible regions which bind to cellular receptors. However, since none of the
MAbs defining the epitopes comprising these domains interfered with the
attachment of virus to cells, it is evident that these antibodies are not directed
against the viral binding site(s). This, in turn, suggests that the viral attachment
determinantts) may be located in a different area. on the RVFV envelope proteins
to the epitopes defined by these antibodies.
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Certain epitopes involved in viral entry into the cell, on the other hand, were
identified. The fact that both G1 and G2-specific MAbs were capable of
inhibiting virus internalization clearly demonstrates that both envelope
glycoproteins have an important function in entry of RVFV into the host cell,
This finding is of considerable significance as it is the first time that the
involvement of both envelope proteins in RVFV entry into the cell have been
definitively shown.
The actual mechanisms involved in entry and penetration of RVFV into the host
cell cytoplasm have not been clearly defined to date. Studies on several of the
other Bunyaviridae members suggest an entry route involving pH-dependent fusion
with acidic intracellular vesicles, which is associated with concomitant specific
conformational changes in one or both of the viral envelope proteins (Arikawa et
al, 1985; Gonzalez-Scarano, 1985). To obtain insight into the RVF viral fusion
mechanism, the MAbs were therefore used to investigate the location of any
changes in the surface glycoproteins induced by acidic pH.
Exposure of RVFV to low pH was shown to induce an apparent irreversible
allosteric change in the G1 surface protein as revealed by the increased binding
of several of the Gl-specific MAbs to acidified antigen. Such a rearrangement
of the G1 polypeptide which results ir, the greater exposure of certain sites is in
keeping with the idea that treatment cf a surface fusion protein to mildly acid pH
results in the subsequent exposure of a hydrophobic face (Subbarao et ai, 1987)
which may play an important role in the initiation of the fusion reaction. The
biological significance of the pfl-dependent irreversible conformational changes
in these 01 epitopes thus may well lie in the proposed endosomal route of RVFV
entry into the host cell cytoplasm.
Unlike tne RVFV G1 protein, the G2 glycoprotein epitopes appear to be resistant
to low pH. Since the induction of membrane fusion may involve multiple
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interactions between various virus components (Fuller and Spear, 1987), the
conformation change undergone by RVFV G1 at acidic pH may possibly expose
other sites on the G1 molecule which comprise the actual fusogenic sites.
Alternatively, the allosteric changes in the G1protein may serve to expose the G2
protein, thereby facilitating involvement of the latter protein in the physical event
of RVFV fusion, as has been suggested for LACV (Ludwig et al, 1989; Pobjecky
et ol, 1989). Thus, while the actual fusogenic determinants have not been
conclusively identified here, the pH-induced changes in the RVF'V 61 protein
strongly implicate involvement of acidic endosomes in t,Ie entry process of the
virus. The postulated endocytic uptake and plf-dependent fusion for RVFV
penetration and release of the viral genome was further supported by the
demonstration that viral uncoating and subsequent replication was inhibited by
raising endosornal pH with the lysosomotrophlc agent ammonium chloride.
8.S Concluding remarks
The possibility that any particular panel of hybridoma antibodies is able to discern
only a portion of the total antigenicity must always be considered. However,
although additional sites may be involved in the natural immune response to the
RVFV glycoproteins, the antigenic determinants identified here conceivably
account for a significant portion of the immunologically relevant domains of these
envelope proteins. By correlating the biological activities of the MAbs with
epitope specificities, antigenic sites with a neutralizing/haemagglutination
function, as well as those associated with C'-dependent neutralization, were
identified for both proteins. Protective determinants were shown to occur on both
Gl and G2, indicating that both RVFV envelope proteins are important in viral
pathogenesis. The neutralization studies, in turn, revealed that the inhibition of
virus attachment is not the principal means of antibody-mediated neutralization of
RVFV. Instead, such neutralization appears to be the result of several different
processes, including synergistic neutralization by combinations of different
antibodies, prevention of virus binding, virus internalization and the blocking of
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the viral life cycle at an intracellular stage. Further insight into RVFV infectivity
was obtained by showing that both glycoproteins are involved in virus entry into
the host cell. Finally I the present findings strongly support an endosomal route
of entry and penetration for RVFV, associated with concomitant allosteric changes
in the Gl protein.
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APPENDIX A: ELISA buffers
1. ELISA coating buffer
15mM sodium carbonate and 35 mM sodium hydrogen carbonate, pH 9,6.
2. ELISA wash buffer
Phosphate buffered saline (PBS) containing 0,01 % Tween-20.
3. ELISA blocking solution
4% Bovine serum albumin in PBS.
4. ELISA diluent
PBS with 5 % foetal calf serum.
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APPENDIX B: SDS~polyacrylamide slab gel electrophoresis (Laemmli, 1970;
Smith and Brown, 1977).
Stock solutions:.
1. Aerylamide-Diallyltartramide (DATD)
Prepared in the ratio 30:1,6 and stored in a dark bottle.
2. Resolving gel buffer
1M Tris-He! pH 8,8.
3. Stacking gel buffer
1M Tris-HCI pH 6,8.
4. Electrophoresls buffer (10 x)
0,25 M Tris-HCI pH 8,3; 1,92 M glycine; 1% (w/v) SDS.
5. Dissociation buffer
10% (w/v) SDS; 10% (v/v) Bvmercaptoethanol; 15% (v/v) glycerol;
0,02% (v/v) bromophenol blue in 1 M Tris-HeI pH 6,8.
All the above solutions were kept at 4°C.
Sample preparation:
Dissociation buffer was added to each sample at a 1:5 ratio and boiled for 5 min
prior to loading wells.
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Slab gel formulations:
Resolving gel
Stock solution 12% final acrylamide gel
concentration
(ml)
Acrylamide~DATD 32,0
Resolving gel buffer 30,0
Distilled water 13,2
10% SDS (w/v) 0,8
1,5% fresh ~S201S (w/v) 4,0- -
Temed (Jtl)
I
20
Total volume 80 ~
Stacking gel
-
Stock solution 4% acrylamide
(ml) -
Acrylamide-DATD 2,0
Stacking gel buffer 1,9-
Distilled water 9,25
10% SDS (w/v) 0,15
87% glycerol 1,0
1,5% fresh ~S201S (w/v) 0,7
Temed (Ill) 20
Total volume 15
====-"
1 NH4S20s = ammonium persulphate
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Electrophoretic separation:
Electrophoresis was performed at 16 rnA until the bromophenol blue tracking dye
reached the bottom of the resolving gel (+ 16 h).
}rocessing of gels for autoradiograph~
(a) Fixation of proteins in gel
Gels were immersed in 45% methanol! 7% acetic acid solutions for 1 h
after electrophoresis, then soaked in Amplify reagent (Amersham
International, U .K.) containing 5% glycerol for 30 min.
(b) Gel. hydration
The fixed gels were placed on sheets of Whatmann No 3 MM filter paper,
covered with clingw.rap plastic and dried under vacuum at 70°C for 2 h.
(c) Autoradiography
The dried gels were taped into X-ray cassettes and (3-maxautoradiographic
films (Amersham International, U.K.) were placed over the gels. The
cassettes were stored in the dark at -70°C and after ~herequired exposure,
the autoradiographic films were developed according to the manufacturers
instructions.
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APPENDIX C: Potassium tartrate-glycerol gradients (Objeski et al, 1974)
1. TE buffer
2mM EDTA in 2mM Tris-HCI pH 7,4.
2. Solution A
60% (w/w) sodium potassium tartrate (Sigma) in TE buffer.
3. Solution G
30% (w/w) glycerol in TE buffer.
4. Solution B ~F
These were prepared by mixing solutions A and G in the following ratios:
Solution Solution A Solution G
B SOg 109-~
C 40g 20g
D 30g 30g
E 20g 40g
F 109 SOg
Gradients were prepared by hand by successively layering 1,5 ml of solutions A -
G in a Beckman Ultra-Clear centrifuge tube.
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APPENDIX D: Animal Ethics Committee approval
All experimental work involving the use of mice was approved by the Animal
Ethics Screening Committee, University of the Witwatersrand. This included the:
1) Production of MAbs.
2) Production of hybridoma ascitic fluid*.
3) In-vivo protection studies.
Copies of the certificates are included.
* Since 23 hybridomas were produced instead of the estimated 20, it was
necessary to use several extra mice for the production of hybr' ' ..scltic fluid.
The subsequent use of mice for only four virus particle dilutions (10-3 to 10-6)
instead of the allocated seven dilutions (10.1 to 10-7) for the determination of the
virus LDso in the in-vivo protection experiments nevertheless ensured that the total
number of mice approved for the study was not exceeded.
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APPENDIX E: List of abbreviations
BABS borate buffered saline with 0,4% bovine albumin
BBS borate buffered saline _.'-
BSA bovine serum albumin
C' complement
CBA competitive binding assay --
CF complement fixation
CPE cytopathic effect
c.p.m. counts per minute
CsCl caesium chloride
DMSO dimethy lsulphoxide
EDTA ethylenediaminetetra-acetic acid
ELISA enzyme linked immunosorbent assay
EMEM Earle's minimum essential medium .
PCS foetal calf serum
HA haemagglutination --
HAP hyperimmune ascitic fluid
HAT hypoxanthine aminopterin thymidine
HI haemagglutination-inhibition
HMEM Hank's minimum essential medium
HRPO horseradish peroxidase
HT hypoxanthine thymidine
i.c, intracerebral
IFA indirect immunofluorescence antibody assav
i.p. intraperitoneal
LACV La Crosse virus-
LDso 50 % lethal dose
MAb monoclonal antibody
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APPENDIX E: List of abbreviations
.-----.,.:
I
m.o.i, multiplicity of infection-
O.D. optical density
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PEG polyethylene glycol
PFU plaque forming units
PRNT plaque reduction neutralization test
RlPA radioimmune precipitation assay
rpm revolutions per minute~. - --
rt room temperature~
RVFV Rift Valley fever virus--_._--
8DS sodium dodecyl sulphate
TCID tissue culture infective dose
Tris Tris(hydroxymethyl)aminomethane
VBS veronal buffered saline
WN West Nile
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